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Abstract 
Cardiovascular diseases (CVD) is a leading cause of death in the world. Despite 
effective treatment regimens for ischaemic heart disease (IHD) and ischaemic 
stroke, mortality and recurrence rates remain high. Antiplatelet therapy is on 
effective treatment and reduces the risk of recurrent heart attack and stroke. 
Nevertheless, there are patients who stopped or interrupted their antiplatelet 
therapy for certain reasons or some patients may be resistant or poor 
responders to antiplatelet therapy. Furthermore, there is evidence of rebound 
effect in platelet activity after antiplatelet cessation and this may associate 
with increased risk of cardiovascular event. This thesis is divided into five main 
chapters (chapters 3 to 7) which attempt to provide data to help resolve the 
uncertainty. 
 
Chapter 1 highlights the background of cardiovascular diseases and the global 
burden of cardiovascular and cerebrovascular diseases. The metabolism of 
platelets, antiplatelet therapy and current antiplatelet therapy guidelines are 
described, followed by discussion of the risk of cardiovascular event and 
changes in antiplatelet therapy.  
 
Chapter 2 describes the data source from Virtual International Stroke Trial 
Archive (VISTA) and National Health Service Greater Glasgow and Clyde 
(NHSGGC) Safe Haven, followed by definition of outcome measures. 
 
In chapter 3, Virtual International Stroke Trial Archive (VISTA) data was 
examined to test whether continue with the same antiplatelet therapy or 
changing to a new antiplatelet regimen reduces the risk of subsequent events 
in patients who experience a stroke whilst taking antiplatelet therapy. The 
findings indicate that subjects who switch to a new antiplatelet regimen after 
stroke did not have a lower early recurrence rate than subjects who continued 
with the same antiplatelet therapy. Observations on bleeding complications 
were similar in both groups. However, changing antiplatelet regimen after 
stroke was associated with more favourable functional outcome across a full 
scale modified Rankin Scale (mRS) at 90 days. 
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In chapter 4, association between early or later initiation of antiplatelet with 
a recurrent ischaemic stroke and bleeding complications was assessed using 
VISTA data. The findings indicate that there was no association between a 
recurrent ischaemic stroke and timing of initiation of antiplatelet drug after 
stroke. However, early initiation was associated with increased risk of bleeding. 
In terms of functional outcomes, this study demonstrated that the mid-time 
and late initiation of antiplatelet therapy after acute stroke are associated with 
better functional outcomes compared with early initiation. 
 
In chapter 5, a nested case-control study was performed to explore the rate of 
antiplatelet cessation and interruption in a sample of patients with recent 
ischaemic stroke and to assess the risk of cardiovascular events associated with 
cessation and interruption of antiplatelet. It was found that there was no 
increased risk of cardiovascular event among patients who had early cessation 
or interrupted/stopped antiplatelet therapy within 90 days following acute 
ischaemic stroke. 
 
In chapter 6, the incidence and predictors of cardiovascular events after DAPT 
cessation were evaluated. The incidence of cardiovascular event while taking 
DAPT and following discontinuation of DAPT was 15.7% and 16.7% respectively. 
This study found that increasing age was associated with an increased risk of 
cardiovascular event, whereas, revascularization-treated patients and longer 
duration of DAPT, were each associated with a decreased risk. The duration of 
DAPT six months and less was associated a significantly higher risk for 
cardiovascular event. 
 
In chapter 7, an untargeted metabolomics analysis was performed while on 
DAPT (aspirin plus ticagrelor) and once they stopped ticagrelor to identify 
metabolite changes associated with cardiovascular events after stopping DAPT. 
Ten ACS patients were recruited in this study and data were analysed for seven 
patients. Three hundred eleven putative metabolites were identified. This 
study found 16 putative metabolites significantly altered following ticagrelor 
cessation. Of these, seven metabolites were from lipid pathway and down-
regulated some up to 3-fold. On the other hand, adenosine, from nucleotide 
metabolism was upregulated up to 2.6-fold. It concluded that there are changes 
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in numerous pathways following DAPT discontinuation and whether these 
changes differ in patients who have cardiovascular event after stopping DAPT 
warrant further investigation. 
 
In chapter 8, a summary of the findings of this thesis are presented as well as 
the future directions of research in this area.  
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COX Cyclooxygenase 
CRF Case report form 
CRP C-reactive protein 
CV Cardiovascular event 
CVA Cerebrovascular accident 
CVD Cardiovascular disease 
DALY Disability-adjusted life year 
DAPT Dual antiplatelet therapy 
DES Drug eluting stent 
ECG Electrocardiographic 
ECH Extracerebral haemorrhage 
ERDP Extended-release dipyridamole 
ESO European Stroke Organisation 
FDA Food and drug administration 
GI Gastrointestinal 
GP Glycoprotein 
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GRACE Global Registry of Acute Coronary Events 
HR Hazard ratio 
ICD-10 International Classification of Diseases, Tenth Revision 
ICH Intracranial haemorrhage 
IHD Ischaemic heart disease 
IL Interleukin 
IQR Interquartile range 
IRR Incidence rate ratio 
ISD Information services division 
LC-MS Liquid Chromatography Mass Spectrometry Analysis  
LOQ Limit of quantitation 
LV Left ventricular 
LVEF Left ventricular ejection fraction 
MACE Major adverse cardiovascular events 
MI Myocardial infarction 
MMAS-4 Morisky medication adherence scales 
mRS Modified Rankin Scale 
NICE National Institute for Health and Care Excellence 
NIHSS National Institutes of Health Stroke Scale 
NHS National Health Service 
NSAIDS Nonsteroidal anti-inflammatory drugs 
NSTEMI Non ST elevation myocardial infarction 
OPCS-4 Office of Population Censuses and Surveys 
OR Odds ratio 
PAD Peripheral arterial disease 
PAI-1 Plasminogen activator inhibitor 
PAR Protease-activated receptor 
PCI Percutaneous coronary intervention 
PDE Phosphodiesterase 
PE Pulmonary embolism 
PTCA Percutaneous transluminal coronary angioplasty 
QC Quality control 
RR Risk ratio 
RRR Relative risk reduction 
rt-PA recombinant tissue plasminogen activator 
SAE Serious adverse event 
sCD40L Soluble CD40-ligand 
SCI-DC Scottish Care Information – Diabetes Collaboration 
SD Standard deviation 
SIGN Scottish Intercollegiate Guidelines Network 
SMC Smooth muscle cell 
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SMR01 Scottish Morbidity Records 
STEMI ST elevation myocardial infarction 
TIA Transient ischaemic attack 
TIMI Thrombolysis in Myocardial Infarction 
tPA Tissue plasminogen activator 
TPa Thromboxane receptor protein antagonist 
TX A2 Thromboxane A2 
uPA Urokinase-type plasminogen activator 
USA Unstable angina 
VISTA Virtual International Stroke Trials Archive 
VKA Vitamin K antagonist 
vWF von Willebrand factor 
WHO World Health Organisation 
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1 Introduction 
1.1 Antiplatelet therapy and cardiovascular diseases 
Antiplatelet therapy is a key in pharmacological treatment for prevention of 
coronary heart disease (CHD) and stroke. Depending on indication, duration of 
antiplatelet monotherapy or dual therapy is varied. Antiplatelet therapy is 
indicated to prevent a recurrence of cardiovascular event, however, extended 
duration of dual antiplatelet therapy (DAPT) associated with increased risk of 
bleeding. Furthermore, antiplatelet therapy itself is known to associate with 
adverse events (AE) like gastrointestinal and non-gastrointestinal bleeding, 
intracranial haemorrhage (ICH) and allergic reactions. Thus, this leads to 
premature discontinuation of antiplatelet therapy which later associates with 
increased risk of cardiovascular event after antiplatelet cessation. In this 
chapter, I am going to discuss the background of cardiovascular diseases and 
antiplatelet therapy used in patients with cardiovascular disease. 
 
1.2 Cardiovascular diseases 
Cardiovascular disease (CVD) is defined by World Health Organisation (WHO) as 
any disorder related to the heart and blood vessels. It is the most serious and 
common disease in the world. CVD disorders include CHD, stroke 
(cerebrovascular disease), hypertension, peripheral artery disease, rheumatic 
heart disease, congenital heart disease and heart failure. In 2015, CVD was the 
leading cause of death from non-communicable diseases (GBD 2015 Mortality 
and Causes of Death Collaborators, 2016). It is estimated that approximately 
17.9 million people died due to CVD in 2015. The number of global deaths due 
to cardiovascular disease increased by 12.5% between 2005 and2015 (GBD 2015 
Mortality and Causes of Death Collaborators, 2016). Circulatory disease and CVD 
accounts for 11.8% of global DALY (Murray, et al., 2012). 
 
In this section, I am going to discuss in depth CHD and stroke exploring the 
burden of these two disorders, their pathophysiology, signs and symptoms and 
evidence based treatment. 
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1.3 Coronary heart disease 
1.3.1 Background 
Coronary heart disease is also known as ischaemic heart disease (IHD) and can 
present with symptoms of stable angina, sudden death, an acute coronary 
syndrome (ACS) or symptoms of heart failure. ACS are caused by disruption of 
blood flow to the heart muscle due to rupture of fatty substance or 
atherosclerotic plaques in coronary arteries (Grech and Ramsdale, 2003). 
Traditionally, ACS is subdivided into unstable angina, non-ST elevation 
myocardial infarction (NSTEMI) and ST elevation myocardial infarction (STEMI). 
Unstable angina occurs due to partially or totally block of the blood coronary 
blood vessel leading to myocardial ischaemia. Acute myocardial infarction 
occurs due to prolonged myocardial ischaemia which causes myocardial necrosis 
(Thygesen, et al., 2012). 
 
Coronary heart disease is the leading cause of death globally (GBD 2015 
Mortality and Causes of Death Collaborators, 2016). In 2015, CHD killed 8.9 
million people, and deaths increased by 16.6% between 2005 and 2015. Its has 
an impact worldwide, in every country and population. CHD burden globally 
was 150 million DALY in 2013, which represents an increase of 8.4% compared 
to 2005 (GBD 2013 DALYs and HALE Collaborators, 2015). In the United Kingdom 
(UK), CHD burden was 1.4 million in 2010 (Murray, et al., 2013). In Scotland, it 
is estimated 8000 people die from CHD and in 2012, it is estimated around 7.3% 
male and 5.7% female are living with CHD (NHS National Services Scotland, 
2014). 
 
One month after the acute event, patients with ACS are very vulnerable 
physically, mentally and emotionally due to chest pain and anxiety 
(Kristofferzon, et al., 2005; Bach, et al., 2011; Rančić, et al., 2013). Besides 
that, the rates of all-cause mortality increased in the first 6 months, especially 
in the first 30 days after an acute episode of ACS (Das, et al., 2006). In Scotland, 
around 92% of people survived 30 days or more following heart attack in year 
2012/2013 and the age and sex standardised mortality rate for heart attacks 
was 47.4 per 100,000 population in the same year (NHS National Services 
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Scotland, 2014). In terms of risk of recurrence AMI, a study found about 14% 
men and 17% women who survived their first AMI experienced a recurrence AMI 
within 7 years (Smolina, et al., 2012). 
 
In order to minimise risk of recurrence and death, patients with ACS are 
typically offered pharmacotherapy in the form of antiplatelet therapy, lipid 
lowering therapies and blood pressure lowering drugs and many undergo 
procedures such as percutaneous angioplasty and stenting. Dual antiplatelet 
therapy (DAPT) is normally prescribed following ACS. At present there are few 
combinations of DAPT available such as aspirin plus clopidogrel or aspirin plus 
ticagrelor. Current guidelines recommend that DAPT should be continued for 
between three and 12 months after the acute episode (O'Gara, et al., 2012; 
Scottish Intercollegiate Guidelines Network (SIGN), 2013a). After this period, 
all patients with ACS will continue aspirin in whom it is not contraindicated for 
lifelong to prevent a recurrence of ACS.  
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Figure 1-1: Healthy years of life lost (above) and mortality rates (below) attributed 
to coronary heart disease within European countries.  
Source:  www.who.int  (Permissions  obtained  from  World  Health  Organization  
(Permission authorization for WHO copyrighted material); ID number 196107 & 
196108) (World Health Organization, 2004c; World Health Organization, 2004a)  
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1.3.2 Pathophysiology of acute coronary syndrome  
Acute coronary syndrome is caused by atherosclerotic plaque build-up inside 
coronary arteries. The atherosclerotic plaque narrows the coronary arteries and 
decreases blood flow to the heart. There are two forms of atherosclerotic 
lesions in human coronary arteries; stenotic and non-stenotic lesions (Libby and 
Theroux, 2005). Stenotic lesions are few but in the form of smaller lipid cores 
and covered with thick fibrous caps. Non-stenotic lesions tend to have large 
lipid cores with thin fibrous caps and are vulnerable to rupture and thrombosis.  
 
The fibrous caps of atherosclerotic plaque consists of macrophages and smooth 
muscle cells and may disintegrate, tear or break at any point (Falk, et al., 1995) 
This will cause the atherosclerotic plaque to be exposed to the flowing blood 
and provoke thrombosis. Platelet activation is triggered by the collagen 
(produced by the smooth muscle cells in the plaque) and the coagulation 
cascade is activated by macrophages and smooth muscle cells (Libby and 
Theroux, 2005). Once platelets become activated, fibrin is formed and von 
Willebrand factor is released (Figure 1-2). The thrombus can either grows until 
it occludes the blood vessel or breaks away from the atherosclerotic plaque and 
embolise distally (Guyton and Hall, 2006). 
 
The resting coronary blood flow in the heart is about 225 ml/min, which is 70 
ml/min/100g of cardiac tissue (Guyton and Hall, 2006). When the occlusion of 
coronary arteries more than 80%, this condition will cause ischaemia to the 
surrounding tissue due to the insufficient blood flow to cardiac muscle and lack 
of oxygen. Extreme cardiac ischaemia will lead to infarction to the tissue 
(Guyton and Hall, 2006). For unstable angina and NSTEMI, coronary arteries are 
partially or intermittently occluded, whereas in STEMI, there is typically 
complete occlusion (Kumar and Cannon, 2009; Overbaugh, 2009). 
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Figure 1-2: Determinants of thrombosis in coronary atherosclerotic plaques.  
tPA=tissue plasminogen activator, uPA=urokinase-type plasminogen activator, PAI-
1=plasminogen activator inhibitor, SMC=smooth muscle cell. Adapted from Libby and 
Theroux (2005). (Permissions obtained from Wolters Kluwer Health, License Number 
3785951496889)  
 
 
1.3.3 Differences between types of acute coronary syndrome 
There are three types of ACS that occur due to an atherosclerotic plaque 
rupture and the abrupt narrowing and occlusion in the coronary arteries. The 
type of ACS is depending on the location of the blockage, the amount of time 
that blood flow is blocked and the amount of damage to the myocardium area. 
Diagnosis of ACS are depending on the clinical presentation, 
electrocardiographic (ECG) changes and biochemical cardiac markers (Scottish 
Intercollegiate Guidelines Network (SIGN), 2013a). 
 
Unstable angina does not cause myocardial damage, but it may progress to 
myocardial infarction. Signs and symptoms include pain with or without 
radiation to the arm, neck or epigastric region and shortness of breath, 
diaphoresis, and nausea. Signs and symptoms of unstable angina are less severe 
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than in ST- and NSTEMI and the diagnosis is supported by the absence of ECG 
changes and with normal cardiac biomarkers (Overbaugh, 2009). 
 
NSTEMI is less serious than STEMI as the blood supply to the myocardium is not 
completely blocked but it still causes damage to the myocardium. The 
myocardial damage is followed by the release of a biomarker of myocardial 
necrosis into the circulation, i.e. troponins T or I, or creatinine kinase (CK-MB) 
(Kumar and Cannon, 2009). Signs and symptoms of NSTEMI can be more severe 
than in unstable angina. Cardiac biomarkers are also elevated with ECG changes 
show either ST-segment depression or T-wave inversion. 
 
STEMI is the most serious types of ACS. A thrombus fully occludes the coronary 
artery and caused infarction and ischaemia to the surrounding tissue of 
myocardium. Signs and symptoms of STEMI are longer in duration and more 
severe than in unstable angina. Cardiac biomarkers are elevated in this type of 
ACS with ECG changes show ST-segment elevation or a new left bundle branch 
block (Overbaugh, 2009).  
 
1.3.4 Current management of acute coronary syndrome 
Once a patient has arrived at the hospital and received a diagnosis of ACS, 
management aims to decrease the extent of myocardial damage and prevent 
major cardiovascular events such as death and nonfatal MI. The therapeutic 
approach for ACS are depending on the underlying pathophysiology of unstable 
angina, NSTEMI and STEMI.  
 
In unstable angina and NSTEMI, the related coronary artery is usually partially 
or intermittently occluded, thus the goal of treatment is to prevent further 
thrombosis, reocclusion and recurrent ischaemia. In early management, DAPT 
and anticoagulant should be offered. For intermediate and high risk patients 
(based on Global Registry of Acute Coronary Events [GRACE] or Thrombolysis in 
Myocardial Infarction [TIMI] scoring system), coronary angiography will be 
offered and follow with percutaneous coronary intervention (PCI) if indicated 
(National Institute for Health and Care Excellence, 2010; Scottish 
Intercollegiate Guidelines Network (SIGN), 2013a). Once a patient has 
Chapter 1 Introduction 31 
stabilized, lipid-lowering therapies, beta-blocker and angiotensin-converting-
enzyme (ACE) inhibitor are used over the long term. The medications and doses 
of therapy used for ACS are shown in Table 1-1. 
 
Whereas in STEMI, as the coronary artery is totally occluded, the goal is to 
obtain normal coronary blood flow via pharmacological approach or catheter-
based reperfusion. Percutaneous coronary intervention should be initiated 
within 120 minutes of ECG diagnosis or if this cannot be provided, a patient 
should receive thrombolytic therapy such as streptokinase (O'Gara, et al., 2012; 
Scottish Intercollegiate Guidelines Network (SIGN), 2013a). The timing of 
reperfusion therapy in STEMI treatment is important to improve patient 
outcomes (Andersen, et al., 2003a; Andersen, et al., 2003b). The rest of 
pharmacological treatment should be initiated as soon as possible or once a 
patient has stabilized (Table 1-1).  
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Table 1-1: Selected routine medical therapies  
Therapy Medications 
Unstable angina / NSTEMI 
Antiplatelet Aspirin 300mg stat, then 75mg daily 
Clopidogrel 600mg stat, then 75mg daily 
Prasugrel 60mg stat, then 10mg daily 
Ticagrelor 180mg stat, then 90mg twice a day 
Anticoagulant Unfractionated heparin iv bolus 60ii/kg then 
infusion 12ii/kg/h for 48 hours 
Enoxaparin 1mg/kg sc every 12 hours up to 8 days 
Fondaparinux 2.5mg iv, then 2.5mg sc daily up to 8 
days 
Anti-ischaemic Nitroglycerin 0.4 mg sublingual every 5 min 
Beta-blocker Metoprolol 25-50mg every 6-12 hours 
Carvedilol 6.25-25mg twice daily  
ACE inhibitor / ARB Lisinopril 2.5-10mg daily 
Captopril 6.25-50mg three times daily 
Ramipril 2.5-5mg twice daily 
Valsartan 20-160mg twice daily 
Cholesterol-lowering Atorvastatin 80mg daily 
STEMI 
Fibrinolytic  Tenecteplase Single iv weight-based bolus 
Reteplase 10ii + 10ii iv bolus given 30 min apart 
Alteplase 90-min weight-based infusion 
Streptokinase 1.5 MU iv over 30-60min 
Antiplatelet Aspirin 300mg stat, then 75mg daily 
Clopidogrel 600mg stat, then 75mg daily 
Prasugrel 60mg stat, then 10mg daily 
Ticagrelor 180mg stat, then 90mg twice a day 
Anticoagulant Unfractionated heparin iv bolus 60ii/kg then 
infusion 12ii/kg/h for 48 hours 
Enoxaparin 1mg/kg sc every 12 hours up to 8 days 
Fondaparinux 2.5mg iv, then 2.5mg sc daily up to 8 
days 
Anti-ischaemic Nitroglycerin 0.4 mg sublingual every 5 min 
Beta-blocker Metoprolol 25-50mg every 6-12 hours 
Carvedilol 6.25-25mg twice daily  
ACE inhibitor / ARB Lisinopril 2.5-10mg daily 
Captopril 6.25-50mg three times daily 
Ramipril 2.5-5mg twice daily 
Valsartan 20-160mg twice daily 
Cholesterol-lowering Atorvastatin 80mg daily 
 
ACE=angiotensin-converting-enzyme, ARB=Angiotensin receptor blocker, 
mg=milligrams, MU=mega unit, iv=intravenous, sc=subcutaneous.  
(O'Gara, et al., 2012; Scottish Intercollegiate Guidelines Network (SIGN), 2013a) 
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1.4 Stroke 
1.4.1 Background 
Forty years ago, the WHO introduced definition of stroke as ‘rapidly developing 
clinical signs of focal (or global) disturbance of cerebral function, lasting more 
than 24 hours or leading to death, with no apparent cause other than that of 
vascular origin’ (Aho, et al., 1980). In 2013, the American Heart 
Association/American Stroke Association suggested a new definition of stroke 
reflecting the greater understanding of pathophysiology and the wide spectrum 
of cerebrovascular diseases (Table 1-2). There are two major subtypes of 
stroke; ischaemic stroke and haemorrhagic stroke. Ischaemic stroke occurs due 
to reduction blood flow to the brain and causing neurological dysfunction and 
infarction. Haemorrhagic stroke occurs after rupture of a blood vessel in brain 
tissue.  
 
In 2015, 6.3 million people died of cerebrovascular disease. Of these, about 3 
million people died of ischaemic stroke and 3.3 million died of haemorrhagic 
stroke (GBD 2015 Mortality and Causes of Death Collaborators, 2016). In 2005, 
stroke burden was 107 million DALYs and the number increased to 112 million 
DALYs in year 2015 (GBD 2013 DALYs and HALE Collaborators, 2015). In 2010, 
stroke was the third leading cause of years of life lost in the UK (Murray, et al., 
2013). Many stroke survivors suffer prolonged disability and neurological 
complications such as cognitive decline, dementia, depression or seizures 
(O'Brien, et al., 2003; Rothwell, et al., 2004; Hong, et al., 2010). The UK spends 
about 9 billion pounds a year caring for these patients (Saka, et al., 2009). 
 
A patient who presents with an acute onset of ischaemic stroke may be offered 
a therapy with fibrinolytic treatment within 4.5 hours and oral aspirin 
antiplatelet therapy within 24 to 48 hours after stroke onset. A patient with a 
first-ever ischaemic stroke, single antiplatelet therapy is offered normally 
aspirin unless contraindicated. As per guidelines, this treatment should be 
continued for a life-long. 
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Table 1-2: Definition of stroke 
The term “stroke” should be broadly used to include all of the following: 
 
Definition of CNS infarction: CNS infarction is brain, spinal cord, or retinal 
cell death attributable to ischemia, based on 
1. pathological, imaging, or other objective evidence of cerebral, spinal cord, 
or retinal focal ischemic injury in a defined vascular distribution; or 
2. clinical evidence of cerebral, spinal cord, or retinal focal ischemic injury 
based on symptoms persisting ≥24 hours or until death, and other etiologies 
excluded. (Note: CNS infarction includes hemorrhagic infarctions, types I and 
II; see “Hemorrhagic Infarction.”) 
Definition of ischemic stroke: An episode of neurological dysfunction 
caused by focal cerebral, spinal, or retinal infarction. (Note: Evidence of CNS 
infarction is defined above.) 
Definition of silent CNS infarction: Imaging or neuropathological evidence 
of CNS infarction, without a history of acute neurological dysfunction 
attributable to the lesion. 
Definition of intracerebral hemorrhage: A focal collection of blood within 
the brain parenchyma or ventricular system that is not caused by trauma. 
(Note: Intracerebral hemorrhage includes parenchymal hemorrhages after 
CNS infarction, types I and II—see “Hemorrhagic Infarction.”) 
Definition of stroke caused by intracerebral hemorrhage: Rapidly 
developing clinical signs of neurological dysfunction attributable to a focal 
collection of blood within the brain parenchyma or ventricular system that is 
not caused by trauma. 
Definition of silent cerebral hemorrhage: A focal collection of chronic blood 
products within the brain parenchyma, subarachnoid space, or ventricular 
system on neuroimaging or neuropathological examination that is not caused 
by trauma and without a history of acute neurological dysfunction attributable 
to the lesion. 
Definition of subarachnoid hemorrhage: Bleeding into the subarachnoid 
space (the space between the arachnoid membrane and the pia mater of the 
brain or spinal cord). 
Definition of stroke caused by subarachnoid hemorrhage: Rapidly 
developing signs of neurological dysfunction and/or headache because of 
bleeding into the subarachnoid space (the space between the arachnoid 
membrane and the pia mater of the brain or spinal cord), which is not caused 
by trauma. 
Definition of stroke caused by cerebral venous thrombosis: Infarction or 
hemorrhage in the brain, spinal cord, or retina because of thrombosis of a 
cerebral venous structure. Symptoms or signs caused by reversible edema 
without infarction or hemorrhage do not qualify as stroke. 
Definition of stroke, not otherwise specified: An episode of acute 
neurological dysfunction presumed to be caused by ischemia or hemorrhage, 
persisting ≥24 hours or until death, but without sufficient evidence to be 
classified as one of the above. 
 
Ref: Sacco, et al. (2013) 
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Figure 1-3: Healthy years of life lost (above) and mortality rates (below) attributed 
to stroke within European countries. 
Source:  www.who.int  (Permissions  obtained  from  World  Health  Organization  
(Permission authorization for WHO copyrighted material); ID number 196109 & 
196110). (World Health Organization, 2004d; World Health Organization, 2004b) 
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1.4.2 Pathophysiology of ischaemic stroke 
Ischaemic stroke occurs due to occlusion of intracranial arteries the blood 
vessels that supply blood to the brain tissue. The occlusion can be caused by a 
thrombus formed once the atherosclerotic plaque ruptures and activates 
platelet aggregation. The occlusion can also be caused by embolus, blood clot 
or other particles, travelling in the arteries from the central circulation. This 
obstruction leads to a reduction of blood flow in the brain that will cause lack 
of oxygen, brain ischaemia and acute loss of brain function in a localized area.  
 
The normal rate of blood flow through the brain is between 50-65ml/min/100g 
of brain tissue. Neuron, a nerve cell in the brain requires a constant supply of 
oxygen and glucose and susceptible to hypoxic changes. Once blood flow 
reduces below 15ml/min/100g, ischaemic cascade at cellular level stimulates 
(Paciaroni, et al., 2009). Ischaemic cascade causes loss of potassium ion and 
adenosine triphosphate (ATP), thus lead to malfunction of an ion gradient. At 
the same time, ischaemia releases glutamate and aspartate, excitatory 
neurotransmitters in the brain, which leads to activation of disordered enzymes 
(e.g. lipases, proteases) and ultimately leads to cell death (Deb, et al., 2010). 
The extent of brain tissue damage is depending on the severity of ischaemia. If 
tissue ischaemia is mild, restoring blood flow may reduce and reverse the brain 
injury as the area is not yet infarcted (penumbra). However, if severe ischaemia 
happens the affected tissues dies (infarction) (Giraldo, 2013). 
 
1.4.3 Types of ischaemic stroke 
The complete occlusion of an artery may lead to an ischemic infarction, an area 
of necrotic cells caused by the obstruction of blood flow. There are four main 
types of ischaemic stroke i.e. cardioembolic, cryptogenic, small vessel and 
large artery disease. Large vessel disease is caused by ischaemia via embolism 
or reduction of blood flow. Whereas, small vessel disease is caused by 
accumulation of hyaline (a pathological protein) in the subendothelial which 
leads to narrowing and occlusion of a single deep perforating artery (Brainin 
and Heiss, 2009). Narrowing of carotid arteries in the neck and small arteries 
inside the brain, usually because of atherosclerotic plaque, reduces blood flow 
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to the brain. The complete occlusion of an artery may lead to an ischaemic 
infarction. Around 20% of ischaemic strokes are due to occlusion of carotid 
artery (Petty, et al., 1999). On the other hand, the occlusion of arteries caused 
by an embolus is called embolic stroke. The embolus carried in the bloodstream 
will lodge in the intracranial artery and caused occlusion which will lead to a 
reduction of blood flow (Frizzell, 2005; Deb, et al., 2010). 
 
Diagnosis of stroke is important to provide optimal patient care and treatment. 
Diagnosis of stroke should include a full neurological and cardiovascular 
assessment; diagnostic testing (e.g. ECG, chest x-ray, blood work) and brain 
imaging (computed tomographic scan or magnetic resonance imaging) (Frizzell, 
2005). A graded stroke severity assessment, the National Institute of Health 
stroke scale (NIHSS), would be used to rate the severity as a result of stroke 
(National Institute of Neurological Disorders and Stroke, 2008). Signs and 
symptoms of ischaemic stroke are depending on the area of the brain affected 
(Table 1-3).  
 
1.4.4 Current management of stroke 
Once a patient has arrived at the hospital and diagnosis has been made, the 
aims of management are to preserve tissue in the ischaemic penumbra, reduce 
the high risk of recurrent stroke and disability after stroke. The therapeutic 
approach for acute ischaemic stroke is to limit the severity of ischaemic tissue.  
 
In early management of ischaemic stroke, the time window after stroke onset 
is important as this is the fibrinolytic therapy (alteplase) is administered. 
Alteplase is recommended for patients, who met the eligibility criteria, be 
treated within 4.5 hours after the onset of ischaemic stroke (Hacke, et al., 
2008a; Scottish Intercollegiate Guidelines Network (SIGN), 2008; Wahlgren, et 
al., 2008; Kernan, et al., 2014). Aspirin, should be initiated within 24 to 48 
hours after stroke onset, but it should be delayed for 24 hours if patients 
received alteplase. 
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Table 1-3: Clinical presentation in ischaemic stroke (Brainin and Heiss, 2009) 
Artery Symptoms 
Anterior cerebral 
(Arboix, et al., 
2009; Brainin 
and Heiss, 2009) 
dysarthria, aphasia; unilateral contralateral motor 
weakness (leg/shoulder > arm/hand/face); minimal 
sensory changes (two-point discrimination) in the same 
distribution as above left limb apraxia; urinary 
incontinence 
Middle cerebral  contralateral hemiparesis, hemi-hypesthesia, 
hemianopsia, and ipsilateral conjugated eye and head 
deviation; left lesion: aphasia and ideomotor apraxia; right 
lesion: contralateral multimodal hemineglect (visual, 
motor, sensitive, visual, spatial, auditive), anosognosia 
(denial of illness), anosodiaphoria (indifference to illness) 
Vertebral contralateral hemiparesis sparing the face (corticospinal 
tract), contralateral lemniscal sensory loss (medial 
lemniscus) and ipsilateral tongue paresis; contralateral 
thermoalgesic deficit (spinothalamic tract), dysphagia, 
dysphonia, pharynx and vocal cord weakness 
Basilar paresthesias, dysarthria, hemiparesis, dizziness 
Posterior 
cerebral 
dyschromatopsia, visual agnosia or alexia-without 
agraphia with a left lesion, spatial disorientation 
(topographagnosia), palinopsia, amusia, Balint syndrome 
(asimultanognosia or incapacity to see a scene as a 
whole, ocular apraxia or poor hand–eye coordination and 
optic ataxia or apraxia of gaze), metamorphosia, and 
prosopagnosia 
 
For a patient with embolic stroke from cardiac source should be offered vitamin 
K antagonist (VKA) i.e. warfarin (Kernan, et al., 2014). There is likelihood that 
cardiogenic embolism happened in patients with atrial fibrillation; acute 
myocardial infarction and left ventricular thrombus; cardiomyopathy; vulvular 
heart disease and prosthetic heart valves. Other than warfarin, newer agent 
such as apixaban, dabigatran and rivaroxaban are all indicated in patients with 
nonvulvular atrial fibrillation to prevent future stroke 
 
On the other hand, antiplatelet therapy is recommended for patients with non-
cardioembolic stroke (Kernan, et al., 2014). Initiation of aspirin or clopidogrel 
as a monotherapy or combination of aspirin and extended-release dipyridamole 
is indicated after ischaemic stroke. However, in a patient who had an ischaemic 
stroke while taking aspirin, currently, there is no study to show that single agent 
or combination treatment is appropriate for this patient. Secondary 
preventative medications should be initiated as soon as possible and these may 
include antihypertensive, lipid-lowering therapies and lifestyle modification. 
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1.5 Platelet metabolism 
Platelets, the smallest of human blood cells, were first described in 1865 by 
Professor Max Schultze (1825-1874). The discovery of the role of platelets in 
haemostasis was later established by Dr Giulio Bizzozero (1846-1901) (Brewer, 
2006). Platelets are produced in the bone marrow and released in the form of 
megakaryocytes into the blood circulation (Thon and Italiano, 2010). A mature 
platelet with a diameter size 2-3micrometer is usually remains alive for about 
5 to 9 days. Only 2/3 of the platelets circulate in the blood and the rest is 
stored in the spleen. The normal platelet count in the body is about 150,000-
400,000 per microliter of blood. In a day, a healthy adult can produce about 
1,000 million platelets and for old platelets, they are destroyed in the spleen 
and liver (Ghoshal and Bhattacharyya, 2014). 
 
Platelets are essential in haemostasis. In normal condition, when the 
endothelium remains biochemically and physically intact, platelets remain in 
an inactive state. When there is vascular injury, collagen and von Willebrand 
factor (vWF) in the endothelium wall are exposed. Platelets in the blood 
circulation bind to the exposed collagen through interaction with glycoprotein 
VI/Ia receptor on the platelet surface and the exposed vWF binds to 
glycoprotein Ib/V/IX receptor. These bindings form a monolayer of activated 
platelets and lead to platelet adhesion (Brass, 2003; Jennings, 2009). Then, the 
adherent platelets release adenosine diphosphate (ADP) and thromboxane A2 
(TxA2) where it leads to platelets change in shape and platelet activation. 
 
When platelets become activated, platelet activation is initiated via multiple 
pathways. Other than stimulated by collagen exposure, ADP and TxA2, 
serotonin and thrombin pathways are also involving in platelet activation 
(Brass, 2003; Davi and Patrono, 2007; Varga-Szabo, et al., 2008). Secretion and 
accumulation of these agonists leads to recruitments of platelets from the 
blood circulation and formed platelet aggregations or stable platelet plugs. This 
stage is also known as primary aggregation. The secretion of platelet activators 
such as ADP, TxA2 and other substances, initiate secondary aggregation by 
provide positive feedback and strengthen the platelet-rich clot (Ghoshal and 
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Bhattacharyya, 2014). These processes lead to wound healing of the vascular 
injury. 
 
Platelets are also responsible for the formation of arterial thrombus that 
normally occurs at sites of atherosclerosis and results in acute coronary 
syndrome or cerebral infarction (Ghoshal and Bhattacharyya, 2014). Rupture of 
atherosclerotic plaque will expose collagen and tissue factor to circulating 
platelets and thus promoting platelet activation and coagulation cascade. 
Activated platelets stimulate production of thrombin from prothrombin. Then, 
thrombin converts fibrinogen to fibrin leading to the formation of platelet and 
fibrin plug and further platelet activation and aggregation (Libby and Theroux, 
2005; Guyton and Hall, 2006). This process can lead to thrombus formation, 
ischaemia and infarction of the affected area.  
 
1.5.1 Adenosine diphosphate  
ADP released from damaged endothelium and also from activated platelets will 
bind to platelet ADP receptors and consequently releasing more ADP (Geiger, 
et al., 1999; Kunapuli, et al., 2003). This will lead to further enhance platelet 
activation and recruit more platelets by coupled to inhibitory G-protein and 
release of intracellular calcium. The available ADP receptor antagonists are 
thienopyridines i.e. clopidogrel, ticlopidine and prasugrel; and non-
thienopyridine i.e. ticagrelor. Mechanism of actions of these antiplatelet agents 
have been discussed in section 1.4.2. There are two ADP receptors on the 
platelet membrane i.e. P2Y1 and P2Y12. When the antiplatelet binds to the P2Y1 
receptor, it will result in release of intracellular calcium and leads to transient 
inhibition of platelet aggregation. On the other hand, binding to the P2Y12 
receptor results in more powerful and continuous inhibition of platelet 
aggregation (Bavry, et al., 2007). 
 
1.5.2 Thromboxane 
Thromboxane A2, produced via the arachidonic acid (AA) pathway, is an 
important platelet activation pathway (Figure 1-4). This pathway activates the 
TP-receptor and induces further platelet activation. Activation of platelets and 
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platelet bridging encourage production of thrombin and procoagulant activity 
and the formation of stable platelet plugs (Andrews and Berndt, 2004). Aspirin, 
a drug widely used in treating cardiovascular diseases, inhibits platelet 
aggregation via inactivation of cyclooxygenase (COX) and thus resulting in the 
blockage of production of TxA2. 
 
As shown in Figure 1-4, 11-dehydro-thromboxane B2 (11-dhTXB2) is one of the 
product produced from the AA pathways and it is a stable metabolite of TxA2. 
11-dhTxB2 is useful in testing the extent of TxA2 inhibition for aspirin resistance 
and also in monitoring platelet activation for those who did not taking aspirin 
(Catella, et al., 1986; Eikelboom, et al., 2002; Baigent, et al., 2009). 11-dhTxB2 
levels can be measured in plasma or urine. A study (McConnell, et al., 2001) 
found that 11-dhTxB2 levels are elevated during acute ischaemic stroke, 
especially in those who did not taking aspirin. A high concentration of 11-
dhTxB2 level in patients treated with aspirin therapy indicate an inadequate 
inhibition of TxA2 synthesis. Furthermore, higher concentrations of 11-dhTXB2 
level have been associated with an increased risk of cerebral infarction, 
myocardial infarction, saphenous vein graft thrombosis after coronary artery 
bypass graft surgery, and cardiovascular death (Eikelboom, et al., 2002; 
Eikelboom, et al., 2008; Gluckman, et al., 2011). 
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Figure 1-4: Arachidonic acid thromboxane pathway. 
[Ref: Born and Patrono (2006)] 
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1.5.3 Antiplatelet withdrawal and the rebound phenomenon 
There is evidence of increased risk of cardiovascular events following 
antiplatelet cessation. There are suggestions that this event maybe due to a 
rebound in platelet activity (Lordkipanidze, et al., 2009; Sambu, et al., 2011a; 
Sambu, et al., 2011b). Lordkipanidze, et al. (2009) has proposed that 
suppression of TxA2 by aspirin might lead to higher production of TxA2 than 
normal and it can cause rebound platelet aggregation once aspirin is 
discontinued. Similarly, while on clopidogrel, the P2Y12 receptor increase in 
expression and sensitivity, thus, once discontinued, resulting in more efficiently 
activation of GP IIb/IIIa and cause an increase in platelet aggregation.  
 
There is clinical evidence that cardiovascular events increased when changing 
from dual to mono antiplatelet therapy. While on DAPT, such as the 
combination of aspirin and clopidogrel, both pathways would be affected i.e. 
AA pathway and ADP pathway, as discussed earlier. There is evidence that 
clopidogrel influences AA pathways, thus resulting more effective inhibition 
platelet aggregation by aspirin (Frelinger, et al., 2006; Shankar, et al., 2006; 
Armstrong, et al., 2009; Armstrong, et al., 2010). Therefore, it is suggested 
that after discontinuation of clopidogrel, the synergistic effect will be lost and 
resulting in rebound attenuation of the antiplatelet effect of aspirin (Sambu, 
et al., 2011b). 
 
With all these theories of rebound effect, there are studies done to support 
these theories. Diehl, et al. (2011) found levels of ADP increased at 2 weeks 
after clopidogrel cessation. Mylotte, et al. (2011) found an increased in platelet 
aggregation response to ADP and epinephrine when compared before and one 
week after cessation of clopidogrel. On the other hand, studies by Sambu, et 
al. (2011a) and Djukanovic, et al. (2011) found no evidence to support these 
theories. However, most of these studies do not include any measurement 
before the antiplatelet therapy. 
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1.6 Antiplatelet therapy 
Platelets play an important role in haemostasis and thrombosis. There are many 
studies to support that inhibition of platelet aggregation significantly reduce 
mortality and morbidity in ischaemic atherothrombotic events (Gent, et al., 
1996; Chen, et al., 1997; Sandercock, et al., 2014). Therefore, antiplatelet is 
a key in pharmacological treatment and prevention of CHD and cerebrovascular 
disease. The current antiplatelet agents available include acetylsalicylic acid 
(aspirin); thienopyridines (ticlopidine, clopidogrel, and prasugrel); reversible 
P2Y12 receptor antagonists (ticagrelor, cangrelor) and dipyridamole. In this 
section, we are going to discuss the background of antiplatelet development, 
their mechanism of action, their indications and their common side effects.  
 
1.6.1 Aspirin 
The first antiplatelet drug is acetylsalicylic acid or commonly known as aspirin. 
Aspirin was first developed in 1897 as an analgesic and antipyretic agent (Miner 
and Hoffhines, 2007). In 1968, Weiss, et al. (1968) found that aspirin may 
prolong bleeding time and inhibited platelet aggregation and subsequently few 
years later others (Smith and Willis, 1971; Hamberg, et al., 1975; Roth and 
Majerus, 1975) had found the molecular mechanism of action of aspirin. Since 
the first introduction of antiplatelet, several new antiplatelet agents have been 
developed and marketed (Figure 1-5).  
 
Antiplatelet drugs prevent thrombus formation and reduce platelet 
aggregation. Mechanisms of the platelet activation site and site of action of 
antiplatelet agents are shown in Figure 1-6. Aspirin has shown irreversible 
antiplatelet activity by reducing production of TxA2 through inhibition of the 
enzyme cyclooxygenase 1 (COX-1) (Roth and Majerus, 1975; Catella-Lawson, et 
al., 2001) and thus, inhibits thrombus formation and decreases platelet 
aggregation. Aspirin as antiplatelet therapy is used to prevent and reduce the 
risk of cardiovascular events. Aspirin is the most prescribed drug in antiplatelet 
therapy and cheaper than any other antiplatelet.  
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There are many trials have evaluated the effects of aspirin alone and in 
combination with P2Y12 inhibitor in patients with ACS. In patients with acute 
myocardial infarction and patients with previous myocardial infarction, 
antiplatelet therapy, aspirin reduced the outcome of any vascular event 
compared to placebo (Baigent, et al., 2002; Baigent, et al., 2009).  However, 
coronary lesions behave like unstable plaques and dual antiplatelet 
combination (e.g. aspirin plus clopidogrel) has proven to reduce cardiovascular 
death, nonfatal MI, or stroke compared to aspirin alone in non-ST elevation ACS 
(Yusuf, et al., 2001).  
 
 
 
 
Figure 1-5: Year of introduction of antiplatelet drugs to the clinical management of 
cardiovascular disease. 
[Ref: Sugidachi, et al. (2000); Sugidachi, et al. (2001); van Giezen and Humphries 
(2005); Born and Patrono (2006); Miner and Hoffhines (2007); Maffrand (2012)] 
 
 
Chapter 1 Introduction 46 
 
 
Figure 1-6: Platelet activation targets for antiplatelet agents.  
ADP=adenosine diphosphate, ATP=adenosine triphosphate, GP=glycoprotein, 
PAR=protease-activated receptor, TPa=thromboxane receptor protein antagonist, 
5HT=serotonin, 5HT2A=serotonin 2A receptor, αIIbβ3=GPIIb/IIIa. Adapted from Storey 
(2011) and Angiolillo (2012). (Permission obtained from Springer, License Number 
3957510629094) 
 
Aspirin has been proven to reduce recurrence stroke among patients with a 
recent stroke or TIA (Farrell, et al., 1991; Altman, et al., 1994). In a meta-
analysis conducted by Johnson, et al. (1999), aspirin reduces the risk of stroke 
by 15% compared with placebo in patients with previous TIA or stroke (risk ratio 
(RR), 0.85; 95% CI, 0.77-0.94). Another study by The SALT Collaborative Group 
(1991) also found aspirin alone reduced recurrent stroke or death in patients 
with TIA or minor ischaemic stroke compared with placebo. A time-course 
analysis of randomized trials by Rothwell, et al. (2016) found that aspirin 
reduces the six weeks risk of recurrent ischaemic stroke by 60% (HR, 0.42; 95% 
CI, 0.32-0.55) compared with controls and reduces disabling or fatal ischaemic 
stroke by 70% (HR, 0.29; 95% CI, 0.20-0.42). In the first six weeks after 
randomization in trials in secondary prevention after TIA and ischaemic stroke, 
patients treated with aspirin shifted to better functional outcome (OR, 0.42; 
95% CI, 0.26-0.70) (Rothwell, et al., 2016). 
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Antiplatelet therapy is indicated in patients undergone coronary artery bypass 
grafting (CABG) to prevent major complication such as graft occlusion and to 
prevent long-term cardiovascular events. Aspirin is essential to prevent platelet 
activation and should be initiated before undergoing surgery and continue long-
term therapy post-CABG (Baigent, et al., 2002; Kulik, et al., 2009; O'Gara, et 
al., 2012). In a meta-analysis of 17 randomized trials, aspirin was significantly 
reduced the odds of graft occlusion compared with placebo (odds ratio (OR), 
0.60; 95% CI, 0.51–0.71; p<0.0001) (Fremes, et al., 1993). 
 
1.6.2 Dipyridamole 
Dipyridamole was introduced in the early 1960s as a coronary vasodilator (Born 
and Patrono, 2006). Bunag, et al. (1964) found that dipyridamole inhibited 
adenosine uptake by platelet on platelet aggregation and soon few more studies 
(Emmons, et al., 1965; Elkeles, et al., 1968) found that dipyridamole inhibited 
platelet aggregation. Dipyridamole was then developed as an antithrombotic 
agent.  
 
Dipyridamole acts by increase local adenosine concentration and also inhibits 
intracellular phosphodiesterase (PDE) enzyme. By these two actions, 
intracellular cyclic adenosine monophosphate (cAMP) concentration increased 
and prevent platelet activation and aggregation (Harker and Kadatz, 1983). 
Dipyridamole is a prodrug and irreversible inhibit PDE. 
 
1.6.3 Ticlopidine 
Ticlopidine was first marketed in France in 1978 but the drug was found few 
years earlier by Dr Ferdinand Eloy. In 1972, he was looking for new anti-
inflammatory drugs related to Tinoridine, a thienopyridine with anti-
inflammatory and analgesics property. While he was testing these new 
compounds, none of the new compounds had anti-inflammatory or analgesic 
effect. However, some of these thienopyridine compounds showed antiplatelet 
and antithrombotic properties. This is where they found ticlopidine, one of the 
most active thienopyridine compound (Maffrand, 2012).   
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Ticlopidine is selective and irreversibly inhibits the P2Y12 receptor and prevent 
platelet activation. Ticlopidine is a prodrug and once absorbed in the intestine, 
they metabolized in the liver to form active metabolites (Savi and Herbert, 
2005). However, the usage of ticlopidine was limited because of severe 
haematological disorders and life threatening side effects, including 
leucopenia, neutropenia, thrombocytopenia, agranulocytosis, pancytopenia 
and thrombotic thrombocytopenic purpura. This led to the development of 
clopidogrel with an improved safety profile. 
 
Ticlopidine has been evaluated in three large trials of patients with 
cerebrovascular disease. In CATS (Canadian American Ticlopidine Study) trial, 
the risk of stroke, MI or vascular death was lowered in ticlopidine group 
compare to placebo (10.8% vs 15.3% per year; relative risk reduction (RRR), 
30.2%; 95% CI, 7.5-48.3%) in patients who had sustained a thromboembolic 
stroke (Gent, et al., 1989). In another trial, ticlopidine has been found to be 
superior to aspirin (Hass, et al., 1989). Due to ticlopidine life-threatening side 
effect, ticlopidine is rarely used in current clinical practice.  
 
1.6.4 Clopidogrel 
Due to the life-threatening side effect of ticlopidine, the researchers tried to 
look for more stable and powerful antiplatelet effect. They synthesized more 
than thousand ticlopidine analogues, and found dextrogyre (S)-isomer 
(clopidogrel) which is more active and better tolerated than ticlopidine 
(Maffrand, 2012). Clopidogrel was launched in 1998 after 10 years development.  
 
Clopidogrel has a similar mechanism of action as ticlopidine. It is selectively 
and irreversibly inhibit the P2Y12 receptor and prevent platelet activation. 
Clopidogrel is also a prodrug where it needs to metabolize in the liver to form 
active metabolites (Savi and Herbert, 2005). Clopidogrel used was limited to 
high inter-individual variability and potential of drug-drug interaction. 
However, clopidogrel is preferred over ticlopidine, as clopidogrel has better 
tolerability and enhanced safety (Bertrand, et al., 2000). 
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There are many data to support the clinical benefit of clopidogrel in the 
treatment of CVD. For example, in clopidogrel versus aspirin in patients at risk 
of ischemic events (CAPRIE) study, a randomized trial, to evaluate the efficacy 
of clopidogrel versus aspirin monotherapy in the secondary prevention of 
atherosclerotic vascular diseases. This study involved 19,185 patients observed 
that patients treated with clopidogrel had an 8.7% reduction in the relative risk 
of ischaemic stroke, MI or vascular death compared with aspirin (p=0.043) 
(Gent, et al., 1996). 
 
In the clopidogrel for high atherothrombotic risk and ischemic stabilization, 
management, and avoidance (CHARISMA) trial, a prospective, multicentre, 
randomized, double-blind, placebo-controlled study, compared the efficacy 
and safety of clopidogrel compared with placebo in aspirin treated patients. 
The combination of clopidogrel and aspirin demonstrated similar efficacy to 
aspirin among patients at high risk for a cardiovascular event in reducing MI, 
stroke or death (RR, 0.93; 95% CI, 0.83-1.05; p=0.22) (Bhatt, et al., 2006). 
 
Clopidogrel, when given together with aspirin and fibrinolytic therapy has been 
shown to reduce the rate of death or re-infarction without major increased 
bleeding risk following ST-elevation MI (Chen, et al., 2005; Sabatine, et al., 
2005b). Further, in the CURE trial, patients who presented within 24 hours after 
the onset of ACS were randomised to receive clopidogrel or placebo in addition 
to aspirin for 3 to 12 months. Compared to placebo, patients who were treated 
with clopidogrel had lower rates of death from cardiovascular causes, non-fatal 
MI or stroke (9.3 % vs 11.4 % in placebo) (Yusuf, et al., 2001). 
 
Intracoronary thrombosis is likely to occur following PCI, thus, aspirin and P2Y12 
inhibitors has been used to reduce the risk of stent thrombosis (Schomig, et al., 
1996; Bertrand, et al., 1998; Leon , et al., 1998). The combination of aspirin 
and ticlopidine has been shown to reduce the bleeding rates and subacute stent 
occlusion compared with an oral anticoagulant (Bertrand, et al., 1998). Few 
years later, another study by Bertrand, et al. (2000) demonstrated that 
clopidogrel and ticlopidine in combination with aspirin have similar efficacy in 
reducing cardiac events and the safety of clopidogrel is superior compared with 
ticlopidine. Recently, there is evidence that clopidogrel pre-treatment before 
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PCI significantly decreased the incidence of cardiac events (Mehta, et al., 2001; 
Sabatine, et al., 2005a). Major study findings of antiplatelet therapy for ACS 
are summarized in Table 1-4. 
 
For ACS patients treated with CABG, the combination of aspirin plus clopidogrel 
had a lower rate of graft occlusion (RR, 0.59; 95% CI, 0.43–0.82; p=0.02) and in-
hospital or 30-day mortality (0.8% vs 1.9%; p<0.0001) compared to aspirin alone 
(Deo, et al., 2013). In the TRITON-TIMI 38 trial, 346 CABG patients who were 
treated with prasugrel had a lower rate of death compared to patients treated 
with clopidogrel (adjusted OR, 0.26; 95% CI, 0.08–0.85; p=0.025) (Smith, et al., 
2012).  
 
Clopidogrel monotherapy is indicated for secondary prevention of stroke. In the 
prevention regimen for effectively avoiding second strokes (PRoFESS) trial, the 
efficacy and safety between clopidogrel versus aspirin plus extended-release 
dipyridamole regimen were compared. No difference was found in the risk of 
stroke recurrence between clopidogrel and aspirin plus extended-release 
dipyridamole (ERDP) (HR, 1.01; 95% CI, 0.92-1.11) (Sacco, et al., 2008).  
 
In the clopidogrel in high-risk patients with acute non-disabling cerebrovascular 
events (CHANCE) study, the combination of aspirin and clopidogrel versus 
aspirin alone were compared among patients with TIA or minor ischaemic 
stroke. In the first 90 days, aspirin plus clopidogrel group had lower risk of 
stroke compared those in the aspirin group (8.2% vs 11.7%; hazard ratio (HR), 
0.68; 95% CI, 0.57-0.81; p<0001) without increased risk of bleeding (Wang, et 
al., 2013). Major study findings of antiplatelet therapy following ischaemic 
stroke are summarized in Table 1-5. On the other hand, clopidogrel has become 
another reasonable option for those who is allergic to aspirin or unable to 
tolerate combination aspirin and dipyridamole.  
 
1.6.5 Prasugrel 
Prasugrel was found in 1993 by Japanese scientists. It is the third generation of 
thienopyridine. The group tested a series of hydropyridine compound and found 
some of the compound showed antithrombotic activities (Koike, et al., 1993). 
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They found prasugrel which is more potent than clopidogrel (Sugidachi, et al., 
2000; Sugidachi, et al., 2001). Prasugrel was launched in 2009 and approved by 
the United State Food and Drug Administration (US FDA). The mechanism of 
action of prasugrel is similar to other thienopyridine. 
 
Prasugrel has similar efficacy and risks of bleeding over clopidogrel in patients 
with unstable angina or NSTEMI treated medically. In TRILOGY-ACS trial, 
compared with clopidogrel, prasugrel therapy was not associated with 
significantly lowered rates of cardiovascular death, MI or stroke in 7243 with 
unstable angina or MI who did not undergo PCI (Roe, et al., 2012). 
 
Prasugrel is another proven antiplatelet used for the treatment of ACS after 
PCI. In the TRITON-TIMI 38 trial, prasugrel was compared with clopidogrel 
among aspirin treated patients with ACS scheduled for PCI. The rates of 
ischaemic complications were reduced in prasugrel treated group but the risk 
of major bleeding was increased (Wiviott, et al., 2007). 
 
1.6.6 Ticagrelor 
Ticagrelor, the first reversibly-binding oral ADP receptor antagonist, was 
launched in 2010. It was started when investigators looking for an analogue of 
ATP, a compound known to inhibit the ADP-induced platelet aggregation. A 
series of potent P2Y12 receptors’ antagonist was identified and discovered 
cangrelor. However, cangrelor is intravenous, short-acting and no clinical 
efficacy was found. Further development of P2Y12 receptors antagonist lead to 
identification of selective P2Y12 receptor antagonist, ticagrelor (van Giezen and 
Humphries, 2005). 
 
Ticagrelor is a non-thienopyridine agent. It is reversibly inhibit the P2Y12 
receptor and prevent platelet aggregation (Husted and van Giezen, 2009). 
Ticagrelor is not a prodrug, thus, it has a rapid onset of action that can be 
achieved within 30 minutes following the loading dose (Gurbel, et al., 2009). 
Ticagrelor has the shortest duration of the antiplatelet effect following 
cessation (Gurbel, et al., 2009) and it has no genetic variants of the CYP2C19 
gene compared with clopidogrel (Tantry, et al., 2010). 
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Ticagrelor, in combination with aspirin is also indicated for the treatment of 
ACS. The PLATO trial, the efficacy and safety of ticagrelor and clopidogrel was 
evaluated. The findings showed that among ACS patients treated with aspirin, 
ticagrelor significantly reduced the rate of ischaemic complications compared 
with clopidogrel (9.8% vs 11.7%; HR, 0.84; 95% CI, 0.77-0.92) (Wallentin, et al., 
2009a). 
 
Ticagrelor, co-administered with low-dose aspirin is also indicated for the 
treatment of post-ACS after PCI. In the PLATO trial, among 11,289 patients who 
received a stent and treated with aspirin, ticagrelor versus clopidogrel 
significantly reduced the rate of stent thrombosis (2.9% vs 3.8%; HR, 0.77; 95% 
CI, 0.62-0.95; p=0.01) (Wallentin, et al., 2009a). With this new evidence, 
ticagrelor is recommended over clopidogrel in post-ACS patients with PCI.  
 
The use of ticagrelor in ACS patients with CABG was supported by the post-hoc 
analysis of 1261 patients who underwent CABG within 7 days of receiving study 
drug treatment in PLATO. In this subgroup analysis, the occurrence of cardiac 
events at 1 year was similar in ticagrelor and clopidogrel (HR, 0.84; 95% CI, 
0.60-1.16; p=0.29). However, total mortality for ticagrelor was decreased 
compared with clopidogrel (4.7% vs 9.7%; HR, 0.49; 95% CI 0.32-0.77; p<0.01) 
(Held, et al., 2011). 
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Table 1-4: Key trials in antiplatelet therapy after ACS. 
Trial Details  Comparison  
Number of events/patients 
Effect size 
Intervention group Reference group 
NSTEMI / Unstable angina 
ARMYDA-2 
(Patti, et al., 
2005) 
USA/NSTE
MI (n = 255) 
Antiplatelet (600mg vs 300mg loading dose 
of clopidogrel) and risk of death, MI or 
target vessel revascularization 
High loading dose 
5/126 
Conventional 
loading dose  
16/129 
p-value=0.041 
CURE 
(Yusuf, et al., 
2001) 
USA/NSTE
MI (n = 
12,562) 
Antiplatelet (aspirin + clopidogrel vs 
aspirin) and risk of MI, stroke or CV death  
Aspirin + clopidogrel 
582/6259 
Aspirin + placebo 
719/6303 
RR=0.80, 95% 
CI: 0.72-0.90 
TRILOGY-
ACS 
(Roe, et al., 
2012)  
USA/NSTE
MI (n=7243) 
Antiplatelet (aspirin + prasugrel vs aspirin + 
clopidogrel) and risk of MI, stroke or CV 
death 
Aspirin + prasugrel 
364/3620 
Aspirin + clopidogrel 
397/3623 
HR=0.91, 95% 
CI: 0.79-1.05 
STEMI 
CLARITY 
(Sabatine, et 
al., 2005b) 
STEMI 
(n=3,491) 
Antiplatelet (aspirin + clopidogrel vs 
aspirin) and risk of TIMI flow grade 0 or 1, 
MI or death 
Aspirin + clopidogrel 
262/1752 
Aspirin + placebo 
377/1739 
OR=0.64, 95% 
CI: 0.53-0.76 
COMMIT 
(Chen, et al., 
2005) 
STEMI 
(n=45,852) 
Antiplatelet (aspirin + clopidogrel vs 
aspirin) and risk of death, MI or stroke 
Aspirin + clopidogrel 
2121/22961 
Aspirin + placebo 
2310/22891 
OR=0.91, 95% 
CI: 0.86-0.97 
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ACS 
CURRENT-
OASIS 7 
(Mehta, et al., 
2010) 
ACS (n= 
25,086) 
Antiplatelet (aspirin + clopidogrel 150mg vs 
aspirin + clopidogrel 75mg) and risk of MI, 
stroke or CV death 
Aspirin + clopidogrel 
150mg  
330/8560 
Aspirin + clopidogrel 
75mg  
392/8703 
Adjusted 
HR=0·86, 95% 
CI: 0.74-0.99 
PLATO 
(Wallentin, et 
al., 2009a) 
ACS (n= 
18,624) 
Antiplatelet (aspirin + ticagrelor vs aspirin + 
clopidogrel) and risk of MI, stroke or CV 
death  
Ticagrelor  
864/9333 
Clopidogrel 
1014/9291 
HR=0.84, 95% 
CI: 0.77-0.92 
Percutaneous coronary intervention 
ACCOAST 
(Montalescot, 
et al., 2013) 
NTSEMI 
before PCI 
(n=4033) 
Antiplatelet (aspirin + prasugrel vs aspirin) 
and risk of MI, stroke, urgent PCI or CV 
death  
Aspirin + prasugrel 
203/2037 
Aspirin + placebo 
195/1996 
HR=1.02, 95% 
CI: 0.84-1.25 
CLASSICS 
(Bertrand, et 
al., 2000) 
After 
coronary 
stenting 
(n=1,020) 
Antiplatelet (aspirin + clopidogrel vs aspirin 
+ ticlopidine) and risk of major peripheral 
or bleeding complications, neutropenia, 
thrombocytopenia or early discontinuation 
of study drugs 
Aspirin + clopidogrel 
31/680 
Aspirin + ticlopidine  
31/340 
RR=0.50, 95% 
CI: 0.31-0.81 
CREDO 
(Steinhubl, et 
al., 2002) 
Before 
coronary 
stenting 
(n=2,116) 
Antiplatelet (aspirin + clopidogrel for 12 
months vs aspirin + clopidogrel for 30 
days) and risk of death, MI or stroke 
Aspirin + clopidogrel 
for 12 months 
89/1053 
Aspirin + clopidogrel 
for 30 days  
122/1063 
RRR=26.9%, 
95% CI: 3.9-44.4 
FANTASTIC 
(Bertrand, et 
al., 1998) 
After 
coronary 
stenting 
(n=439) 
Antiplatelet vs anticoagulant and risk of 
subacute stent occlusion  
Aspirin + ticlopidine 
1/249 
Anticoagulant + 
aspirin 
8/236 
OR=0.12, 95% 
CI: 0.01-0.91 
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ISAR 
(Schomig, et 
al., 1996) 
After 
coronary 
stenting 
(n=257) 
Antiplatelet vs anticoagulant and risk of MI, 
CV death, aorta coronary bypass surgery 
or repeated angioplasty  
Ticlopidine  
4/257 
Phenprocoumon 
16/260 
RR=0.25, 95% 
CI: 0.06-0.77 
PCI-
CLARITY 
(Sabatine, et 
al., 2005a) 
STEMI-PCI 
(n=1863) 
Antiplatelet (aspirin + clopidogrel vs 
aspirin) and MI, CV death or stroke from 
PCI 
Aspirin + clopidogrel 
34/933 
Aspirin + placebo 
58/930 
OR=0.54, 95% 
CI: 0.35-0.85 
PCI-CURE 
(Mehta, et al., 
2001) 
NSTEMI-
PCI 
(n=2658) 
Antiplatelet (aspirin + clopidogrel vs 
aspirin) and risk of MI, CV death or urgent 
angioplasty 
Aspirin + clopidogrel 
59/1313 
Aspirin + placebo 
86/1345 
RR=0.70, 95% 
CI: 0.50-0.97 
PRAGUE-18 
(Motovska, et 
al., 2016) 
AMI with 
PCI 
(n=1230) 
Antiplatelet (aspirin + ticagrelor vs aspirin + 
prasugrel) and risk of death, re-infarction, 
urgent revascularization, stroke, bleeding 
Aspirin + ticagrelor 
24/596 
Aspirin + prasugrel 
25/634 
OR=0.98, 95% 
CI: 0.55-1.73 
TRITON-TIMI 
38 
(Wiviott, et 
al., 2007) 
Moderate to 
high risk 
ACS 
scheduled 
for PCI 
(n=13,608) 
Antiplatelet (aspirin + prasugrel vs aspirin + 
clopidogrel) and risk of MI, stroke or CV 
death  
Aspirin + prasugrel 
643/6813 
Aspirin + clopidogrel 
781/6795 
HR=0.81, 95% 
CI: 0.73-0.90 
ACCOAST=Pre-treatment at the Time of Diagnosis in Patients with Non-ST Elevation Myocardial Infarction, ACS=acute coronary syndrome, ARMYDA=Atorvastatin for 
Reduction of MYocardial Damage during Angioplasty, CI=confidence interval, CLARITY= Clopidogrel as Adjunctive Reperfusion Therapy, CLASSICS=CLopidogrel 
ASpirin Stent International Cooperative Study, COMMIT=ClOpidogrel and Metoprolol in Myocardial Infarction Trial, CREDO=Clopidogrel for the Reduction of Events 
During Observation, CURE=Clopidogrel in Unstable Angina to Prevent Recurrent Events, CURRENT-OASIS 7= Clopidogrel and Aspirin Optimal Dose Usage to Reduce 
Recurrent Events−Seventh Organization to Assess Strategies in Ischemic Syndromes, CV=cardiovascular, HR=hazard ratio, ISAR= Intracoronary Stenting and 
Antithrombotic Regimen, MI=myocardial infarction, NSTEMI=non-ST-elevation MI, OR=odds ratio, PCI=Percutaneous coronary intervention, PLATO= Platelet 
Inhibition and Patient Outcomes, RR=relative risk, STEMI=ST-elevation MI, TRILOGY-ACS= Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically 
Manage Acute Coronary Syndromes, TRITON-TIMI= Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–
Thrombolysis in Myocardial Infarction, USA=unstable angina. 
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Table 1-5: Key trials in antiplatelet therapy after ischaemic stroke. 
Trial Details  Comparison  
Number of events/patients 
Effect size 
Intervention group Reference group 
CATS 
(Gent, et al., 
1989) 
Thromboem
bolic stroke 
(n=1072) 
Antiplatelet (ticlopidine vs placebo) and risk 
of stroke, MI, or vascular death 
Ticlopidine 
74/525 
Placebo 
118/528 
RRR=30.2%, 
95% CI: 7.5-48.3 
CHANCE 
(Wang, et al., 
2013) 
TIA or minor 
stroke 
(n=5,170) 
Antiplatelet (aspirin + clopidogrel vs 
aspirin) and risk of stroke 
Aspirin + clopidogrel 
212/2584 
Aspirin alone 
303/2586 
HR=0.68. 95% 
CI: 0.57-0.81 
EARLY 
(Dengler, et 
al., 2010) 
Acute 
ischaemic 
stroke, 
NIHSS≤20 
(n=543) 
Antiplatelet (early aspirin + dipyridamole vs 
aspirin + dipyridamole after 7 days aspirin) 
and risk of vascular adverse events and 
death 
Early aspirin + 
dipyridamole  
28/283 
Aspirin + later 
dipyridamole 
38/260 
HR=0·73, 95%  
CI: 0.44-1.19 
ESPRIT 
(Halkes, et al., 
2006) 
TIA or minor 
stroke 
(n=2,739) 
Antiplatelet (aspirin + dipyridamole vs 
aspirin) and risk of death from all vascular 
causes, stroke, MI or major bleeding 
Aspirin + 
dipyridamole 
173/1363 
Aspirin alone 
216/1376 
HR=0.80, 95% 
CI: 0.66-0.98 
ESPS-2 
(Diener, et al., 
1996) 
Recent IS or 
TIA 
(n=6602) 
Antiplatelet (aspirin + dipyridamole vs 
placebo) and risk of death and/or stroke 
Aspirin + 
dipyridamole 
286/1650 
Placebo  
378/1649 
OR=0.71, 95% 
CI: 0.59-0.84 
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FASTER 
(Kennedy, et 
al., 2007) 
TIA or minor 
stroke 
(n=392) 
Antiplatelet (aspirin + clopidogrel vs 
aspirin) and risk of stroke  
Aspirin + clopidogrel 
14/198 
Aspirin alone  
21/194 
RR=0.70, 95% 
CI: 0.3-1.2 
IST 
(International 
Stroke Trial 
Collaborative 
Group, 1997) 
IS 
(n=19,435) 
Antiplatelet (aspirin vs placebo) and risk of 
any cause (stroke, CHD, PE, ECH, 
vascular or non-vascular cause)  
Aspirin  
872/9720 
Placebo 
909/9715 
Event prevented 
4 per 1000 (SD 4) 
MATCH 
(Diener, et al., 
2004) 
Recent IS or 
TIA 
(n=7,599) 
Antiplatelet (aspirin + clopidogrel vs 
clopidogrel) and risk of MI, stroke, vascular 
death or rehospitalisation for acute 
ischaemia  
Aspirin + clopidogrel 
596/3797 
Clopidogrel alone 
636/3802 
RRR=6.4%, 95% 
CI: -4.6-16.3 
PROFESS 
(Sacco, et al., 
2008) 
Recent IS 
(n=20,332) 
Antiplatelet (aspirin + dipyridamole vs 
clopidogrel) and risk of first recurrence of 
stroke 
Aspirin + 
dipyridamole 
916/10,181  
Clopidogrel 
898/10,151 
HR=1.01, 95% 
CI: 0.92-1.11 
SOCRATES 
(Johnston, et 
al., 2016) 
High risk 
TIA or non-
severe 
stroke 
(n=13199) 
Antiplatelet (ticagrelor vs aspirin) and risk 
of stroke, MI, death 
Ticagrelor 
442/6589 
Aspirin 
497/6610 
HR=0.89, 95% 
CI: 0.78-1.01 
SPS3 (The 
SPS3 
Investigators, 
2012) 
Symptoma-
tic lacunar 
infarct 
(n=3020) 
Antiplatelet (aspirin + clopidogrel vs 
aspirin) and risk of recurrent stroke 
Aspirin + clopidogrel 
125/1517 
Aspirin 
138/1503 
HR=0.92, 95% 
CI, 0.72-1.16 
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TASS 
(Hass, et al., 
1989) 
Cerebral/ 
retinal 
ischaemia 
or TIA 
(n=3069) 
Antiplatelet (ticlopidine vs aspirin) and risk 
of recurrence of stroke 
Ticlopidine Aspirin 
RRR=21%, 95% 
CI: 4-38 
CATS=Canadian American Ticlopidine Study, CHANCE= Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events, 
CI=confidence interval, CHD=coronary heart disease, CV=cardiovascular, EARLY=Early treatment with aspirin plus extended-release dipyridamole for 
transient ischaemic attack or ischaemic stroke within 24 h of symptom onset, ECH=extracranial haemorrhage, ESPRIT= European/Australasian Stroke 
Prevention in Reversible Ischaemia Trial, ESPS-2=Second European Stroke Prevention Study, FASTER= Fast Assessment of Stroke and TIA to prevent 
Early Recurrence, HR=hazard ratio, IS=ischaemic stroke, IST=International Stroke Trial, MATCH=Management of ATherothrombosis for Continued 
Health, MI=myocardial infarction, NIHSS=National Institutes of Health Stroke Scale, OR=odds ratio, PE=pulmonary embolism, PRoFESS=Prevention 
Regimen For Effectively avoiding Second Strokes, RRR=relative risk reduction, SD=standard deviation, SOCRATES=Acute Stroke or Transient Ischaemic 
Attack Treated with Aspirin or Ticagrelor and Patient Outcomes, SPS3=Secondary Prevention of Small Subcortical Strokes, TASS=Ticlopidine ASpirin 
Stroke trial, TIA=transient ischaemic attack. 
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1.7 Current antiplatelet therapy guidelines 
Antiplatelet therapy is a cornerstone of treatment for patients with 
atherosclerotic vascular disease. We have discussed pathophysiology of ACS and 
ischaemic stroke in the previous section and we understood that these events 
are triggered by rupture of atherosclerotic plaque which results in platelet 
activation and formation of thrombus. Therefore, therapeutic platelet 
inhibition is a crucial aspect of ACS and stroke management and secondary 
prevention. Antiplatelet therapy is also indicated for secondary prevention in 
patients discharged from hospital following post–PCI, and post–CABG, TIA and 
patients with peripheral arterial disease (PAD).  
 
1.7.1 ACS and PCI 
In patients presented or suspected with STEMI, the National Institute for Health 
and Care Excellence (NICE) and Scottish Intercollegiate Guidelines Network 
(SIGN) guidelines recommend a loading dose of aspirin 300mg in all patients and 
followed by aspirin 75mg daily as maintenance therapy and continued 
indefinitely (National Institute for Health and Care Excellence, 2013; Scottish 
Intercollegiate Guidelines Network (SIGN), 2013a). In those patients to be 
treated with primary PCI, a loading dose of ticagrelor 180mg is recommended 
followed by maintenance therapy with 90mg twice daily for up to 12 months 
(National Institute for Health and Clinical Excellence, 2011). 
 
In patients who had STEMI and treated with a bare metal stent (BMS) or drug 
eluting stent (DES), a loading dose of clopidogrel 300mg or 600mg is 
recommended. Clopidogrel 75mg daily is then continued for up to 12 months. 
On the other hand, in patients with STEMI and medically managed with or 
without thrombolytic agent, clopidogrel 75mg daily should be continued for at 
least one month and may consider to continue for up to 12 months (Chen, et 
al., 2005; Sabatine, et al., 2005b; National Institute for Health and Clinical 
Excellence, 2013). NICE guideline recommends prasugrel as a treatment of 
option in those to be treated for primary PCI, patients with stent thrombosis 
while on clopidogrel or patients who had diabetes (National Institute for Health 
and Clinical Excellence, 2014). 
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In patients with NSTEMI or unstable angina, initial treatment includes a loading 
dose aspirin 300mg and ticagrelor 180mg or clopidogrel 300mg (Yusuf, et al., 
2001; Wallentin, et al., 2009a). A maintenance dose of aspirin 75mg daily should 
be continued indefinitely. It is recommended ticagrelor 90mg twice daily or 
clopidogrel 75mg daily continued as maintenance therapy for up to 12 months 
(National Institute for Health and Care Excellence, 2010; National Institute for 
Health and Clinical Excellence, 2010; National Institute for Health and Clinical 
Excellence, 2011).  
 
For all patients with ACS, following hospital discharge, it is recommended to 
continue low dose aspirin for a long term without interruption. For patients 
allergic or intolerance of aspirin, clopidogrel is indicated as an alternative to 
aspirin (Gent, et al., 1996). The recommended duration of antiplatelet therapy 
for ACS patients with or without PCI are summarized in Table 1-6. 
 
For ACS patients with obstruction coronary arteries, PCI is indicated to induce 
atherosclerotic plaque rupture and followed by the implantation of stent in the 
artery. PCI has been proven to reduce rates of recurrent angina, 
rehospitalisation, MI and death (Bavry, et al., 2006; Hoenig, et al., 2010). DAPT 
is prescribed at the time of procedure and following the placement of BMS or 
DES in order to prevent stent thrombosis (Mehta, et al., 2001; Steinhubl, et al., 
2002). 
  
Chapter 1 Introduction 61 
Table 1-6: Recommended duration of antiplatelet therapy  
Antiplatelet 
drug and 
dosage 
Indication Duration 
Aspirin  
(300mg loading, 
then 75-150mg 
daily) 
ACS (with or without PCI) Long term 
TIA or ischaemic stroke Long term (alone) 
Clopidogrel  
(300-600mg 
loading, then 
75mg daily) 
Unstable angina/ NSTEMI (medically 
managed) 
At least 1 month 
and up to 12 months 
Unstable angina/ NSTEMI (with PCI 
and BMS or DES) 
At least 12 months 
Unstable angina/ NSTEMI (managed 
by CABG) 
Minimum 1 months 
and up to 12 months 
STEMI (with or without fibrinolysis) At least 1 month or 
up to 12 months 
STEMI (with PCI and BMS or DES) At least 12 months 
TIA or ischaemic stroke Long term (alone) 
Prasugrel  
(60mg loading, 
then 10mg 
daily) 
STEMI (with PCI and BMS or DES) At least 12 months 
Ticagrelor  
(180mg loading, 
then 90mg 
twice a day) 
Unstable angina/ NSTEMI (moderate 
to high risk*) 
Up to 12 months 
Unstable angina/ NSTEMI (medically 
managed) 
Up to 12 months 
Unstable angina/ NSTEMI (with PCI 
and BMS or DES) 
At least 12 months 
Unstable angina/ NSTEMI (managed 
by CABG) 
At least 12 months 
STEMI (with PCI and BMS or DES) At least 12 months 
Dipyridamole 
ER (200mg 
twice a day) 
TIA or ischaemic stroke Long term (alone) 
*as defined in ≥2 or more of (1) ischaemic ST changes on electrocardiogram; (2) 
positive biomarkers; or (3) 1 of the following: ≥60 years of age, previous MI or CABG, 
Coronary artery disease >50% stenosis in 2 vessels, previous ischaemic stroke, 
diabetes, peripheral arterial disease, or chronic renal dysfunction.  
ACS=acute coronary syndrome, BMS=bare-metal stents, CABG= coronary artery bypass 
grafting, DES=drug-eluting stents, ER= extended-release, PCI=percutaneous coronary 
intervention, TIA=transient ischaemic attack. (Wallentin, et al., 2009a; Bell, et al., 
2011; National Institute for Health and Clinical Excellence, 2011; O'Gara, et al., 
2012; Scottish Intercollegiate Guidelines Network (SIGN), 2013a; Tanguay, et al., 
2013; Amsterdam, et al., 2014) 
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1.7.2 Ischaemic stroke 
Following TIA or non-cardioembolic stroke, patients should be treated with 
antiplatelet therapy. NICE and SIGN guidelines on the management of acute 
ischaemic stroke and TIA recommend that for patients who had a suspected 
TIA, either high or low risk, aspirin 300mg daily should be started immediately. 
Whereas for patients with acute ischaemic stroke, as soon as possible, aspirin 
300mg should be given within 24 hours of symptom onset. Thereafter, aspirin 
should be continued for 2 weeks after the onset of stroke symptoms, at which 
time definitive long term antiplatelet therapy should be initiated (National 
Institute for Health and Clinical Excellence, 2008; Scottish Intercollegiate 
Guidelines Network (SIGN), 2008). An alternative antiplatelet agent should be 
given for those who is allergic or intolerant to aspirin. 
 
In recent NICE and SIGN guidelines, clopidogrel is recommended as an option 
for patients diagnosed with ischaemic stroke. DAPT with aspirin and modified-
release dipyridamole is recommended for those patients with TIA or patients in 
whom clopidogrel is contraindicated or not tolerated (National Institute for 
Health and Clinical Excellence, 2010; Scottish Intercollegiate Guidelines 
Network (SIGN), 2013b). 
 
1.7.3 Peripheral artery disease (PAD) 
Antiplatelet therapy is also recommended for vascular prevention in patients 
with PAD. There are two types of patients with PAD, asymptomatic and 
symptomatic patients. For patients with asymptomatic PAD, with either a bruit 
along the major blood vessel or reduced or absent peripheral pulsation with an 
ankle-brachial index (ABI) ≤ 0.9, low-dose aspirin may be considered. Aspirin is 
indicated for those with high risk of atherosclerotic risk factors and without risk 
for bleeding (Fowkes, et al., 2010). For patients with symptomatic PAD with 
evident IHD or cerebrovascular disease, antiplatelet therapy is as indicated for 
ACS or ischaemic stroke treatment, which have been discussed in the previous 
section. Whereas for patients without IHD or ischaemic stroke, low-dose aspirin 
or clopidogrel is recommended, providing the risk of bleeding is low (Berger, et 
al., 2009). 
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NICE guidelines on the management of lower limb PAD recommend aspirin 75mg 
daily (National Institute for Health and Clinical Excellence, 2012). The dose was 
as effective as higher doses. The NICE technology appraisal 210 (National 
Institute for Health and Clinical Excellence, 2010) recommends clopidogrel as 
an option for those with PAD. However, in treating patients with PAD, 
combination therapy of aspirin and clopidogrel should be used cautiously as the 
combination of both drugs had a higher risk of bleeding complications (Bhatt, 
et al., 2006). 
 
1.7.4 Duration of antiplatelet therapy 
According to NICE guidelines for management of ischaemic stroke and PAD, 
antiplatelet regimen should be continued for a long term in order to reduce the 
risk of recurrence event. Whereas, for ACS with or without PCI, after a period, 
DAPT is stopped and continue with mono antiplatelet therapy. The reason 
behind this is that the long term usage of DAPT beyond certain period does not 
lower the risk of major cardiovascular event and at the same time, it is 
associated with an increased risk of bleeding. Table 1-6 summarized the 
recommendation duration of DAPT in patients with ACS. 
 
1.7.5 Adverse events of antiplatelet therapy 
Antiplatelet therapy is associated with adverse events like gastrointestinal and 
non-gastrointestinal bleeding, intracranial haemorrhage (ICH) and allergic 
reactions (swelling of the lips, tongue or face, coughing, wheezing or shortness 
of breath and anaphylaxis). The risk of bleeding due to antiplatelet therapy is 
because antiplatelet inhibits platelet activation or aggregation pathways 
(Meadows and Bhatt, 2007). There are about 3% incidence of gastrointestinal 
tract bleeding in patients treated with antiplatelet (Alli, et al., 2011). Bleeding 
at puncture and surgery site is another common types of bleeding, especially in 
patients undergoing PCI or CABG surgery, with an incidence of 1-2% patients 
(Mehta, et al., 2001; Kastrati, et al., 2004; Kapetanakis, et al., 2006). However, 
among patients treated with antiplatelet therapy, ICH is rare but it is associated 
with increased death (Gent, et al., 1996; Yusuf, et al., 2001; Chen, et al., 2005; 
Sandercock, et al., 2014). 
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Aspirin is associated with an increased risk of bleeding that is mainly 
gastrointestinal and rarely intracranial when compared with placebo. Low-dose 
aspirin (<100mg) was associated with the lowest risk, and moderate doses (100-
200mg) caused slightly high bleeding event rate, particularly in minor, 
gastrointestinal, stroke and total bleeding (Serebruany, et al., 2005a). Side 
effects of aspirin include allergic reaction and gastrointestinal complications. 
The risk of symptomatic ulcer was higher in aspirin user compared to non-users 
and increased with any doses as low as 75mg daily (García Rodríguez and 
Hernández-Díaz, 2004). 
 
Incidence of ICH and gastrointestinal bleeding in clopidogrel is comparable with 
aspirin (Gent, et al., 1996). However, a combination of DAPT is associated with 
an increased risk of bleeding than those who received aspirin alone (Yusuf, et 
al., 2001). Other side effects of clopidogrel are gastrointestinal problems. 
Severe rash also associated with clopidogrel which was more frequent with 
clopidogrel than aspirin (Gent, et al., 1996). Neutropenia was rare with 
clopidogrel. Although prasugrel reduced the incidence of ischaemic events 
when compared with clopidogrel, prasugrel was found to associate with about 
30% increase in the relative risk of bleeding (Wiviott, et al., 2007). Adverse 
reactions following prasugrel include hypersensitivity reaction including 
angioedema and thrombotic thrombocytopenic purpura . 
 
On the other hand, ticagrelor has similar rates of total major bleeding or life-
threatening or fatal bleeding when compared with clopidogrel (Wallentin, et 
al., 2009a; Cannon, et al., 2010). Ticagrelor is associated with dyspnea. 
Incidence of dyspnea in patients treated with ticagrelor was between 14% to 
39% and it was reported higher in ticagrelor group compared with clopidogrel 
(Wallentin, et al., 2009b; Storey, et al., 2010). 
 
Hematologic adverse reactions are a known adverse event caused by 
ticlopidine. Ticlopidine is associated with an incidence of neutropenia of up to 
2.1% of ticlopidine-treated patients (Gent, et al., 1989). Other side effects of 
ticlopidine include diarrhea, nausea and vomiting and occur in 30% to 50% of 
patients (McTavish, et al., 1990). 
 
Chapter 1 Introduction 65 
Recently, there are doubts about the safety of discontinuation of DAPT in ACS 
population (Ho, et al., 2010; Charlot, et al., 2012), and this is discussed in 
details in the next section.  
 
1.8 Can antiplatelet be better targeted?  
Despite major improvements in antiplatelet therapy, ischaemic complications 
remain a concern after ACS and ischaemic stroke. Recently, there have been 
reports of increased risk of cardiovascular events from discontinuation of 
antiplatelet therapy (D'Ascenzo, et al., 2014). This cardiovascular event 
includes all-cause mortality, hospitalization for MI and/or stent thrombosis (Ho, 
et al., 2010; Mehran, et al., 2013). In this section, we are going to discuss the 
risk of cardiovascular event in patients, despite with antiplatelet therapy, in 
those who changed from DAPT to single antiplatelet and those who stopped or 
interrupted antiplatelet treatment. 
 
1.8.1 Cardiovascular event despite antiplatelet therapy 
Survivors of MI and ischaemic stroke are at increased risk of recurrent 
infarctions and recurrent ischaemic stroke. They have been prescribed with 
evidence based interventions for secondary prevention includes the use of 
antiplatelet therapy. However, there is evidence that the cardiovascular event 
still occurred despite the use of antiplatelet therapy in these populations. 
 
In ACS patients, despite treatment with antiplatelet therapy, recurrent MI 
occurred. In a study by DÖnges, et al. (2001), 91% of the patients with recurrent 
MI had been prescribed with aspirin therapy previously. Later, a study by Thune, 
et al. (2011) also showed that in their recurrent MI sample, 89.2% of patients 
had been taking aspirin before the recurrent event.  
 
Antiplatelet therapy indicated for acute ischaemic stroke or TIA are for a long 
term. Similarly, a cardiovascular event still occurred, whilst patients still taking 
antiplatelet therapy. In the recently published CHANCE study, at least 20% of 
patients had a history of previous stroke and 11% of patients had their index 
stroke whilst taking antiplatelet therapy (Wang, et al., 2013). In North Dublin 
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Stroke study, 34.8% patients in their sample were taking antiplatelet therapy 
before first-ever stroke (Kelly, et al., 2012). However, there was not mentioned 
any assessment on medication adherence before the hospital admission. At the 
same time, guidelines acknowledge that in patients who experience a stroke 
whilst taking antiplatelet therapy, there are no clinical trials to show whether 
switching antiplatelet agents decreases the risk of subsequent events (Furie, et 
al., 2011; Kernan, et al., 2014). 
 
This evidence, has raised questions what are the possibilities that the events 
happened in these patients. There are many factors associated with 
antiplatelet response. There might be resistance or non-response to 
antiplatelet agent. Published data suggest that underdosing, poor compliance, 
poor drug absorption, drug–drug interaction and stress-induced generation 
enzyme cyclooxygenase (COX-2) in platelets or polymorphisms of COX-1 might 
be responsible for the insufficient response to aspirin (Michos, et al., 2006). 
The mechanism of aspirin and clopidogrel resistance are likely to be 
multifactorial and figure 1-7 summarised possible causes for aspirin and 
clopidogrel resistance. 
 
Resistance to antiplatelet therapy might be one of the reasons behind this 
event. Resistance to clopidogrel and aspirin exists and studies have shown that 
aspirin or clopidogrel resistance is associated with an increased risk of 
cardiovascular events (Matetzky, et al., 2004; Mason, et al., 2005; Ozben, et 
al., 2011). Resistance to aspirin is common and may be present in 25 to 30% of 
patients (Alberts, et al., 2004; Hovens, et al., 2007). Studies by Bennett, et al. 
(2008), Boncoraglio, et al. (2009) and Ozben, et al. (2011) did not find any 
significant difference between aspirin-resistant and aspirin-sensitive patients 
with regard to demographics, clinical characteristics, and risk factors. At the 
same time, Karepov, et al. (2008) reported that patients with aspirin resistance 
had significantly increased level of triglycerides compared with aspirin-
sensitive patients. Moreover, Jeon and Cha (2008) and Ozben, et al. (2011) 
found that patients with aspirin resistance had higher stroke severity scores and 
Englyst, et al. (2008) pointed out that patients with aspirin resistance is 
associated with more severe strokes.  
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The dose of aspirin is important to prevent aspirin resistance. Inadequate dosing 
due to poor gastrointestinal absorption maybe possible. There are studies found 
enteric-coated aspirin had insufficient and decreased antiplatelet effect 
compared to plain aspirin (Maree, et al., 2005; Cox, et al., 2006; Peace, et al., 
2010). On the other hand, low-dose of aspirin has been found to reduce 
antiplatelet effect. Lee, et al. (2005) found aspirin dose less than 100mg/day 
is associated with a higher incidence of aspirin resistance in patients with 
coronary artery disease. Moreover, interaction of antiplatelet agent with other 
medications may reduce antiplatelet efficacy. For examples, between aspirin 
and nonsteroidal anti-inflammatory drugs (Catella-Lawson, et al., 2001); or 
clopidogrel and omeprazole (Sibbing, et al., 2009). 
 
Another possible mechanism associates with antiplatelet resistance is increased 
platelet turnover. Previous studies suggested that patients with accelerated 
platelet turnover may have reduced antiplatelet effects (Kour, et al., 2006; 
Airee, et al., 2008; Zimmermann and Hohlfeld, 2008; Li, et al., 2009; Grove, et 
al., 2011). A study by Grove, et al. (2011) pointed out that smoking, diabetes 
and thrombopoietin levels were identified as significant predictors of platelet 
turnover. Synthesis of thromboxane A2 by COX-2 may be another possible cause 
of aspirin resistance but inhibition of COX-2 might need higher doses of aspirin 
(500mg/day) (Kour, et al., 2006; Airee, et al., 2008). Other than COX-2, 
platelets can be activated towards other aggregating factors such as 
erythrocyte induced platelet activation; cigarette smoking; or diabetic patients 
caused increased production of prostaglandin F2 (Kour, et al., 2006; Gupta and 
Casterella, 2007; Airee, et al., 2008; Zimmermann and Hohlfeld, 2008; Li, et 
al., 2009). 
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(a) 
Reduced aspirin bioavailability 
Failure to prescribe 
Poor compliance 
Inadequate dose 
Enhanced metabolism 
Interaction with other medications 
Concurrent administration of NSAIDS 
leading to competition for active 
binding site 
 
Alternative pathways of platelet 
activation 
Cytokine induced activation of COX-2 
leading to TXA2 synthesis despite 
presence of aspirin 
Direct platelet activation by increased 
levels of catecholamine 
Oxidave stress leading to production of 
TXA2 through pathways not blocked 
by aspirin 
Generation of COX-1 in nucleated cells 
augmenting TXA2 production 
 
 
 Genetic variation 
Mutation and/or polymorphism of 
COX-1 gene 
Platelet glycoprotein receptor 
polymorphism 
Overexpression of COX-2 in 
platelets and endothelial cells 
 
Accelerated platelet turnover 
Increased platelet production by the 
bone marrow in response to stress 
Introducing new platelets unexposed to 
aspirin 
    
(b) Reduced clopidogrel bioavailability 
Failure to prescribe 
Poor compliance 
Inadequate dose (perhaps in ACS or 
stenting) 
Enhanced metabolism 
Interaction with other medications 
involving the cP450 CYP3A4 
system 
 
Baseline individual variability 
Increased baseline platelet reactivity 
Increased body mass index 
Diabetes or insulin resistance 
Up-regulation of other platelet 
pathways in setting of stress 
Variations in metabolism by cP450 
CYP3A4 
  
 
Genetic variation 
Polymorphism of the P2Y12 gene 
Polymorphism of the P450 CYP3A 
gene 
 
Accelerated platelet turnover 
Increased platelet production by the 
bone marrow in response to stress 
Introducing new platelets unexposed 
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Figure 1-7: Proposed mechanisms for (a) aspirin and (b) clopidogrel resistance.  
ACS=acute coronary syndrome; COX=cyclooxygenase; NSAIDs=nonsteroidal anti-
inflammatory drugs; TXA2=thromboxane A2. (Permissions obtained from Elsevier, 
License Number 3742560329349)(Michos, et al., 2006) 
Aspirin 
resistance 
Clopidogrel 
resistance 
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Genetic polymorphisms involved in platelet activation may lead to less 
antiplatelet effect. For example, individuals with genetic variants of CYP2C19*2 
and CYP2C19*3, had a decreased conversion of clopidogrel to its active 
metabolite (Hulot, et al., 2006; Mega, et al., 2009; Sofi, et al., 2011). Thus, 
they may experience a subsequent thrombotic event despite receiving 
clopidogrel (Kour, et al., 2006; Gupta and Casterella, 2007; Gurbel and Tantry, 
2007; Airee, et al., 2008; Zimmermann and Hohlfeld, 2008; Bonello, et al., 
2009; Li, et al., 2009). On the contrary, prasugrel may offer as an alternative 
in clopidogrel resistance as it is not activated in the liver (Gupta and Casterella, 
2007; De Miguel, et al., 2008; Bonello, et al., 2009; Angiolillo, et al., 2010). 
 
It is possible that patients who resistance to a certain antiplatelet agent should 
be switched to another class of antiplatelet. Furthermore, there are no trials 
to show switching antiplatelet agents after an acute event decreases the risk 
of subsequent events. Thus, we are going to answer this question by using acute 
stroke trial population. 
 
1.8.2 Risks of changing from DAPT to single 
Antiplatelet therapy is required after an ACS. DAPT typically using aspirin and 
an ADP receptor antagonist such as clopidogrel, is superior to use than a single 
agent in terms of reducing subsequent cardiovascular risk. There were patients 
who experience thrombotic events within the first 3 to 6 months after 
completed the recommended duration of DAPT.  
 
There are reports supported the cardiovascular risk is increased in the period 
following cessation of DAPT and initiation of monotherapy. This has been 
reported in both medically and PCI-treated patients after ACS. In 2008, a study 
from the Veterans Health Administration (Ho, et al., 2008b) found the first 90 
days after stopping clopidogrel were associated with an increased risk of 
cardiovascular events. Later on, another study by Ho, et al. (2010) found a 
higher risk of death or MI at day 0 to 90 days compared to day 91 to 180 days 
after stopping clopidogrel. They found the risk of death or MI in the 0-90-day 
interval after clopidogrel cessation was two times higher compared with later 
time intervals. The timing of the events suggests they are specific to clopidogrel 
discontinuation and there were no differences in terms of the type of stent 
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used. Further, they found no increase in event rate after stopping ACE inhibitors 
further suggesting a causal relationship with clopidogrel cessation rather than 
a general effect of discontinuing medications. 
 
The evidence of cardiovascular event after DAPT discontinuation did not only 
observed in observational studies, but also observed in a systematic review and 
meta-analysis which has higher power and precision of estimates of treatment 
effects and exposure risks. In a systematic review and meta-analysis of 49,586 
patients found that ACS patients undergoing PCI experienced more 
cardiovascular events (OR, 1.19; 95% CI, 1.07–1.32) than medically-treated 
patients (OR, 1.13; 95% CI, 0.95–1.35) if they stopped DAPT over 12 months 
(D'Ascenzo, et al., 2014). They concluded that this result was hypothesis 
generating and should be confirmed in randomized controlled trials. 
 
There is one prospective observational study tried to address these clinical 
important issues. The Patterns of non-adherence to Antiplatelet Regimens In 
Stented patients (PARIS) study recently showed that the effect of DAPT 
cessation on cardiac risk after PCI may be related to the reason that DAPT was 
stopped. This study includes patients undergoing PCI with stent implantation 
and followed them up at 1, 6, 12 and 24 months after implantation. They found 
out that there was no excess risk if DAPT was stopped as planned post ACS. 
Where it was interrupted due to a planned procedure such as surgery there was 
similarly no increased risk. However, where DAPT was stopped due to bleeding 
or non-compliance, there was an increased risk (Mehran, et al., 2013). 
 
In patients undergoing PCI, stent thrombosis is the common cardiovascular 
event occurred after discontinuation of DAPT. Iakovou, et al. (2005) found that 
premature DAPT discontinuation as an independent predictors of stent 
thrombosis. Similarly, Park, et al. (2006) found the incidence of stent 
thrombosis is significantly increased in patients with premature discontinuation 
of aspirin or clopidogrel or both. Later, Airoldi, et al. (2007) showed 
discontinuation of thienopyridine therapy was the predictors of stent 
thrombosis within the first six months.  
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It is clear that data showed cessation of DAPT therapy, may put patients at risk. 
This has raised demands what are the possibilities that events happened in 
these patients and a better understanding of this may allow strategies to 
mitigate this risk. 
 
There are few factors associated with increased risk of cardiovascular events 
while changing from dual to single antiplatelet therapy. Duration of DAPT plays 
an important role to cause increased risk of cardiovascular event following 
DAPT discontinuation. Several studies (Airoldi, et al., 2007; Ho, et al., 2008b; 
Ho, et al., 2010; Mauri, et al., 2014) have established associations between 
duration of DAPT and risk of cardiovascular event. Duration of clopidogrel 
treatment less than 6 months was associated with increased risk of death or MI 
within 90 days after stopping clopidogrel (Ho, et al., 2010). Boggon, et al. 
(2011) found that the hazard of death or non-fatal MI was significantly higher 
among patients who discontinued clopidogrel compared with patients who 
continued to receive a clopidogrel prescription. However, some studies (Mauri, 
et al., 2014; Bulluck, et al., 2015) found that longer DAPT duration more than 
one year was associated with increased risk of bleeding. 
 
Patients with ACS can be managed with medication regimens or with PCI. 
Medically-treated patients without other cardiac interventions were found to 
have higher risk of death or recurrent ACS within 90 days after discontinuation 
of clopidogrel (Ho, et al., 2008b; Ho, et al., 2010; Stephenson, et al., 2011). In 
addition, Stephenson, et al. (2011) found patients with BMS experienced a 
higher incidence of death or recurrent ACS compared with DES. In contrast, a 
recent systematic review and meta-analysis pointed out the risk of 
cardiovascular events was higher in patients receiving stents but not in 
medically-treated patients (D'Ascenzo, et al., 2014). However, the meta-
analysis only included studies evaluating DAPT duration longer than 12 months. 
 
Different modes of DAPT discontinuation also plays an important role in 
increased risk of thrombotic events following DAPT discontinuation. There were 
three modes of DAPT cessation studied by Mehran, et al. (2013) i.e. 
discontinuation, interruption and disruption. Between these three modes, 
disruptions of DAPT due to bleeding or non-compliance were associated with 
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increased risk of major adverse cardiovascular events (MACE) following DAPT 
withdrawal. On the other hand, this study found that discontinuation of DAPT 
by physician-guided was associated with lower MACE.  
 
There are suggestions that the clustering of cardiovascular events occurs 
following DAPT cessation maybe due to rebound phenomena that associated 
with prothrombotic or proinflammatory response (Sambu, et al., 2011b). 
Previous studies have investigated the effect of clopidogrel discontinuation on 
inflammatory biomarkers (Wykrzykowska, et al., 2009), platelet reactivity 
(Sibbing, et al., 2010) and combination of inflammatory biomarker and platelet 
reactivity in diabetic population (Angiolillo, et al., 2006). Recently, Sambu, et 
al. (2011a) investigated the effect of clopidogrel withdrawal after one year DES 
PCI on arachidonic acid-induced platelet aggregation and ADP-induced platelet 
aggregation, and biomarkers of vascular inflammation, including soluble CD40 
ligand (sCD40L), high-sensitivity C-reactive protein (hsCRP) and interleukin 6 
(IL-6) at multiple time-points following clopidogrel cessation. There was a 
significant increased in ADP-induced platelet aggregation, arachidonic acid-
induced platelet aggregation and a decreased in IL-6 at 1, 2 and 4 weeks; and 
a decreased hsCRP at 4 weeks following clopidogrel cessation. Table 1-7 
summarises the key trials on mechanism occurs following DAPT cessation. 
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Table 1-7: Key trials on mechanism occurs following DAPT cessation. 
Studies Details  Comparison  Findings 
Angiolillo, et 
al. (2006) 
54 patients with 
diabetes, 
undergone PCI 
and treated with 
clopidogrel for 1 
year 
Within 1 month 
while patients on 
aspirin and 
clopidogrel vs 1 
month after 
withdrawal 
(patients only on 
aspirin) 
Significant increased 
in ADP-induced 
platelet aggregation 
and inflammatory 
biomarker (CRP) 
Wykrzykowsk
a, et al. 
(2009) 
98 non-diabetic 
patients, 
following drug-
eluting stents 
and treated with 
clopidgrel for 12 
months 
Last day on 
clopidogrel 
(baseline) vs 1,2,3 
and 4 weeks after 
withdrawal 
Significant increased 
in sCD40L biomarker 
at 4 time-points; 
significant increased 
in P-selectin at week 
1 and 2; significant 
decreased in CRP at 
week 1, 2 and 3. 
Sibbing, et al. 
(2010) 
69 patients 
following DES 
were 
randomized to 
tapering group 
vs abrupt 
clopidogrel 
group 
After study 
inclusion and at 
weeks 2,3 and 4 
after randomization 
(while tapering 
clopidogrel dose or 
abrupt clopidogrel 
withdrawal); and 
weeks 5,6,7 and 8 
(complete 
clopidogrel 
withdrawal for both 
groups) 
Increased in ADP-
induced platelet 
aggregation for both 
groups during weeks 
5 to 8 (after complete 
clopidogrel 
withdrawal) 
Sambu, et al. 
(2011a) 
33 patients after 
one year DES 
PCI treated with 
clopidogrel for 1 
year 
At 4 weeks and 24 
hours before 
clopidogrel 
withdrawal and at 
24,48 hours, 1,2,4 
weeks after 
clopidogrel 
withdrawal 
Significant increased 
in ADP-induced 
platelet aggregation, 
AA-induced platelet 
aggregation and a 
decreased in IL-6 at 
1, 2 and 4 weeks; 
and a decreased 
hsCRP at 4 weeks 
following clopidogrel 
cessation 
AA=arachidonic acid; ADP=adenosine diphosphate; CRP=C-reactive protein; DES=drug-
eluting stent; hsCRP=high-sensitivity C-reactive protein; IL=interleukin; 
PCI=percutaneous coronary intervention; sCD40L=soluble CD40 ligand. 
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1.8.3 Cardiovascular event after stopped or interrupted 
antiplatelet therapy 
As listed in Figure 1-7, non-compliance or non-adherence to antiplatelet 
therapy may be one of the possible mechanisms of antiplatelet resistance and 
it is the most common cause of inadequate of antiplatelet effect (Schwartz, et 
al., 2008). About 50% of patients who were prescribed with aspirin or 
clopidogrel either discontinue taking their medication, or fail to adhere to their 
given dose at 1 year (Hamann, et al., 2003; Serebruany, et al., 2009; Herlitz, 
et al., 2010). 
 
A clustering of cardiovascular events has been reported previously after aspirin 
cessation as well as after cessation of heparin. A study by Collet, et al. (2004) 
compared the rates of death and death or myocardial infarction between 
patients who were nonusers of oral antiplatelet, prior users of oral antiplatelet 
and recent withdrawers of oral antiplatelet. They found that, recent 
withdrawers (aspirin, n=70; ticlopidine, n=3) had a 2-fold increase in the rates 
of both death and death or myocardial infarction compared with prior users and 
nonusers. Kulkarni, et al. (2006) found the rates of patients who discontinued 
aspirin after one year was 18% of patients with established coronary artery 
disease. They found that the risk factors of withdrawal medication were older 
age, female, low levels of education, and unmarried status. 
 
Withdrawal of antiplatelet therapy has been shown to have association with 
increased risk of stroke. The reported rates of aspirin discontinuation vary from 
less than 10% to almost 50% (Sud, et al., 2005; Lago, et al., 2006). One study 
found that among the 2197 cases of ischaemic stroke, 5.2% cases occurred 
within 60 days after antithrombotic withdrawal (Broderick, et al., 2011). In this 
study, stroke events were clustered mostly in the first 7 days after stopping 
medication and the antithrombotic medication was stopped for various reasons 
such as stopped by physicians for procedures, patient compliance, bleeding 
complications and cost.  
 
In another study by García Rodríguez, et al. (2011), among 673 patients who 
had diagnosed with ischaemic stroke or TIA, 71.3% patients were taking aspirin 
on the day of event and 10% discontinued aspirin within 31-180 days before the 
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event. The group who discontinued aspirin, is associated with a 40% increased 
risk of stroke. This study shown that the events happened while patients still 
taking aspirin and within 6 months after aspirin withdrawal.  
 
There are many reasons antiplatelet medication was stopped or interrupted. 
Antiplatelet therapy is commonly interrupted by physicians for procedures. In 
order to reduce the risk of bleeding during procedures, physicians make a 
decision to stop antiplatelet therapy, but this may expose patients to an 
increased risk for cardiovascular event and death (Iakovou, et al., 2005; Biondi-
Zoccai, et al., 2006; Rossini, et al., 2011; Fleisher, et al., 2014). In contrast, if 
they decided to continue antiplatelet therapy in order to prevent 
cardiovascular event, this may cause increased risk of bleeding and need for 
blood transfusions during invasive procedures (Antiplatelet Trialists' 
Collaboration, 1994; Pulmonary Embolism Prevention (PEP) trial Collaborative 
Group, 2000; Burger, et al., 2005; Devereaux, et al., 2014). Figure 1-8 showed 
the balance between thrombotic and haemorrhagic risk in patients with 
coronary stents requiring surgery. Other reasons for stopping or interrupted 
antiplatelet therapy include patient non-compliance, bleeding complications 
and financial pressure.  
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Figure 1-8: Balance between thrombotic and haemorrhagic risk in patients with coronary stents requiring surgery.  
(Permissions obtained from Wolters Kluwer Health, License Number 3742551222999)(Franchi, et al., 2014) 
Chapter 2 Introduction 77 
1.9 Metabolomics profiling in cardiovascular diseases 
Despite the advancements in treatment of cardiovascular diseases, the 
pathophysiology of these diseases is very complex. Thus, if we are able to 
predict who is at risk for an acute cardiovascular event, it would be beneficial 
as we can prevent this event. One of the development and technology that 
facilitate the discovery of biomarkers is metabolomics technique. Metabolomics 
has been used as a research tool to understand pathophysiology and 
mechanisms involve in pathways of interest and also as detection and 
identifying new biomarkers in diseases of interest.  
 
Metabolomics involves a technology using the methods of separation and 
detection complex of small molecules that characterize biochemical pathways 
of interest. The small molecules can be either from intermediate or final 
products of metabolism within a biological sample. The small molecules include 
carbohydrates, peptide, lipids, amino acids and drug metabolites (Martinez-
Pinna, et al., 2010). In sets of biological samples, the patterns and changes of 
these metabolites can be measured. Thus, these detected and significant 
metabolites are useful for identifying new biomarkers. In patients who are 
taking DAPT and at risk of developing cardiovascular event after stopping DAPT, 
identification of significant biomarker could reveal pathophysiologic 
mechanisms behind this.   
 
 
1.10 Summary of literature review and rationale for the 
present study 
Cardiovascular disease is a leading cause of death and disability worldwide. 
Effective treatments exist, but there are several outstanding questions. We do 
not know whether a person who has a stroke or TIA and is already taking aspirin 
be prescribed the same or an increased dose of aspirin after the stroke. We do 
not know whether to change their antiplatelet regimen for this group of patient. 
Furthermore, we are not sure the risk associated with stopping or interrupting 
antiplatelet early after stroke. At the same time, we want to know more about 
the risk associated when changing DAPT to single and we do not know if there 
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are any metabolite changes associated when stopping DAPT. Thus, the aims and 
objectives listed below will be used as knowledge gaps that need to be filled. 
 
1.11 Aim and objectives of the thesis 
1.11.1 Aim 
To assess certain aspects of clinical equipoise when using antiplatelet in routine 
practice. 
 
1.11.2 Objectives 
1. To evaluate whether, in patients who suffer ischaemic stroke whilst taking 
antiplatelet, a change of antiplatelet regimen is associated with a lower risk 
of recurrence than continuing on the same antiplatelet drug. 
 
2. To evaluate whether, in patients who have suffered ischaemic stroke, early 
initiation of antiplatelet is associated with better outcomes than later 
initiation. 
 
3. To evaluate whether, in patients who have suffered ischaemic stroke, early 
cessation, stopped or interrupted of antiplatelet is associated with an 
increased risk of cardiovascular event than persistent antiplatelet regimen. 
 
4. To assess the incidence and predictors of cardiovascular event after 
discontinuation of DAPT in patients who have suffered ACS. 
 
5. To determine whether, in patients who have suffered ACS, there are 
metabolite changes that are affected after stopping of DAPT.  
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2 Materials and Methods 
2.1 Introduction 
Several studies have been conducted in order to achieve the aims and 
objectives listed in the previous chapter. These include data analyses using 
multiple data sources and a prospective experimental study. The studies 
included patients with CHD and cerebrovascular disease.  
 
Three studies were performed using data from the Virtual International Stroke 
Trials Archive (VISTA) and one study was performed using data contained in the 
National Health Service Greater Glasgow and Clyde (NHSGGC) Safe Haven. The 
prospective study included patients with recent acute coronary syndrome who 
were taking DAPT. 
2.2 Data source 
2.2.1 VISTA database 
VISTA is a collaborative registry that collates and provides access to completed 
acute stroke trial data and it was established in 2001. VISTA data are stored at 
the Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK.  
Data in VISTA are anonymized in relation to patients’ and trials’ identity, as the 
majority of the informed consent and institutional review board approvals that 
have been gathered restrict storage and transmission to anonymized data (Ali, 
et al., 2007).  
 
VISTA contains patients’ demographic data such as age, sex and ethnicity; 
smoking history and medical histories including diabetes, hypertension, prior 
stroke, transient ischaemic attack and myocardial infarction. The date of stroke 
onset, race, height, weight, and baseline blood pressure are also available for 
selected trials. The majority of data in VISTA includes acute trials, thus, only 
short-term outcomes (between 21 to 180 days) are available within VISTA. The 
outcome measures available include 90-day Scandinavian Stroke Scale; Barthel 
Index; modified Rankin Scale (mRS); National Institutes of Health Stroke Scale 
(NIHSS); and Orgogozo, Mathews, and European Stroke Scales. Medication 
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details are also available within VISTA. Adverse events (AE) and some laboratory 
measurements are available from certain trials.  While the main aim of VISTA 
is to facilitate the planning of future randomized clinical trials, the VISTA 
database does not permit further testing of any trial data that will test 
treatment effects in any individual trial (Ali, et al., 2007; Ali, 2008). 
 
Data extraction 
For the purpose of my research, VISTA data were obtained from VISTA Acute 
which contains trials that were conducted between 1998 and 2008. A proposal 
to acquire VISTA data was sent and data on patient’s baseline characteristics; 
drug history which include prior and current medications; outcomes which 
include recurrent stroke, cardiovascular event, mRS at 90 days and NIHSS at 90 
days; and AEs which include minor and major bleeding and ICH were requested. 
Based on these data requirements, I was given accessed to an anonymised 
dataset of 10,304 patients from VISTA. The use of the anonymised dataset for 
research studies is approved by the VISTA-Acute Steering Committee (letter 
dated 7 Feb 2013) (Appendix 1). 
 
Data cleaning and coding 
The anonymised dataset obtained from VISTA were given in five different 
datasets. There were datasets for baseline and clinical characteristics, prior 
medications, current medications, AEs and serious adverse events (SAE). The 
baseline and clinical characteristics dataset was straightforward. However, the 
rest of datasets are needed to be cleaning and coding before it can be used.  
 
In VISTA, the majority of medications were coded using the World Health 
Organization’s Anatomical Therapeutic Chemical (ATC) classifications. In this 
classification system, drugs are divided according to the organ or system on 
which they act and according to their chemical, pharmacological and 
therapeutic properties (World Health Organization (WHO) Collaborating Centre, 
2003). For medications without ATC codes, their ATC codes were coded 
manually. Medications that used brand names were changed manually to their 
generic names, for example, Trombyl which is also known as aspirin. The coding 
for both prior and current medications were done separately. Then, each 
dataset was sorted by patient identification number and medication’s generic 
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name. The data on prior antiplatelet treatment with ATC code: B01AC were 
extracted into a new dataset (prior antiplatelet dataset). SAS software was used 
to transpose antiplatelet generic name, start day and end day of each 
antiplatelet agent according to patient identification number. This step was 
repeated for the current medication dataset. These datasets i.e. prior 
antiplatelet and current antiplatelet were then merged with the baseline and 
clinical characteristics dataset based on patient identification number. 
 
Whereas for AE and SAE dataset, specific keywords were used and searched. 
For recurrent stroke, the keywords used include infarct or ischaemia or 
ischaemic or stroke or cerebrovascular accident (CVA). The terms used for the 
extraction can be found in Appendix 2. For ACS, the terms used were unstable 
angina or acute coronary syndrome or myocardial infarction. For transient 
ischaemic attack, the term used as it is. For bleedings, the terms used to 
extract this information is listed in Appendix 3. Afterwards, each dataset was 
sorted by patient identifier and recurrent stroke event. SAS software was used 
to transpose recurrent stroke, the AE start day and end day according to patient 
identification number. These datasets then merged with the baseline and 
clinical characteristics dataset by patient identification number. The process 
was repeated for the rest of AE, i.e. ACS, TIA, intracranial haemorrhage (ICH) 
and extracranial haemorrhage (ECH).  
 
Patient selection in VISTA 
For VISTA analysis, all patients with missing baseline characteristics and 
antiplatelet information were excluded especially patients with missing 
information on initiation day of antiplatelet therapy. Furthermore, patients 
with concurrent use of vitamin K antagonist such as warfarin were excluded as 
it may influence clinical (Abdul-Rahim, et al., 2014) and safety (Shireman, et 
al., 2004) outcomes in acute ischaemic stroke patients. A flow diagram showing 
the selection of final data from VISTA is presented in figure 2.1. The inclusion 
and exclusion criteria for each study using VISTA dataset are described in their 
individual section in Chapter 3, 4 and 5.  
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Figure 2-1: Flow chart for selection of ischaemic stroke patients from VISTA. 
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Patients with complete baseline data 
n= 10,291 
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antiplatelet data 
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No information on antiplatelet post-
stroke, n=3664 
Missing antiplatelet start date, n=1525 
Concomitant use with vitamin K 
antagonist post-stroke, n=1052 
The Virtual International 
Stroke Trials Archive 
Acute Ischaemic Stroke  
(data from Neuroprotection Trials) 
n=10,304 
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2.2.2 NHS Greater Glasgow and Clyde Safe Haven 
NHS Scotland has set up regional Safe Havens located within Aberdeen, Dundee, 
Edinburgh and Glasgow, for delivering research excellence and the need for 
rapid access to high quality health data for research purposes (NHS Research 
Scotland, 2016). NHSGGC and the Robertson Centre for Biostatistics develop a 
Safe Haven and provide access to local healthcare data in the West of Scotland. 
In the Safe Havens, they consist of many administrative datasets that are useful 
for research purposes such as Scottish Morbidity Record (SMR01), General 
Register Office for Scotland (GROS) death registration and Prescribing 
Information System. The SMR01 collects information on all admissions to acute 
care hospitals in Scotland, including the date of the admission, the type of 
admission, the disease codes for the current admission and admissions for 
surgical procedures. The GROS death registration collects information on all 
deaths that occur in Scotland including the date of death. The PIS database 
records the date dispensed and the number of days supplied for each dispensed 
medication. 
 
Data extraction  
For the purpose of my research, the SMR01 database was used to search all 
admission for ACS that occurred in the West of Scotland. A proposal to acquire 
this dataset was sent to NHSGGC Safe Haven team and data on patient’s 
baseline characteristics; prescribing history; diagnosis of ACS which include 
unstable angina, STEMI and NSTEMI; stroke; death and major bleeding 
complications which include subarachnoid, intracranial, intraocular and 
retroperitoneal haemorrhage were requested. Based on these data 
requirements, I was given accessed to an anonymised dataset of 7232 ACS 
patients hospitalised from between 2008 and 2013. The use of the anonymised 
dataset for research studies is approved by the Local Privacy Advisory 
Committee (LPAC) group, NHSGGC (GSH/13/CA/005) (Appendix 4). The details 
of patient extraction are shown in Figure 2-2. 
 
Data cleaning and coding 
The anonymised dataset obtained from NHSGGC were given in three different 
datasets. There were datasets for demographic data, admissions for ACS and 
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antiplatelet prescribing history. Demographic dataset contains information on 
patient date of birth, date of death and gender. Demographic dataset was 
straightforward. Similarly, as VISTA data, the rest of datasets are needed to be 
cleaning and coding before it can be used. 
 
The admission dataset contains information on date of admission, diagnosis for 
the current admission and admissions for surgical procedures. This dataset was 
also used to search for recurrent ACS, ischaemic stroke, TIA, heart failure, 
cardiac death and major bleeding following the first admission of ACS. The ACS, 
ischaemic stroke, heart failure, cardiac death (Appendix 5) and major bleeding 
(Appendix 6) were coded based using the International Classification of 
Diseases, Tenth Revision (ICD-10) codes. There were patients with more than 
one admission, thus each event was reviewed with their date of admission 
manually. Then, this dataset was sorted by patient identifier. SAS software was 
used to transpose recurrent stroke, AE start day and end day according to 
patient identification number. These datasets then merged with the 
demographic dataset based on patient identification number. 
 
Antiplatelet prescribing dataset in NHS Scotland data were coded using the BNF 
(British National Formulary). The BNF Code contains 15-digit code, where the 
first seven digits are according to the drug classes in the BNF and the last 8 
digits characterize the medicinal product, form, strength and the link to the 
generic equivalent product (NHS National Services Scotland). In this dataset, it 
also includes antiplatelet strength dispensed to the patient, dispensed date and 
dispensed quantity. Dual antiplatelet therapy regimen (Figure 2-2) and duration 
of antiplatelet prescribed for each patient were searched and calculated 
manually using the data provided. Then, this dataset was sorted by patient 
identification number and antiplatelet regimen. SAS software was used to 
transpose antiplatelet regimen, start day and end day of each medication 
according to patient identification number. This dataset then merged with the 
demographic dataset according to patient identification number. 
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Figure 2-2: Flow chart for selection of acute coronary syndrome from NHS 
Scotland National Safe Haven.  
ICD=International Classification of Diseases, DAPT=dual antiplatelet therapy. 
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2.3 Outcome measures 
2.3.1 VISTA analysis 
There are several outcomes measured in VISTA analysis. Because of VISTA 
characteristics, short-term outcomes within 90 days after acute ischaemic 
stroke were used. The primary efficacy outcome was a recurrent ischaemic 
stroke at 90 days. This information about recurrence ischaemic stroke was 
extracted in all patients from AE and SAE reports.  
 
The primary safety outcome was a bleeding complication. This information was 
extracted from AE and SAE datasets. Bleeding complications were divided into 
two different categories i.e. ICH and ECH.  Intracranial haemorrhage was 
defined as any ICH and haemorrhagic transformation 1 and 2 of cerebral 
infarction were excluded. Whereas, ECH was defined as gastrointestinal (GI) 
and non-GI bleeding. Gastrointestinal bleeding was defined as patients with 
overt GI bleeding, whereas non-GI bleeding with no evidence of overt GI 
bleeding. The list of key terms used to identify ICH and ECH is listed in 
Appendix 3. 
 
Another outcome measures used in VISTA analysis is modified Rankin Scale 
(mRS). It is one of the common outcome measures that were used in stroke 
research (Quinn, et al., 2009). The mRS is a scale used to assess degree of 
disability or dependence in daily activities after stroke. It is ordinal hierarchical 
scale ranging from 0 to 6 which assess functional status of patients. This 
information is available within VISTA, thus it was used to measure functional 
outcome at day 90 after acute ischaemic stroke. The mRS scores as described 
in Table 2-3. 
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Table 2-1: Scores on a modified Rankin scale (Saver, 2007). 
Score Description 
0 No symptoms at all 
1 
No significant disability despite symptoms; able to 
perform all usual duties and activities 
2 
Slight disability; unable to perform all previous activities, 
but able to take care of self without assistance 
3 
Moderate disability; requiring some help, but able to walk 
without assistance 
4 
Moderately severe disability; unable to walk without 
assistance and unable to attend to own bodily needs 
without assistance 
5 
Severe disability; bedridden, incontinent, and requiring 
constant nursing care and attention 
6 Dead 
 
 
2.3.2 NHS Scotland National Safe Haven analysis 
For NHS SNSH analysis, cardiovascular events occurred following ACS and after 
DAPT cessation were measured. Cardiovascular events include recurrent ACS, 
ischaemic stroke and death. Further description of this study will be described 
more in Chapter 6. 
 
2.4 Experimental study  
The study participants, ethics approval, inclusion and exclusion criteria, and 
study methods for the prospective study are described in Chapter 7. 
 
2.5 Statistical analysis 
Statistical advice was sought from Stroke Trials statistician Dr Rachael MacIsaac 
at Acute Stroke Unit, Institute Cardiovascular and Medical Sciences, University 
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of Glasgow. The statistical methods used for each study are described in the 
methodology section of each chapter. 
 
2.6 Statistical software for analyses 
Statistical analyses were performed with IBM SPSS Statistics version 21.0 (IBM 
Corp, 2012).
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3 Antiplatelet therapy following ischaemic 
stroke – Continue or change pre-existing 
therapy? 
3.1 Introduction 
Antiplatelet therapy is recommended for patients with ischaemic stroke or 
transient ischaemic attack (TIA) due to atherosclerotic disease (Hacke, et al., 
2008b; Furie, et al., 2011; Lansberg, et al., 2012; Jauch, et al., 2013). 
Antiplatelet drugs are prescribed to prevent further ischaemic stroke, minimize 
the risk of early death and to improve long-term outcome (Gent, et al., 1996). 
Use of aspirin leads to fewer deaths (nine per 1000 treated) and more patients 
with a good functional outcome (seven per 1000 treated) at 30 days after 
ischaemic stroke compared to no aspirin use (Sandercock, et al., 2008) and in 
the longer term antiplatelet drugs reduce the risk of recurrent cardiovascular 
events and prevents approximately 1/5 of recurrent strokes (Baigent, et al., 
2002; Baigent, et al., 2009). 
 
Guidelines recommend that antiplatelet regimens choices are individualised 
based on numerous factors including patient risk factor profiles, cost, 
tolerability and relative effectiveness (Kernan, et al., 2014). One potentially 
important factor is pre-existing anti-platelet therapy. In the recently published 
CHANCE study, at least 20% of patients had a history of previous stroke and 11% 
of patients had their index stroke whilst taking antiplatelet therapy (Wang, et 
al., 2013). In North Dublin Stroke study, 34.8% patients in their sample were 
taking antiplatelet therapy before first-ever stroke (Kelly, et al., 2012). 
 
Guidelines acknowledge that in patients who experience a stroke whilst taking 
antiplatelet therapy, there are no clinical trials to show whether switching 
antiplatelet agents decreases the risk of subsequent events (Furie, et al., 
2011). There are reasons why switching regimen may be advantageous. Failure 
of antiplatelet treatment could be due to disease severity (no drug will be 100% 
effective), lack of adherence or resistance to the effect of the antiplatelet 
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drug. Resistance to clopidogrel may be present in 10 to 25% of patients and 
associated with an increased risk of cardiovascular events (Muller, et al., 2003; 
Matetzky, et al., 2004; Serebruany, et al., 2005b; Wang, et al., 2010). It is 
possible resistant patients should be switched to another class of antiplatelet. 
In this study, we compared the rate of recurrent stroke and bleeding 
complications after ischaemic stroke in patients who were already taking 
antiplatelet drugs according to whether they continued on the same drugs or 
changed regimen. 
 
3.2 Methods 
3.2.1 Study setting and study population 
General details of the study setting and study population are described in 
section 2.2.1. Briefly, the data used are contained in the Virtual International 
Stroke Trials Archive (VISTA) database. The VISTA data are anonymous to 
included patients and clinical trials. We included participants who had suffered 
ischaemic stroke whilst taking antiplatelet drugs (for at least 7 days prior to 
stroke) and who were recommenced on antiplatelet therapy within 90 days 
after ischaemic stroke.  
 
3.2.2 Definition of antiplatelet Exposure  
Data on antiplatelet treatments were based on platelet aggregation inhibitors 
(which includes derivatives of salicylic acid, thienopyridine and dipyridamole). 
Patients were divided into two different groups; a change or continue group. 
The change group comprised patients who changed to a new antiplatelet 
regimen after the index ischaemic stroke. The continue group comprised 
patients who continued the same antiplatelet therapy after the index ischaemic 
stroke. Further details will be explained using Figure 3-1. 
 
Schematic diagram for antiplatelet exposure and recurrent events for four 
subjects is shown in Figure 3-1. Antiplatelet regimen before the stroke 
represented by continuous line. For those who continued with similar 
antiplatelet regimen following an acute stroke, the continuous line continued 
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until an event occurred, represented by black dots (subject A) or until the study 
end, represented by unfilled circle at the end of individual’s line segment 
(subject B). Subject A and subject B were categorized as continue group. On 
the other hand, for patients who changed to a new antiplatelet regimen, the 
continuous line was changed to the dashed line (subject C and subject D). 
Subject C and subject D were categorized as change group. Among those 
subjects, two had an event (subject A and subject C). Two of the subjects were 
censored (subject B and subject D) at the end of the study, at 90 days.  
 
 
Figure 3-1: Schematic depiction of antiplatelet exposure (represented by 
continuous or dashed line), recurrent event (represented by black dots) and 
censoring data (represented by unfilled circle) for four patients, with a time 
dependent covariate. 
 
3.2.3 Outcome measures 
The primary outcome was the occurrence of recurrent ischaemic stroke and the 
secondary outcome was bleeding complications within 90 days post-stroke. The 
modified Rankin Scale (mRS) at 90 days was used to measure functional 
outcomes. The information about recurrent ischaemic stroke and bleeding 
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complications in all patients were extracted from AE and SAE reports. A 
recurrent ischaemic stroke was defined as a clear statement of a new adverse 
event including terms ischaemic stroke, cerebral infarction or cerebrovascular 
accident. Other events such as worsening of initial stroke symptoms or oedema 
were not included.  
 
For bleeding complication, the event was identified using these key terms: 
hematoma, haemorrhage, bleeding, blood or melaena. Bleeding complications 
were categorized into two i.e. intracranial haemorrhage (ICH) and extracranial 
haemorrhage (ECH). Intracranial haemorrhage was defined as any ICH but 
excluding haemorrhagic transformation infarction 1 and 2. Exclusion of 
haemorrhagic transformation was done by identifying these key terms: 
haemorrhagic conversion (1 and 2) or haemorrhagic transformation (1 and 2). 
Whereas, ECH was defined as any bleeding episode from another source and 
this includes gastrointestinal (GI) and non-GI bleeding. The information on data 
extraction from the VISTA has been described in Chapter 2 (section 2.2.1 and 
section 2.3.1). 
 
3.2.4 Statistical analysis 
Descriptive statistics were recorded for recent stroke patients, comparing those 
who changed antiplatelet regimen versus those who continued the same 
antiplatelet regimen post-stroke. For categorical variables such as 
demographics and medical history data, they were summarised using 
frequencies and proportions and were compared using the Chi-square test or 
Fisher’s exact test, where appropriate. Whereas for continuous variables, they 
were summarised using mean [standard deviation (SD)] or median [interquartile 
range (IQR)] and were compared using Student t-test or non-parametric Mann-
Whitney test. 
 
Our outcome measures were the occurrence of recurrent stroke, ICH, ECH by 
90 days post-stroke and the ordinal shift of the mRS at day 90 using the full 
scale. We calculated the odds ratio (OR) and corresponding 95% confidence 
intervals (95% CI) using binary logistic regression for dichotomized outcome and 
ordinal logistic regression for mRS distribution. Adjustments were made for age 
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and baseline NIHSS. Age and baseline severity are the two most powerful 
prognostic factors for stroke and are usually included in outcome distribution 
analyses (Lees, et al., 2006; Konig, et al., 2008; Bath, et al., 2012). 
 
We also assessed the effect of changed or continued antiplatelet regimen on 
outcome measures in subgroups: clinical condition (atrial fibrillation or not, 
prior stroke or not and treated with intravenous thrombolysis or not). We 
conducted subgroup analyses in these populations as their stroke risk 
recurrence (Burn, et al., 1994; Penado, et al., 2003) and neurological recovery 
(The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study 
Group, 1995) are different. Similarly, the same method was repeated by 
comparing patients who were changed from aspirin to clopidogrel to those who 
continued aspirin with aspirin post-stroke.   
 
A p-value <0.05 was used to define statistical significance. All analyses were 
performed using IBM SPSS Statistics version 21.0 (IBM Corp, 2012). 
 
3.3 Results 
3.3.1 Patients sample 
Complete data on antiplatelet therapy were available for analysis of the 
outcome measures in 4050 patients. (See Figure 2-1 for information on the 
completeness of VISTA data). 
 
Of 4050 ischaemic stroke patients, 2921 were excluded as they have no prior 
use of antiplatelet therapy. Demographic and patient characteristics for the 
remaining 1129 stroke patients who were included cohort (Figure 3-2) are 
shown in Table 3-1. Of the 1129 patients, 538 (47.7%) were changed to a new 
antiplatelet drug post-stroke, whereas 591 (52.3%) were not. The change group 
comprised a higher percentage of men, a lower rate of atrial fibrillation, a 
lower NIHSS score, and a higher percentage of previous stroke. 
 
Table 3-2 shows proportion of antiplatelet used based on prior antiplatelet. The 
majority of subjects in this study were taking aspirin prior to stroke and 
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approximately half of them continued on aspirin after stroke. Likewise, about 
half of subjects were taking aspirin after stroke. Nearly half of those subjects 
in change group were changed to clopidogrel and about half of those subjects 
were taking aspirin previously. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-2: Selection of eligible patients includes in data analyses. 
 
  
VISTA analysis 
n=4050 
Continue  
aspirin-aspirin 
n=534 
Patients with no prior 
antiplatelet, n=2921 
Patients prescribed with AP  
pre- and post-stroke 
n=1129  
Change  
aspirin-clopidogrel 
n=227 
Continue group 
n=591 
Change group 
n=538 
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Table 3-1: Baseline characteristics 
Characteristics 
Change 
(n=538) 
Continue 
(n=591) 
p-value 
Age, years* 70.91 (11.25) 72.08 (10.49) 0.091 
Male  332 (61.7) 329 (55.7) 0.040 
Caucasian 469/527 (89.0) 531/571 (93.0) 0.020 
Current Smoker 172/524 (32.8) 145/471 (30.8) 0.491 
Baseline NIHSS† 13 (9-17) 14 (9-18) 0.036 
Medical history    
Hypertension‡ 444/537 (82.7) 448/590 (75.9) 0.005 
Diabetes‡ 153/538 (28.4) 155/590 (26.3) 0.414 
AF‡ 79/537 (14.7) 135/590 (22.9) 0.000 
Heart failure‡ 48/513 (9.4) 51/548 (9.3) 0.978 
IHD‡ 229/525 (43.6) 204/471 (43.3) 0.922 
Prior TIA‡ 68/490 (13.9) 67/554 (12.1) 0.391 
Prior stroke‡ 190/527 (36.1) 133/568 (23.4) 0.000 
Thrombolysed, rt-PA 234 (43.5) 174 (29.4) 0.000 
AP duration post-stroke 
≤ 30 days 109 (20.3) 156 (26.4) 0.041 
31- 60 days 36 (6.7) 31 (5.2)  
61- 90 days 393 (73.0) 404 (68.4)  
 
All values are reported as no. (%) unless otherwise noted. *Values are reported as 
mean (SD); †median (IQR); ‡missing some data at baseline. AF=atrial fibrillation, 
AP=antiplatelet, IHD= ischaemic heart disease, NIHSS=National Institutes of Health 
Stroke Scale, rt-PA=recombinant tissue plasminogen activator. TIA=transient 
ischaemic attack, SD=standard deviation, IQR=interquartile range.
Chapter 3 Continue or Change Pre-existing AP? 96 
 
Table 3-2: Proportion of antiplatelet pattern pre- and post-stroke 
Antiplatelet 
Pre-stroke 
Antiplatelet post-stroke 
Total 
Aspirin 
Aspirin+ 
Clopidogrel 
Aspirin+ 
Dipyridamole 
Clopidogrel Dipyridamole Others 
Aspirin 
534 27 64 227 13 35 900 
(82.3) (62.8) (73.6) (85.7) (86.7) (50.0) (79.7) 
Aspirin+clopidogrel 
19 4 5 6 0 0 34 
(2.9) (9.3) (5.7) (2.3) (0.0) (0.0) (3.0) 
Aspirin+dipyridamole 
11 2 10 3 0 2 28 
(1.7) (4.7) (11.5) (1.1) (0.0) (2.9) (2.5) 
Clopidogrel 
46 10 3 21 0 0 80 
(7.1) (23.3) (3.4) (7.9) (0.0) (0.0) (7.1) 
Dipyridamole 
6 0 2 1 1 1 11 
(0.9) (0.0) (2.3) (0.4) (6.7) (1.4) (1.0) 
Others 
33 0 3 7 1 32 76 
(5.1) (0.0) (3.4) (2.6) (6.7) (45.7) (6.7) 
Total 
649 43 87 265 15 70 1129 
(100) (100) (100) (100) (100) (100) (100) 
All values are reported as no. (%) unless otherwise noted.
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3.3.2 Clinical outcomes 
There was no difference in recurrent stroke rate between groups. Recurrent 
stroke occurred in 22 patients (4.1%) in the change group, as compared with 25 
patients (4.3%) in the continue group (adjusted OR, 0.97; 95% CI, 0.54-1.75; 
p=0.929) (Table 3-3).  
 
The numbers of patients with ICH were 13 (2.4%) in the change group and 15 
(2.6%) in the continue group. We found no significant difference between the 
two groups (adjusted OR, 1.02; 95% CI, 0.48-2.18; p=0.955) (Table 3-3). 
Similarly, there was no significant difference in the rate of ECH event between 
the change (25 [4.7%]) and continue groups (17 [2.9%]) (adjusted OR, 1.82; 95% 
CI, 0.96-3.43; p=0.065).  
 
The distribution of mRS at 90 days for change versus continue group is shown in 
Figure 3-3(a). We found that change to a new antiplatelet post-stroke was 
associated with more favourable functional outcome across a full scale mRS at 
90 days after adjustments for age and baseline NIHSS (adjusted OR, 1.48; 95% 
CI, 1.19-1.86; p=0.0006), compared with continue group. Additional analyses 
adjusted for age, baseline NIHSS, hypertension, AF, previous TIA, previous 
stroke, and treated with rt-PA are shown and illustrated in Appendix 7, showing 
a significant increase risk of ECH in change group compared with continue group 
(adjusted OR, 2.03; 95% CI, 1.04-3.98; p=0.039). 
 
Table 3-3: Clinical outcomes at 90 days (adjusted for age and baseline NIHSS) 
Outcomes 
Change 
n=538 
Continue 
n=591 
Adjusted OR 
(95% CI) 
p-value 
Recurrent 
stroke 
22/532 
(4.1) 
25/588 
(4.3) 
0.97 (0.54-1.75) 0.929 
ICH 
13/532 
(2.4) 
15/581 
(2.6) 
1.02 (0.48-2.18) 0.955 
ECH 
25/527 
(4.7) 
17/584 
(2.9) 
1.82 (0.96-3.43) 0.065 
 
All values are reported as no. (%) unless otherwise noted. CI=confidence interval, 
ICH=intracranial haemorrhage, ECH=extracranial haemorrhage, OR=odds ratio. 
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(a) Change vs continue group 
 
 
(b) Aspirin-clopidogrel vs aspirin-aspirin group 
 
 
Figure 3-3: Distribution of mRS outcome at day 90 in patients suffering ischaemic stroke.  
Diagram showing association of functional outcome at day 90 between (a) change and continue group and (b) aspirin-clopidogrel and aspirin-aspirin 
group. Values provided in each box denote the percentage of patients belonging to a specific treatment category (change or continue) and 
representing the mRS score corresponding to the box. 
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3.3.3 Subgroup analysis 
There is a significant difference in the prevalence of atrial fibrillation between 
the two groups being higher in the continue group, and the prevalence of prior 
stroke and thrombolysis treated patients being higher in the change group 
(Table 3-1). Analyses of these subgroups are presented in Figure 3-4. However, 
we did not find a significant influence on the occurrence of recurrent stroke, 
ICH and ECH events between the change and continue group in these 
populations. 
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 Change 
n=538 
Continue 
n=591 
Adjusted OR  
(95% CI) 
Adjusted OR  
(95% CI) 
p-value 
Recurrent ischaemic stroke    
AF 
3/78 
(3.8) 
5/132 
(3.8) 
 1.05 (0.24-4.70) 0.946 
No AF 
19/453 
(4.2) 
20/455 
(4.4) 
 0.96 (0.51-1.83) 0.906 
Prior stroke 
4/187 
(2.1) 
7/131 
(5.3) 
 0.39 (0.11-1.36) 0.140 
No prior stroke 
18/334 
(5.4) 
18/434 
(4.1) 
 1.32 (0.68-2.60) 0.414 
Thrombolysed  
8/231 
(3.5) 
8/171 
(4.7) 
 0.75 (0.27-2.05) 0.568 
Non-thrombolysed 
14/301 
(4.7) 
17/417 
(4.1) 
 1.14 (0.55-2.36) 0.723 
Intracranial haemorrhage    
AF 
3/78 
(3.8) 
3/134 
(2.2) 
 
2.26 (0.42-12.32) 0.346 
No AF 
10/453 
(2.2) 
12/446 
(2.7) 
 0.84 (0.36-1.98) 0.698 
Prior stroke 
5/186 
(2.7) 
4/132 
(3.0) 
 1.01 (0.26-3.92) 0.985 
No prior stroke 
8/335 
(2.4) 
9/428 
(2.1) 
 1.30 (0.49-3.48) 0.596 
Thrombolysed  
9/229 
(3.9) 
5/166 
(3.0) 
 1.44 (0.47-4.43) 0.522 
Non-thrombolysed 
4/303 
(1.3) 
10/415 
(2.4) 
 0.59 (0.18-1.91) 0.377 
Extracranial haemorrhage    
AF 
5/76 
(6.6) 
6/134 
(4.5) 
 1.66 (0.47-5.84) 0.433 
No AF 
20/450 
(4.4) 
11/449 
(2.4) 
 1.93 (0.91-4.09) 0.087 
Prior stroke 
10/184 
(5.4) 
6/131 
(4.6) 
 1.31 (0.46-3.75) 0.614 
No prior stroke 
15/333 
(4.5) 
11/431 
(2.6) 
 1.98 (0.89-4.41) 0.096 
Thrombolysed  
8/227 
(3.5) 
3/171 
(1.8) 
 2.50 (0.63-9.83) 0.191 
Non-thrombolysed 
17/300 
(5.7) 
14/413 
(3.4) 
 1.82 (0.87-3.78) 0.111 
 
 
 
Figure 3-4: Clinical outcomes at 90 days (adjusted for age and baseline NIHSS) by 
subgroup 
All values are reported as no. (%) unless otherwise noted. AF=atrial fibrillation, 
OR=odds ratio, CI=confidence interval.  
Change better      Continue better 
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3.3.4 Additional analyses 
We formed another cohort from 761 ischaemic stroke patients, of whom 227 
(29.8%) were changed from aspirin to clopidogrel and 534 (70.2%) were 
remained with aspirin post-stroke. A flow diagram showing the selection of this 
cohort is presented in Figure 3-2. Detailed baseline characteristics are given in 
Table 3-4.  
 
The effect of aspirin-clopidogrel group versus aspirin-aspirin group on the rates 
of the recurrent stroke, ICH and ECH were comparable between these two 
groups. Similarly, in subgroup analysis, there was no significant different on the 
occurrence of recurrence stroke, ICH and ECH across subgroups. Adjusted ORs 
(95% CI) are provided in Figure 3-5. We also found that change from aspirin to 
clopidogrel post-stroke was associated with more favourable functional 
outcome across full scale mRS at 90 days after adjustments for age and baseline 
NIHSS (adjusted OR, 1.59; 95% CI, 1.19-2.13; p=0.0018), compared with aspirin-
aspirin group (Figure 3-3(b)). 
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Table 3-4: Baseline characteristics 
Characteristics 
Aspirin-Clopidogrel 
n=227 
Aspirin-Aspirin 
n=534 
p-value 
Age, years* 71.56 (11.213) 72.17 (10.427) 0.497 
Male  
138 296 
0.172 
(60.8) (55.4) 
Caucasian 
207/226 478/515 0.562 
(91.6) (92.8)  
Current Smoker 
82/227 131/429 0.146 
(36.1) (30.5)  
Baseline NIHSS† 12 (8-16) 14 (9-19) 0.014 
Medical history    
Hypertension‡ 
195/227 407/534 0.003 
(85.9) (76.2)  
Diabetes‡ 
65/227 141/534 0.526 
(28.6) (26.4)  
AF‡ 
31/227 126/534 0.002 
(13.7) (23.6)  
Heart failure‡ 
17/222 44/493 0.575 
(7.7) (8.9)  
IHD‡ 
98/227 186/429 0.964 
(43.2) (43.4)  
Prior TIA‡ 
22/209 56/506 0.833 
(10.5) (11.1)  
Prior stroke‡ 
67/227 111/513 0.021 
(29.5) (21.6)  
Thrombolysed, rt-PA 
104 159 0.000 
(45.8) (29.8)  
AP duration post-stroke   
≤ 30 days 
38 142 0.014 
(16.7) (26.6)  
31- 60 days 
14 30  
(6.2) (5.6)  
61- 90 days 
175 362  
(77.1) (67.8)  
 
All values are reported as no. (%) unless otherwise noted. *Values are reported as 
mean (SD); †median (IQR); ‡missing some data at baseline. AF=atrial fibrillation, 
AP=antiplatelet, IHD=ischaemic heart disease, IQR=interquartile range, 
NIHSS=National Institutes of Health Stroke Scale, rt-PA=recombinant tissue 
plasminogen activator, SD=standard deviation, TIA=transient ischaemic attack.
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Aspirin-
Clopidogrel  
n=227 
Aspirin- 
Aspirin 
n=534 
Adjusted OR (95% CI) 
Adjusted OR 
(95% CI) 
p-value 
Recurrent stroke     
All 
9/226  
(4.0) 
24/531 
(4.5) 
 0.87 (0.40-1.90) 0.723 
AF 
1/30  
(3.3) 
5/123 
(4.1) 
 0.95 (0.10-8.90) 0.966 
No AF 
8/196  
(4.1) 
19/408 
(4.7) 
 0.86 (0.37-2.01) 0.730 
Prior stroke 
2/67  
(3.0) 
7/109 
(6.4) 
 0.44 (0.09-2.19) 0.316 
No prior stroke 
7/159  
(4.4) 
17/401 
(4.2) 
 1.04 (0.42-2.59) 0.929 
Thrombolysed  
2/104  
(1.9) 
8/156 
(5.1) 
 0.35 (0.7-1.70) 0.192 
Non-thrombolysed 
7/122  
(5.7) 
16/375 
(4.3) 
 1.33 (0.53-3.36) 0.545 
Intracranial haemorrhage     
All 
3/226  
(1.3) 
12/524 
(2.3) 
 0.63 (0.18-2.29) 0.487 
AF 
0/31  
(0) 
2/125 
(1.6) 
 - 0.998 
No AF 
3/195  
(1.5) 
10/399 
(2.5) 
 
0.62 (0.17-2.30) 0.474 
Prior stroke 
2/67  
(3.0) 
4/110 
(3.6) 
 0.87 (0.15-4.97) 0.878 
No prior stroke 
1/159  
(0.6) 
6/395 
(1.5) 
 0.52 (0.06-4.49) 0.550 
Thrombolysed  
3/103  
(2.9) 
4/151 
(2.6) 
 1.22 (0.25-6.03) 0.804 
Non-thrombolysed 
0/123  
(0) 
8/373 
(2.1) 
 - 0.996 
Extracranial haemorrhage     
All 
13/222  
(5.9) 
17/528 
(3.2) 
 2.00 (0.94-4.24) 0.071 
AF 
2/29  
(6.9) 
6/125 
(4.8) 
 1.72 (0.31-9.69) 0.538 
No AF 11/193 (5.7) 
11/403 
(2.7) 
 2.18 (0.92-5.16) 0.075 
Prior stroke 
5/65  
(7.7) 
6/110 
(5.5) 
 1.51 (0.44-5.20) 0.518 
No prior stroke 
8/157  
(5.1) 
11/398 
(2.8) 
 2.01 (0.78-5.19) 0.151 
Thrombolysed  
4/101  
(4.0) 
3/156 
(1.9) 
 2.40 (0.51-11.19) 0.266 
Non-thrombolysed 
9/121  
(7.4) 
14/372 
(3.8) 
 2.14 (0.88-5.21) 0.093 
 
 
Figure 3-5: Clinical outcomes at 90 days (adjusted for age and baseline NIHSS) 
All values are reported as no. (%) unless otherwise noted. AF=atrial fibrillation, 
OR=odds ratio, CI=confidence interval. 
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3.4 Discussion 
In the present study, we found that subjects who experience stroke while on 
antiplatelet therapy and who switch to a new class of antiplatelet regimen after 
stroke did not have a lower early recurrence rate than subjects who continued 
with the same antiplatelet therapy. In terms of safety outcomes, there was no 
difference in the occurrence of ICH. Conversely, patients in the continue group 
tended to have a lower though non-significant risk of ECH. Furthermore, the 
clinical outcomes were not significantly different across pre-defined subgroups. 
We found that change group was associated with an increase in the odds of a 
favourable functional outcome. 
 
Currently, aspirin, a combination of aspirin/dipyridamole, clopidogrel and 
ticlopidine are recommended to prevent recurrent stroke in patients with 
stroke and TIA (Kernan, et al., 2014). In this study, we found that a single 
antiplatelet agent i.e. aspirin was frequently used in our cohort, followed by 
clopidogrel and a combination of aspirin/dipyridamole following ischaemic 
stroke. This may indicate the underutilization of combination antiplatelet 
therapy for prevention of recurrent stroke. The reason behind this probably 
because VISTA contains clinical trial data conducted during the years 1989 to 
2006. Furthermore, the recommendation of clopidogrel alone and combination 
aspirin/dipyridamole are only become available after the European Stroke 
Prevention Study (ESPS-2) (Diener, et al., 1996) trial in 1996 and Prevention 
Regimen for Effectively Avoiding Second Strokes (ProFess) (Sacco, et al., 2008) 
trial in 2008. 
 
There are no trials that show changed antiplatelet therapy after a stroke event 
reducing the risk of subsequent stroke (Kernan, et al., 2014). A recent 
retrospective cohort study by Lee, et al. (2014) compared clopidogrel initiation 
versus aspirin re-initiation among patients with ischaemic stroke who took 
aspirin at least 30 days prior to their index of stroke. They found those who 
changed to clopidogrel after a stroke was associated with fewer vascular events 
than aspirin. In contrast, we did not find any significant relation between those 
who change and continue antiplatelet therapy. The reasons might be because 
our study follow-up was shorter i.e. 90 days compared to study by Lee, et al. 
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(2014) and other related trials which are normally more than 2 years (Sacco, et 
al., 2008). Furthermore, we divided patients into two different groups, whether 
they change or continue with the same antiplatelet therapy and not according 
to specific antiplatelet agent. Although we repeated the analysis and compared 
between aspirin re-initiation vs clopidogrel initiation, the results are similar.  
 
In this study, we tried to answer this question and the risks and benefits of 
either approach have not been well studied. In further analyses of this study, 
we found those who changed antiplatelet regimen or who changed from aspirin 
to clopidogrel was associated with good functional outcome at 90 days than 
those in continue group. There are limited trials compare clopidogrel and 
aspirin monotherapy and assessed functional outcomes such as mRS at 3 months 
in patients with stroke. In PRoFESS trial, the functional outcomes at 90 days 
were similar between clopidogrel and combination aspirin/dipyridamole 
treatment group (Sacco, et al., 2008). Whereas in ESPRIT trial, combination 
aspirin/dipyridamole has superior efficacy to aspirin monotherapy (Halkes, et 
al., 2006). Based on these two trials, we could indirectly assume that 
clopidogrel may be better than aspirin in prevention of recurrent stroke. 
Although the present study found better functional outcomes in change group, 
this might be due to confounding with other variables at the baseline. There 
are differences exist between change and continue groups. In change group, 
stroke severity and patients with atrial fibrillation at baseline were significantly 
lower than continue group and these two factors are known to associate with 
an increased risk of poor outcome following an ischaemic stroke (Muir, et al., 
1996; Adams, et al., 1999; Andersen, et al., 2011; Saposnik, et al., 2011; 
McGrath, et al., 2013). 
 
There are several limitations to this study. The analysis was performed using a 
non-randomized registry data that derived from various clinical trials. Thus, 
selection and other biases could have confounded antiplatelet therapy and the 
decision to stop and continue. The number of included participants was low due 
to the selection criteria and need to be on antiplatelet therapy before and after 
a stroke. Although the recurrent stroke rate was identical and lower between 
groups, we lack statistical power to exclude a potentially clinically significant 
difference between groups. Revised antiplatelet therapy was associated with a 
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lower rate of bleeding that did not reach statistical significance. There are 
studies suggesting differences in stroke recurrence while on antiplatelet 
therapy based on stroke subtype. However, we were unable to investigate this 
association due to the information is not available in most of the patients. On 
the other hand, study subjects were not randomized and the duration and the 
dose of antiplatelet, and the extent of medication adherence for antiplatelet 
agent before and after a stroke were not available. The interpretation of the 
study data might be more meaningful if we have more information on certain 
aspects of medical care such as use of lipid-lowering agents, diabetic and 
hypertensive control or lifestyle changes. 
 
In this study, the analyses were adjusted for age and baseline severity. These 
variables are the two most powerful factors influence stroke prognosis and are 
commonly included in analyses of the distribution of functional outcomes (Lees, 
et al., 2006; Konig, et al., 2008; Bath, et al., 2012). We also provided additional 
analyses adjusted for every patient characteristic that differed between groups 
at baseline. Subgroup analyses in patients with and without prior stroke and 
atrial fibrillation were also included. 
 
There are also strengths in the present study. The data are derived from 
prospective trials with standardized assessments and careful data monitoring, 
providing high quality data. In addition, we were able to adjust for the most 
important prognostic variables.  
 
3.5 Conclusion 
In summary, in patients who suffer ischaemic stroke whilst taking antiplatelet, 
a change of antiplatelet regimen was not associated with a lower risk of 
recurrence than continuing on the same antiplatelet regimen. Despite no clear 
evidence for changing antiplatelet strategies following a cardiovascular event, 
over 50% of patients had their medication changed. Although, the results might 
be applicable to clinical practice, as recommended by the guideline, the 
selection of antiplatelet regimen after ischaemic stroke should be 
individualized on the basis of patient risk factor profiles, cost, tolerance, 
relative known efficacy of the agents and other clinical characteristics (Kernan, 
Chapter 3 Continue or Change Pre-existing AP? 107 
 
et al., 2014). However, this was a small retrospective analysis and future 
prospective trials will be needed.
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4  Association of between outcomes and the 
timing of antiplatelet therapy after ischaemic 
stroke 
4.1 Introduction 
Patients with ischaemic stroke have high risk of recurrent stroke, which often 
occurs in the first few days after the index stroke (Dhamoon, et al., 2006; Giles 
and Rothwell, 2007; Rothwell, et al., 2007; Mohan, et al., 2011). Guidelines 
suggest initiation of antiplatelet therapy within 24 to 48 hours after ischaemic 
stroke onset, unless thrombolytic therapy has been administered where it must 
be avoided for 24 hours. In the US, the American Stroke Association guidelines 
suggest initiation of aspirin within 24 to 48 hours after stroke onset (Jauch, et 
al., 2013). The National Institute for Health and Care Excellence (NICE) 
guideline recommends initiation of the anti-platelet aspirin within 24 hours 
(National Institute for Health and Clinical Excellence, 2008) and the European 
Stroke Organisation (ESO) guidelines suggest aspirin be given within 48 hours 
after ischaemic stroke (Hacke, et al., 2008b). The recommendations are based 
on data from two large trials, the Chinese Acute Stroke Trial (CAST) and 
International Stroke Trial (IST), where outcomes were improved with aspirin 
therapy, commenced within the first 48 hours (Chen, et al., 1997; International 
Stroke Trial Collaborative Group, 1997). 
 
Dual antiplatelet therapy is recommended to be given immediately following 
the diagnosis of ACS (National Institute for Health and Care Excellence, 2013). 
Early initiation of antiplatelet therapy in ACS safely reduces mortality, 
recurrent myocardial infarction and major vascular events (Yusuf, et al., 2001; 
Chen, et al., 2005; Sabatine, et al., 2005b). In CURE trial, although major 
bleeding was significantly higher in DAPT treatment group, there was no excess 
in bleeding that leads to haemorrhagic stroke compare to aspirin monotherapy 
group (Yusuf, et al., 2001). Based on these trials, we could indirectly infer that 
there are benefits of early initiation of antiplatelet therapy immediately after 
ischaemic stroke. 
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The initiation of clopidogrel and aspirin within 24 hours and continued for 3 
weeks reduces recurrent stroke with acceptable risk in comparison to aspirin 
mono-therapy in patients with high-risk transient ischaemic attack or minor 
ischaemic stroke (Wang, et al., 2013). This suggests there are benefits to very 
early initiation (<24 hours after ischaemic stroke) of antiplatelet drugs, but 
whether these benefits extend to very early initiation of antiplatelet drugs in 
the wider stroke population is not known.    
 
The present study assessed recurrent ischaemic stroke rate and bleeding 
complications associated with early or later initiation of anti-platelets using 
data from the Virtual International Stroke Trials Archive (VISTA). 
 
4.2 Methods 
4.2.1 Study setting and study population 
General details of the study setting and study population are described in 
section 2.2.1. Briefly, the data used are contained in the VISTA database. The 
VISTA data are anonymous to patients and clinical trials.  
 
4.1.1 Definition of antiplatelet Exposure 
In VISTA, data on antiplatelet treatment were based on platelet aggregation 
inhibitors with ATC code: B01AC (which includes derivatives of salicylic acid, 
thienopyridine and dipyridamole). Details on data extraction, cleaning and 
coding as described in Chapter 2 (section 2.2.1).  
 
Patients were divided into two different groups based on when they 
commenced their antiplatelet therapy. Medication data on antiplatelet therapy 
in VISTA were recorded as the date the medication was started or first given. 
Patients were defined as early when they initiated antiplatelet therapy on the 
same or following day after stroke; day 0 or 1 and late; day 2 or later. The late 
group was further divided into mid-time initiation (defined as antiplatelet 
Chapter 4 Early and Late Initiation AP 110 
 
initiation on day 2 or 3 post stroke) and late initiation (antiplatelet initiation 
on day 4 or later). Detailed of study flow chart is presented in Figure 4.1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-1: Flow diagram describing the selection of data from the Virtual 
International Stroke Trials Archive for the analysis reported. 
 
 
 
4.2.2 Outcome assessment 
The primary efficacy outcome was recurrent ischaemic stroke within 90 days. 
The primary safety outcome was intracranial haemorrhage (ICH) and the 
secondary safety outcome was extracranial haemorrhage (ECH). The modified 
Rankin Scale (mRS) at 90 days was used to measure the functional outcomes. 
Definition and data extraction for each outcome measures as described in 
Chapter 2 (section 2.2.1 and section 2.3.1). 
 
VISTA analysis 
n=4050 
Mid-time  
n=1446 
Late 
n=919 
Late 
n=2365 
Early 
n=1685 
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4.2.3 Statistical analysis 
Descriptive statistics were recorded for recent stroke patients, comparing two 
groups (early vs late) and three groups (early vs mid-time vs late) of antiplatelet 
initiation. For categorical variables, such as demographics and medical history 
data, they were summarised using frequencies and proportions and were 
compared using the Chi-square test or Fisher’s exact test, where appropriate. 
Whereas for continuous variables, they were summarised using mean [standard 
deviation (SD)] or median [interquartile range (IQR)] and were compared using 
Student t-test or non-parametric Mann-Whitney test when comparing two 
groups and one-way analysis of variance (ANOVA) or non-parametric Kruskal 
Wallis test when comparing three groups.  
 
The occurrence of recurrent stroke, ICH and ECH within 90 days were compared 
between the early and late group; and between the early, mid and late time 
antiplatelet initiation. The odds ratio (OR) of achieving the studied outcome(s) 
against the comparator, and corresponding 95% confidence intervals (95% CI), 
were calculated using logistic regression. Early initiation group was considered 
as the reference group. To account for potential immortal time bias in exposure 
duration (Lévesque, et al., 2010; Liu, et al., 2012), bleeding complications 
analysis was repeated excluding bleeding events within the first four days post 
stroke. We then explored the effect of prior antiplatelet therapy and 
thrombolytic therapy. We also measured the ordinal shift of the functional 
outcome i.e. mRS at day 90 using the full scale and we calculated the OR (95% 
CI) using ordinal logistic regression for mRS distribution. 
 
The effect of between three groups on the outcome measures in subgroup: prior 
antiplatelet therapy and thrombolytic therapy were assessed. Subgroup 
analyses in these populations were conducted as their stroke risk outcome 
(Bejot, et al., 2013) and neurological recovery (The National Institute of 
Neurological Disorders and Stroke rt-PA Stroke Study Group, 1995) are 
different. 
 
All models were adjusted for age and baseline National Institutes of Health 
Stroke Scale (NIHSS) (Konig, et al., 2008; Bath, et al., 2012). A p<0.05 was 
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considered significant. All analyses were performed using IBM SPSS Statistics 
version 21.0 (IBM Corp, 2012), whereas forest plots were produced using 
StatsDirect Statistical Software version 3.0.171. 
 
4.3 Results 
4.3.1 Patients sample 
There were 4050 acute ischaemic stroke patients included. Of these 1685 
(41.6%) patients were in the early group and 2365 patients in the late group. 
The late initiation group which was further divided consists of 1446 (35.7%) in 
the mid-time group and 919 (22.7%) late patients (Figure 4-1).  
 
Patients who were received late antiplatelet therapy had more severe stroke 
symptoms at the baseline and had a lower prevalence of diabetes, ischaemic 
heart disease and prior stroke compared with the early group (Table 4-1). 
Patients who received mid-time antiplatelet therapy had more severe stroke 
symptoms and had a higher prevalence of heart failure compared with the early 
group (Table 4-2). Patients in the late group were more likely to have been 
previously treated with antiplatelet and have atrial fibrillation and ischaemic 
heart disease than those in the early group. More than 90% of patients who 
received thrombolytic therapy were in mid-time and late groups. 
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Table 4-1: Baseline characteristics comparing 2 groups 
Characteristics 
Initiation of AP 
p-value Early 
n=1685 
Late 
n=2365 
Age, years* 68.32 (12.521) 67.73 (12.756) 0.215 
Male 
946 1355 
0.466 
(56.1) (57.3) 
Baseline NIHSS† 11 (8-16) 13 (9-17) 0.000 
Prior AP 
460 669 
0.490 
(27.3) (28.3) 
Thrombolysed, rt-PA 
137 1220 
0.000 
(8.1) (51.6) 
Medical History    
Hypertension‡ 
1171/1660 1605/2295 
0.680 
(70.5) (69.9) 
Diabetes‡ 
405/1684 455/2365 
0.000 
(24.0) (19.2) 
Atrial fibrillation‡ 
232/1660 326/2295 
0.838 
(14.0) (14.2) 
Heart failure‡ 
88/1519 138/2045 
0.247 
(5.8) (6.7) 
Ischaemic heart disease‡ 
399/1577 500/2232 
0.038 
(25.3) (22.4) 
Previous TIA‡ 
137/1583 174/2195 
0.422 
(8.7) (7.9) 
Previous stroke‡ 
304/1581 346/2101 
0.030 
(19.2) (16.5) 
 
All values are reported as no. (%) unless otherwise noted. *Values are reported as 
mean (SD); †median (IQR); ‡missing some data at baseline. AP=Antiplatelet, 
IQR=interquartile range, NIHSS=National Institutes of Health Stroke Scale, rt-
PA=recombinant tissue plasminogen activator, SD=standard deviation, TIA=transient 
ischaemic attack. 
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Table 4-2: Baseline characteristics comparing 3 groups 
Characteristics 
Initiation of AP 
p-value 
Early 
n=1685 
Mid-time 
n=1446 
Late 
n=919 
Age, years* 68.32(12.52) 67.51(13.05) 68.07(12.29) 0.319 
Male 
946 823 532 
0.688 
(56.1) (56.9) (57.9) 
Baseline NIHSS† 11(8-16) 13(9-18) 12(8-17) 0.000 
Prior AP 
460 382 287 
0.031 
(27.3) (26.4) (31.2) 
Thrombolysed, rt-PA 
137 885 335 
0.000 
(8.1) (61.2) (36.5) 
Medical History     
Hypertension‡ 
1171/1660 983/1411 622/884 
0.863 
(70.5) (69.7) (70.4) 
Diabetes‡ 
405/1684 277/1446 178/919 
0.001 
(24.0) (19.2) (19.4) 
Atrial fibrillation‡ 
232/1660 180/1411 146/884 
0.041 
(14.0) (12.8) (16.5) 
Heart failure‡ 
88/1519 86/1297 52/748 
0.492 
(5.8) (6.6) (7.0) 
Ischaemic heart 
disease‡ 
399/1577 269/1382 231/850 
0.000 
(25.3) (19.5) (27.2) 
Previous TIA‡ 
137/1583 113/1350 61/845 
0.459 
(8.7) (8.4) (7.2) 
Previous stroke‡ 
304/1581 206/1333 140/768 
0.026 
(19.2) (15.5) (18.2) 
 
All values are reported as no. (%) unless otherwise noted. *Values are reported as 
mean (SD); †median (IQR); ‡missing some data at baseline. AP=Antiplatelet, 
IQR=interquartile range, NIHSS=National Institutes of Health Stroke Scale, rt-
PA=recombinant tissue plasminogen activator, SD=standard deviation, TIA=transient 
ischaemic attack. 
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4.3.2 Clinical outcomes 
Table 4-3 shows the incidence of the primary outcome and safety outcomes in 
early and late groups. The incidence of recurrent stroke was no different 
between early and late initiation group (adjusted OR for late group 1.12; 95% 
CI, 0.80-1.59; p=0.510). On the other hand, compared to early group, the odds 
of ICH were lowered by 35% (adjusted OR, 0.65; 95% CI, 0.42-0.995; p=0.047 for 
ICH) and the odds of ECH were lowered by 42% (adjusted OR, 0.58; 95% CI, 0.41-
0.83; p=0.003) in the late group. There was no significant difference when only 
bleeding events after day 4 were considered (Table 4-4). 
 
Figure 4-2 shows the incidence of the primary outcome and safety outcomes in 
early, mid-time and late initiation groups. The incidence of recurrent stroke 
was no different (adjusted OR compared to early group, 1.00; 95% CI, 0.67-
1.49; p=0.988 for mid-time and 1.31; 95% CI, 0.86-1.99; p=0.208 for late group 
respectively). There was no excess risk of bleeding in the mid-time group 
compared to the early group but the late group had the lowest rate of ICH 
(adjusted OR for late group 0.35; 95% CI, 0.17-0.72; p=0.005 for ICH and 
adjusted OR, 0.29; 95% CI, 0.16-0.55; p=0.000 for ECH respectively). There was 
no significant difference when only bleeding events after day 4 were considered 
(Figure 4-3).  
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Table 4-3: Clinical outcomes at Day 90 (adjusted for age and baseline NIHSS) 
Outcomes 
Early 
n=1685 
Late 
n=2365 
Adjusted OR 
(95% CI) 
p-value 
Recurrent stroke 
56/1685  
(3.3) 
74/2353 
(3.1) 
0.96 (0.67-1.37) 0.807 
ICH 
43/1685 
(2.6) 
43/2323 
(1.9) 
0.65 (0.42-0.995) 0.047 
ECH 
71/1684 
(4.2) 
62/2316 
(2.7) 
0.58 (0.41-0.83) 0.003 
 
OR is the odds of achieving a 1 on the specified outcome. Early as reference group. 
CI=confidence interval, ECH=extracranial haemorrhage, ICH=intracranial 
haemorrhage, OR=odds ratio, n=number of observations.  
 
Table 4-4: Bleeding complications at Day 90 (excluded event before ≤ day 4) 
between two groups 
Outcomes n (%) 
Adjusted OR  
(95% CI) 
p-value 
Intracranial haemorrhage   
Early n=1685 
14/1656 - 0.556 
(0.8)   
Late n=2365 
26/2306 1.22 (0.63-2.35)  
(1.1)   
Extracranial haemorrhage   
Early n=1685 
23/1636 - 0.842 
(1.4)   
Late n=2365 
37/2291 1.06 (0.62-1.79)  
(1.5)   
 
All models were adjusted for age and baseline NIHSS. OR is the odds of achieving a 1 
on the specified outcome. Early as reference group. CI=confidence interval, OR=odds 
ratio. 
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Outcomes n (%) 
Adjusted OR  
(95% CI) 
Adjusted OR  
(95% CI) 
p-value 
Recurrent stroke    
Early n=1685 56/1685 (3.3) 1.00 (0,0)  
Mid-time n=1446 45/1444 (3.1) 0.95 (0.64-1.42) 0.802 
Late n=919 29/909 (3.2) 0.97 (0.61-1.53) 0.886 
ICH   
Early n=1685 43/1685 (2.6) 1.00 (0,0)  
Mid-time n=1446 34/1437 (2.4) 0.83 (0.52-1.31) 0.422 
Late n=919 9/886 (1.0) 0.35 (0.17-0.72) 0.005 
ECH   
Early n=1685 71/1684 (4.2) 1.00(0,0)  
Mid-time n=1446 50/1435 (3.5) 0.76 (0.52-1.10) 0.150 
Late n=919 12/881 (1.4) 0.29 (0.16-0.55) 0.000 
    
Figure 4-2: Clinical outcomes at Day 90 comparing 3 groups (adjusted for age and baseline NIHSS). 
OR is the odds of achieving a 1 on the specified outcome. Early as reference group. CI=confidence interval, ECH=extracranial 
haemorrhage, ICH=intracranial haemorrhage, OR=odds ratio.
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Outcomes n (%) 
Adjusted OR  
(95% CI) 
Adjusted OR  
(95% CI) 
p-value 
Intracranial haemorrhage 
 
 
  
 
  
Early  
n=1685 
14/1656 1.00 (0,0)  
(0.8)     
Mid-time  
n=1446 
18/1421 1.37 (0.68 - 2.77) 0.385 
(1.3)      
Late  
n=919 
8/885 0.97 (0.40 - 2.35) 0.954 
(0.9)      
Extracranial haemorrhage      
Early  
n=1685 
23/1636 1.00 (0,0)  
(1.4)      
Mid-time  
n=1446 
26/1411 1.20 (0.68 - 2.21) 0.530 
(1.8)      
Late  
n=919 
11/880 0.82 (0.39 - 1.70) 0.590 
(1.3)     
        
Figure 4-3: Bleeding complications at Day 90 (excluded event before ≤ day 4) between three groups. 
All models were adjusted for age and baseline NIHSS. OR is the odds of achieving a 1 on the specified outcome. Early as reference group. OR=odds 
ratio, CI=confidence interval, n=number of observations. 
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4.3.3 Functional outcomes 
The distribution of mRS at 90 days comparing two and three groups are presented 
in Figure 4-4. We found that the late initiation was associated with a significantly 
more favourable functional outcome across full scale mRS at 90 days after 
adjustments for age and baseline NIHSS (OR, 1.31; 95% CI, 1.17-1.47), compared 
with the early initiation group Figure 4-4(a). 
 
When comparing three groups, mid-time initiation was associated with more 
favourable distribution of mRS scores at 90 days (adjusted OR 1.32; 95% CI 1.16-
1.50), compared with the early initiation group. Late initiation was associated 
with a significantly better functional outcome across full scale mRS at 90 days 
(adjusted OR 1.15; 95% CI 1.07-1.24), compared with the early initiation group 
Figure 4-4(b). 
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(a) Early vs late initiation group 
 
(b) Early vs mid-time vs late initiation group 
 
 
Figure 4-4: Distribution of mRS outcome at day 90 by antiplatelet initiation group (a) compared two groups, (b) compared 3 groups.  
All models were adjusted for age and baseline NIHSS. 
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4.3.4 Subgroup analysis 
Subgroup analyses by previous antiplatelet therapy and thrombolytic therapy are 
shown in Figure 4-5. However, we did not find a significant influence on the 
occurrence of recurrent stroke, ICH and ECH event between early, mid-time and 
late groups in these populations. The results were broadly similar. 
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(a) Thrombolysis treatment group 
 
(b) Non-thrombolysis treatment group 
 
Figure 4-5: Forest plot showing outcomes for (a) thrombolysis and (b) non-
thrombolysis treatment group with and without prior antiplatelet therapy.  
Early as a reference group. All models adjusted to age and baseline NIHSS. OR is the 
odds of achieving a 1 on the specified outcome. Early as reference group. 
AP=antiplatelet, CI=confidence interval, OR=odds ratio. 
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4.4 Discussion 
We explored the relationship between time of antiplatelet initiation following 
acute ischaemic stroke and risk of recurrent stroke and bleeding complications. 
There was no difference in recurrent stroke risk, but later introduction of 
antiplatelet therapy (on or after day 4) was associated with the lowest risk of 
bleeding complications. However, the finding should be interpreted with caution 
as they are based on retrospective analysis of data and likely reflect exposure 
bias. 
 
The incidence of recurrence ischaemic stroke in the present study was 3.3% in the 
early group which is slightly higher to that seen in previous trials (2.8%) (1997). 
Similarly, it is higher than the rate in the CAST trial (1.6% vs 2.1% in aspirin and 
placebo treated patients) (Chen, et al., 1997). This may reflect differences in the 
trial populations and also the duration of follow up (90 days in our study vs 4-
weeks in CAST). The rate of recurrent events was lower in the present study than 
in the recent CHANCE trial (where the rate was 8.2% and 11.7% in the aspirin plus 
clopidogrel and aspirin only groups) (Wang, et al., 2013). The CHANCE trial 
included patients with minor stroke and high risk transient ischaemic attack who 
are presumably at higher risk than our study sample. 
 
In this study, the rates of recurrent stroke were particularly low in the early 
initiation of antiplatelet therapy. Subsequently, the rates of recurrent stroke 
increased when initiation of antiplatelet therapy within 48 to 72 hours and more 
than 72 hours. Although the rates of recurrent stroke were low in the early 
initiation, there was no statistically significant different compared to later 
initiation. In clinical practice, it is important to start antiplatelet therapy as soon 
as possible after the onset of stroke symptom because the rate of ischaemic event 
is higher within 24 hours after symptoms appear. Therefore, further analyses are 
required to understand the true clinical impact of early initiation of antiplatelet 
therapy. 
 
In this study, we found that initiation of antiplatelet therapy within the first three 
days after acute ischaemic stroke, was associated with an increased incidence of 
bleeding complications. We found the ICH incidence rate was 2.1% which was 
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higher compared with other trials (Chen, et al., 1997; Wang, et al., 2013). Patients 
age is a known predictor of ICH (Ariesen, et al., 2006; Berger, et al., 2010; Graipe, 
et al., 2015) and the present study included older patients (over 65 years old) than 
previous studies (mean age between 62 and 63 years old). Furthermore, our study 
included patients with more severe stroke (baseline NIHSS 13) and at higher risk 
than previous study (baseline NIHSS ≤ 3). As the immortal time bias could inflate 
the incidence rates for ICH and ECH, we circumvent this issue by repeated the 
bleeding complication analyses and omitting bleeding events occurring after day 
4 and we found the trend toward increased bleeding was attenuated.  
 
This study aimed to assess the impact of earlier initiation of antiplatelet therapy 
in order to provide data to inform guideline recommendations which are limited 
by available data. Early initiation of antiplatelet therapy for the treatment of 
acute ischaemic stroke has been well established. In CAST trial, a large 
randomized controlled trial, have shown that initiation of aspirin within 48 hours 
in patients with suspected acute ischaemic stroke reduces the immediate risk of 
further stroke or death in hospital and the overall risk of death or dependency 
(Chen, et al., 1997). Additionally, in IST trial, patients treated with aspirin within 
48 hours stroke symptoms had a lower recurrence rate within 14 days with no 
increased risk of haemorrhagic strokes (1997). A systematic review (N=43,041) of 
antiplatelet therapy for acute stroke concluded that initiation of aspirin within 48 
hours has been shown to reduce the risk of recurrent ischaemic stroke without 
major risk of early bleeding complications, but also improved long-term outcome 
(Sandercock, et al., 2008). 
 
The results of this study, i.e. the occurrence of recurrent stroke, ICH, ECH and 
functional outcomes differ from those of other trials of antiplatelet therapy with 
aspirin and clopidogrel or dipyridamole after cerebral ischaemic events (Kennedy, 
et al., 2007; Dengler, et al., 2010; Wang, et al., 2013). In this observational study, 
we assessed early use of antiplatelet therapy within 24 hours, 72 hours and beyond 
72 hours after stroke. In the analysis, we included population with all types of 
stroke severity and those who had received all types of antiplatelet that can be 
combination or single antiplatelet therapy. Previous studies included patients with 
less severe strokes and they either compare dual antiplatelet to single or single 
antiplatelet to placebo in patients within 24 hours after an acute minor stroke or 
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TIA. This might be the reason in this study did not show a reduction in the risk of 
ischaemic events, but at the same time showed an increased risk of haemorrhage. 
 
We also found that in patients treated with thrombolytic therapy that early use 
of antiplatelet was associated with higher bleeding risk, particularly in patients 
who were taking antiplatelet before their stroke. This supports the current 
practice of delaying antiplatelet therapy for at least 24 hours after thrombolysis 
in ischaemic stroke (Zinkstok and Roos, 2012). In patients with TIA and minor 
stroke, early and aggressive antiplatelet treatment appears to be beneficial (Bath, 
et al., 2015). In the present study, the median baseline NIHSS scores in study 
groups ranged from 11 to 13. Whether very early and / or enhanced antiplatelet 
therapy is of benefit in ischaemic stroke more widely requires investigation in 
well-designed randomised trials. Our data support the assertion that the risk 
benefit ratio is fine and extrapolation cannot be made from studies of milder 
phenotypes.   
 
Analyses in this chapter also demonstrated that mid-time and late initiation of 
antiplatelet therapy after acute stroke are associated with better functional 
outcomes. However, this observational study can be only seen as suggestive and 
must be interpreted with caution. There were differences at baseline, the 
comorbidity which known to have association with unfavourable functional 
outcome, i.e. atrial fibrillation and/or diabetes were all less prevalent in mid-
time and late initiation groups. Furthermore, thrombolysis is generally associated 
with good outcome after ischaemic stroke and in this study, this treatment was 
common in mid-time and late initiation groups than early group. 
 
There are also limitations to our study that must be considered. The analysis of 
this study was performed using a non-randomized registry data that derived from 
various clinical trials. Thus, it is inevitably incorporates confounders. Baseline 
characteristics can differ between groups due to selection bias. In contrast, we 
have adjusted our analyses for the most important factors i.e age and baseline 
stroke severity (Lees, et al., 2006; Konig, et al., 2008). Due to lack of data, we 
were unable to adjust for every factor that associated with stroke risk recurrence 
such as dysphagia and stroke subtype. In the early stage, we planned to adjust for 
all variables that differed at baseline. However, on trying to adjust with the 
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variables that differed at baseline, in multivariable analysis model for recurrent 
stroke, only one variable reach significant difference for example, diabetes and 
all other important variables such as age and baseline NIHSS were excluded from 
the model. Furthermore, the size sample for the analysis was reduced because 
observations were removed by the statistical program due to missing values for 
the related variables. Alternatively, we provided subgroup analyses in patients 
with and without prior antiplatelet and thrombolytic therapy.  
 
Even though VISTA trials used standardized approaches for data collation, we were 
unable to compensate fully for all the differences. Random error within variables 
is likely as the definition might be varied in different trials. As data in VISTA were 
anonymized for trial source, we were unable to access specific definitions for each 
variable from the pooled databases. The outcome events used in this study 
(recurrent stroke, ICH and ECH), were based on AE and SAE reports as described 
in the Methods section, rather than performing the neurologic examination and 
brain imaging to confirm the diagnosis of ischaemic stroke. Therefore, it is 
possible that our estimates of events are less precise in terms of time. The non-
random allocation of antiplatelet therapy is a flaw. We were unable to determine 
the rationale for each treatment decisions and delays for patients from our 
database. The clinical decision on when to initiate antiplatelet therapy depends 
on the individual clinician’s perception of benefits and risk. 
 
4.5 Summary 
In summary, early initiation of antiplatelet therapy was not associated with better 
outcomes than later initiation in patients who have suffered ischaemic stroke, 
although our analysis is underpowered. Furthermore, there was an increased risk 
of bleeding with early initiation.
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5 Interruption to antiplatelet therapy early after 
acute ischaemic stroke: Nested case-control 
study 
5.1 Introduction 
Antiplatelet therapy is recommended after acute ischaemic stroke to reduce the 
risk of recurrent ischaemic stroke and other vascular outcomes (Gent, et al., 
1996). Guidelines suggest use of either aspirin, clopidogrel or the combination of 
aspirin/dipyridamole (National Institute for Health and Clinical Excellence, 2008; 
National Institute for Health and Clinical Excellence, 2010; Furie, et al., 2011). 
However, persistence with antiplatelet regimens is variable after stroke. The 
reported rates of aspirin discontinuation vary from less than 10% to almost 50% 
(Sud, et al., 2005; Lago, et al., 2006), and data on adherence early after stroke 
are limited. 
 
Evidence shows that interrupting or stopping antiplatelet therapy increases the 
risk of cardiovascular events (Ferrari, et al., 2005; García Rodríguez, et al., 2011). 
However, cessation of antiplatelet drugs may of course be justified and required 
due to withdrawal of care, bleeding episodes or other adverse drug reactions. This 
is particularly true in the period early after ischaemic stroke where recurrence 
rate is also highest. Data to demonstrate the impact of stopping anti-platelets 
early after ischaemic stroke are lacking. We aimed to assess whether, in patients 
who have suffered ischaemic stroke, early cessation, stopped or interrupted of 
antiplatelet is associated with an increased risk of cardiovascular event than 
persistent antiplatelet regimen. 
 
5.2 Methods 
5.2.1 Study setting and study population 
This study used data of acute ischaemic stroke patients within the study cohort 
derived from the Virtual International Stroke Trials Archive (VISTA) database. 
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General details of the study setting and study population are described in section 
2.2.1. The study cohort included information on patient characteristics, medical 
history, medication history and the occurrence of adverse events (AE) and serious 
adverse events (SAE).  
 
5.2.2 Study design 
A matched case-control study design was used to examine association between 
antiplatelet exposure and the cardiovascular event.  
 
5.2.3 Outcome 
The outcome of the study was cardiovascular event within 90 days following acute 
ischaemic stroke. This includes recurrent ischaemic stroke, ACS and TIA. The 
event was identified from AE and SAE reports datasets which has been described 
in section 2.2.1. 
 
5.2.4 Case definition 
Cases were defined as patients who had at least one cardiovascular event in the 
first 90 days after acute ischaemic stroke. Patients who had a cardiovascular event 
within the first two days after ischaemic stroke were excluded as the event might 
not be associated to antiplatelet but due to the specific pattern of ischaemic 
changes after acute stroke (Wasserman, et al., 2014). Figure 5-1 shows the 
flowchart of patient’s selection. 
 
5.2.5 Control definition 
Controls were defined as patients with acute ischaemic stroke, but had no 
cardiovascular event within 90 days after acute ischaemic stroke. The aim was to 
find a matched control to make the two groups as similar as possible.  Selecting 
more than one control per case can increase the statistical power of a matched 
case-control study (Ahrens, et al., 2014). However, there is no additional gain in 
power and it was not worth matching to more than 4 controls per case (Pang, 
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1999; Ahrens, et al., 2014). For these reasons, the decision was taken to select up 
to four controls per case. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-1: Flowchart of patients’ selection.  
ACS=acute coronary syndrome; RS=recurrence stroke; TIA=transient ischaemic 
attack. 
 
  
Patients included in matching 
n=4005 
Excludes patients with 
events ≤2 days: 
 RS, n=12 
 ACS, n=27 
 TIA, n=6 
Patients with 
cardiovascular events 
n=239 
Patients without 
cardiovascular events 
(controls) 
n=3811 
Cases 
n=194 
Controls 
n=776 
Lost after matching, 
n=3035 
VISTA analysis 
n=4050 
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5.2.6 Case-control matching 
Matching in a case-control study refers to the procedure of selection of controls 
for each case on certain characteristics in order to make the two groups as 
comparable as possible (Breslow, 2014). 
 
An algorithm, the automating selection of controls matching programme from 
Mounib and Satchi (2000), was adapted to carry out one-to-four individual 
matching of cases to controls. Two matching criteria were chosen because each 
was found to be associated with the risk of recurrent stroke (Pennlert, et al., 
2014) and were thus potential confounders: i) age (± 10 years) and ii) sex. The 
multiple variables matching programme used is shown in Appendix 8. At the end 
of the matching process, four controls per case were selected at random without 
replacement. The process generated matched sets, each comprising a single case 
and four controls. 
 
5.2.7 Exposures 
The exposure period for each patient began after the diagnosis of acute ischaemic 
stroke and ended at the index date. The index date was defined as follows: for 
cases, it was the first cardiovascular event recorded after the antiplatelet 
exposure; for controls it was the same date as the matched case (Hubbard, et al., 
2002; Garbe and Suissa, 2014). Figure 5-2 shows the exposure period for a 
hypothetical case and matched control. 
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             Cardiovascular  
   event 
 
 
Case             Time 
 
 
 
Acute ischaemic stroke  Index date 
 
 
 
Control           Time 
 
 
    Exposure period 
Figure 5-2: The exposure period for hypothetical case and matched control: from the 
diagnosis of acute ischaemic stroke to the index date. 
 
 
5.2.8 Antiplatelet drug exposure 
Cases and controls were further categorised based on exposure to antiplatelet 
drugs after acute ischaemic stroke and up to the index date. Each individual was 
classified as a persistent user, early cessation user, interrupted user and stopped 
user (Figure 5-3). Persistent users were patients who still took antiplatelet therapy 
three days and more before the index date. Early cessation user was defined as 
patient who took antiplatelet therapy less than three days prior to the index date. 
Patients with two days interruption of antiplatelet but still took at least two days 
before the index date were classified as interrupted users. Patients who stopped 
antiplatelet at least 5 days before the index date were identified as stopped users. 
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a) Persistent user 
 
  
 
 
 
 
 
 
b) Early cessation 
  
 
 
 
 
 
 
 
c) Interrupted 
 
 
    
 
 
 
 
 
 
d) Stopped 
 
   
 
 
 
 
 
Figure 5-3: Determination of persistent user (a), early cessation user (b), interrupted 
user (c) and stopped user (d) of antiplatelet exposure.  
AP=antiplatelet, CV=cardiovascular event. 
  
CV event 
≥3 days AP up to the day before 
event (≤1 day pre event) 
CV event 
<3 days AP post-stroke or 
before event 
CV event 
≥3 days AP 
CV event 
taking AP at 
least 2 days  
pre-event 
≥3 days AP 
≥2 days 
interruption AP 
stopped ≥5 
days pre-event 
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5.2.9 Statistical analysis 
Baseline characteristics of study participants including demographics, medical 
history data, antiplatelet regimen and category of antiplatelet exposures were 
summarised for cases and controls separately. For categorical variables, they were 
summarised using frequencies and percentages. Whereas for continuous variables, 
they were summarised using mean [standard deviation (SD)] or median 
[interquartile range (IQR)]. Baseline characteristics of study participants and 
bleeding events [intracranial haemorrhage (ICH) and extracranial haemorrhage 
(ECH)] were also summarised according to the three types of antiplatelet 
exposures.  
 
To account for the individual matching, conditional logistic regression was 
performed to estimate odds ratio (OR) and 95% confidence intervals (95% CI) for 
cardiovascular event comparing patients who had early cessation, stopped/ 
interrupted and persistent (the reference group) of antiplatelet. First, univariable 
analysis was conducted to estimate crude effects for all variables, including 
antiplatelet exposure. Second, all variables were assessed in a more complex, 
multivariable model. In multivariable analysis, first, all variables were included 
(first model). Then, the least significant variable was consecutively dropped until 
all included variables were significant at p<0.05 (final model). A p<0.05 was 
considered significant. Point estimates OR and 95% CI are presented for all results.  
 
SAS version 9.3 (SAS Institute Inc., Cary, NC, USA) was used to find matched 
controls and the rest of analyses were performed using IBM SPSS Statistics version 
21.0 (IBM Corp, 2012). 
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5.3 Results 
5.3.1 Baseline characteristics 
Complete data were available for analysis of antiplatelet exposure in 4050 
patients. There were 239 cardiovascular events following an acute stroke. Forty-
five of these events were excluded because they occurred within 2 days following 
acute stroke. The remaining 194 case patients were matched with 776 controls 
from the cohort. Table 5-1 shows the incidence of cardiovascular events following 
acute stroke that has become cases. The incidence of recurrent ischaemic stroke 
was higher than acute coronary syndrome and transient ischaemic attack. 
 
Table 5-1: Incidence of cardiovascular events following acute ischaemic stroke. 
Cardiovascular event Number of events Incidence (%) 
Recurrent stroke 126 13.0 
Acute coronary syndrome 45 4.6 
Transient ischaemic attack 23 2.4 
 
 
Table 5-2 summarizes the demographic and medical history characteristics of 
cases and controls. Cases and controls were of similar age at the diagnosis of acute 
ischaemic stroke (median 73 years for cases; 73 years for controls) and shared 
similar proportion of male sex (52.6%). Cases were significantly more likely than 
controls to have diabetes (31.4% versus 21.5%, p=0.003), a history of heart failure 
(10.9% versus 6.7%, p=0.046) or previous TIA (10.8% versus 6.9%, p=0.049). 
Approximately one fifth of cases and controls had previous stroke prior to their 
acute event. 
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Table 5-2: Characteristics of study participants 
Characteristics 
Cases 
n=194 
Controls 
n=776 
OR (95% CI) p-value 
Age, years     
Mean (SD) 70.90 (11.303) 70.97 (10.676) 
- - 
Median (IQR) 73.00 (64-79) 73.00 (66-79)  
Male sex 
102 408 - - 
(52.6) (52.6)  
Caucasian 
161/187 647/747 0.94 (0.58-1.51) 0.782 
(86.1) (86.6)   
Current Smoker 
60/187 207/749 1.25 (0.87-1.79) 0.219 
(32.1) (27.6)   
Baseline NIHSS† 
11.5  
(8-17) 
12  
(8-17) 
0.99 (0.97-1.02) 0.886 
Medical history     
Hypertension‡ 
147/194 545/753 1.19 (0.82-1.72) 0.356 
(75.8) (72.4)   
Diabetes‡ 
61/194 167/776 1.71 (1.20-2.46) 0.003 
(31.4) (21.5)   
Atrial 
fibrillation‡ 
37/194 122/753 1.27 (0.82-1.95) 0.285 
(19.1) (16.2)   
Heart failure‡ 
20/184 45/675 1.80 (1.01-3.20) 0.046 
(10.9) (6.7)   
Ischaemic 
heart disease‡ 
57/187 186/728 1.26 (0.89-1.80) 0.208 
(30.5) (25.5)   
Previous TIA‡ 
19/176 50/725 1.78 (1.01-3.15) 0.049 
(10.8) (6.9)   
Previous 
stroke‡ 
40/186 137/700 1.08 (0.72-1.62) 0.700 
(21.5) (19.6)   
rt-PA 
70 248 1.20 (0.87-1.66) 0.267 
(36.1) (32.0)   
 
All values are reported as no. (%) unless otherwise noted. *Values are reported as mean 
(SD); †median (IQR); ‡missing some data at baseline. CI=confidence interval, 
IQR=interquartile range, NIHSS=National Institute Health Stroke Scale, OR=odds ratio, 
TIA=transient ischaemic attack, rt-PA=recombinant tissue plasminogen activator, 
SD=standard deviation. 
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5.3.2 Distribution of antiplatelet regimen and antiplatelet 
exposures 
Antiplatelet regimen prescribed for cases and controls is shown in Table 5-3. 
Within 90 days following acute stroke, aspirin, clopidogrel, aspirin plus 
clopidogrel, aspirin plus dipyridamole and ticlopidine were the five commonest 
antiplatelet regimen prescribed. Within 90 days after acute stroke onset, 139 
(71.6%) cases and 566 (72.9%) controls had been prescribed with a single 
antiplatelet regimen i.e. aspirin. Approximately one seventh of cases and controls 
were prescribed with clopidogrel after their acute event. About 3 to 5% of cases 
and controls were prescribed with DAPT, either aspirin plus clopidogrel or 
dipyridamole.  
 
Table 5-3: Characteristics of antiplatelet regimen prescribed  
Antiplatelet 
regimen 
Cases 
n=194 
Controls 
n=776 
Odds ratio  
(95% CI) 
p-value 
Aspirin 
139 566 1.00 - 
(71.6) (72.9)   
Clopidogrel 
28 105 1.10 (0.69-1.74) 0.674 
(14.4) (13.5)   
Aspirin+ 
Clopidogrel 
10 25 1.63 (0.75-3.52) 0.215 
(5.2) (3.2)   
Aspirin+ 
Dipyridamole 
10 50 0.82 (0.40-1.68) 0.585 
(5.2) (6.4)   
Ticlopidine 
4 16 1.01 (0.34-3.05) 0.980 
(2.1) (2.1)   
Aspirin+ 
Ticlopidine 
1 1 4.44 (0.28-71.29) 0.293 
(0.5) (0.1)   
Carbasalate 
1 5 0.76 (0.09-6.73) 0.825 
(0.5) (0.6)   
Dipyridamole 
1 5 0.79 (0.09-6.73) 0.825 
(0.5) (0.6)   
Ozagrel 
0 1 - - 
(0.0) (0.1)   
Triflusal 
0 2 - - 
(0.0) (0.3)   
All values are reported as no. (%) unless otherwise noted. CI=confidence interval, 
OR=odds ratio. 
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While the majority of cases and controls were prescribed with aspirin, a few had 
aspirin stopped or interrupted and around 20% of cases and controls had early 
cessation of aspirin. The frequency distribution of antiplatelet exposure among 
cases and controls is shown in Table 5-4. Overall, more than 50% cases and controls 
had persistent antiplatelet exposure with clopidogrel, aspirin plus clopidogrel, 
aspirin plus dipyridamole or ticlopidine.  
 
Table 5-4: Frequency of antiplatelet exposures according to five commonest 
antiplatelet regimen  
Antiplatelet regimen 
Cases 
n=194 
Controls 
n=776 
Aspirin   
Early cessation 27 (19.4) 133 (23.5) 
Stopped/Interrupted 8 (5.8) 45 (8.0) 
Persistent  104 (74.8) 388 (68.6) 
Clopidogrel   
Early cessation 9 (32.1) 29 (27.6) 
Stopped/Interrupted 2 (7.1) 5 (4.8) 
Persistent  17 (60.7) 71 (67.6) 
Aspirin+Clopidogrel   
Early cessation 5 (50.0) 7 (28.0) 
Stopped/Interrupted 0 (0) 3 (12.0) 
Persistent  5 (50.0) 15 (60.0) 
Aspirin+Dipyridamole   
Early cessation 5 (50.0) 8 (16.0) 
Stopped/Interrupted 0 (0) 4 (8.0) 
Persistent  5 (50.0) 38 (76.0) 
Ticlopidine   
Early cessation 2 (50.0) 5 (31.3) 
Stopped/Interrupted 0 (0) 0 (0) 
Persistent  2 (50.0) 11 (68.8) 
All values are reported as no. (%) unless otherwise noted. 
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The demographic and medical history characteristics according to the types of 
antiplatelet exposures are summarized in Table 5-5. Persistent users and 
interrupted/stopped users had similar age and slightly younger than early 
cessation users at the diagnosis of acute stroke (median 72 years for persistent; 
75.5 years for early cessation; 71.5 years for interrupted/stopped). At the 
baseline, interrupted/stopped users had more severity of stroke symptoms 
(median NIHSS 17) than the other two groups (median NIHSS 11 for persistent; 
NIHSS 13 for early cessation). Early cessation users had a more frequent history of 
atrial fibrillation, heart failure or ischaemic heart disease compared to others. 
However, history of previous stroke of interrupted/stopped users were more 
frequently than persistent and early cessation users (29% versus 18% versus 23.3%), 
whereas the frequency of previous TIA was similar among three groups. 
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Table 5-5: Characteristics of study participants according to types of antiplatelet 
exposure 
Characteristics 
Persistent 
user 
n=670 
Early 
cessation 
user 
n=232 
Interrupted/ 
Stopped user 
n=68 
Overall 
n=970 
Age, years     
Mean (SD) 
70.23 
(10.869) 
73.62 
(10.019) 
69.12 
(11.296) 
70.96 
(10.798) 
Median (IQR) 72 (64-78) 75.5 (69-81) 71.5 (63.3-77) 73 (65-79) 
Male sex 
351 122 37 510 
(52.4) (52.6) (54.4) (52.6) 
Ethnicity, 
Caucasian 
556/646 197/222 55/66 808/934 
(86.1) (88.7) (83.3) (86.5) 
Current Smoker 
185/643 57/226 25/67 267/936 
(28.8) (25.2) (37.3) (28.5) 
Baseline NIHSS† 11 (8-16) 13 (9-17) 17 (12-20) 12 (8-17) 
Medical history     
Hypertension‡ 
473/654 169/225 50/68 692/947 
(72.3) (75.1) (73.5) (73.1) 
Diabetes‡ 
164/670 51/232 13/68 228/970 
(24.5) (22.0) (19.1) (23.5) 
Atrial 
fibrillation‡ 
91/654 56/225 12/68 159/947 
(13.9) (24.9) (17.6) (16.8) 
Heart failure‡ 
38/601 21/196 6/62 65/859 
(6.3) (10.7) (9.7) (7.6) 
Ischaemic 
heart disease‡ 
146/628 74/220 23/67 243/915 
(23.2) (33.6) (34.3) (26.6) 
Previous TIA‡ 
48/623 16/212 5/66 69/901 
(7.7) (7.5) (7.6) (7.7) 
Previous 
stroke‡ 
111/617 48/207 18/62 177/886 
(18.0) (23.2) (29.0) (20.0) 
rt-PA 
224 74 20 318 
(33.4) (31.9) (29.4) (32.8) 
 
All values are reported as no. (%) unless otherwise noted. *Values are reported as mean 
(SD); †median (IQR); ‡missing some data at baseline. NIHSS=National Institute Health 
Stroke Scale, TIA=transient ischaemic attack, rt-PA=recombinant tissue plasminogen 
activator, SD=standard deviation, IQR=interquartile range.  
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The distribution of the antiplatelet regimen over the types of antiplatelet 
exposures is presented in Table 5-6. As shown, the majority of antiplatelet users 
were prescribed with aspirin. Following acute stroke, early cessation users were 
prescribed with clopidogrel more frequently than persistent and 
stopped/interrupted users (16.4% versus 13.1% versus 10.3%). Combination of two 
antiplatelet agents were prescribed fairly evenly across the three groups. The 
remaining, 4% persistent, 3.9% early cessation and 1.5% interrupted/stopped users 
were prescribed with ticlopidine, aspirin plus ticlopidine, carbasalate, 
dipyridamole, ozagrel and triflusal. 
 
Table 5-6: Frequency of antiplatelet regimen according to types of antiplatelet 
exposure 
Antiplatelet regimen 
Persistent 
user 
n=670 
Early 
cessation 
user 
n=232 
Interrupted/ 
Stopped 
user n=68 
Overall 
n=970 
Aspirin 
492 160 53 705 
(73.4) (69.0) (77.9) (72.7) 
Clopidogrel 
88 38 7 133 
(13.1) (16.4) (10.3) (13.7) 
Aspirin/Clopidogrel  
20 12 3 35 
(3.0) (5.2) (4.4) (3.6) 
Aspirin/Dipyridamole 
43 13 4 60 
(6.4) (5.6) (5.9) (6.2) 
Ticlopidine 
13 7 0 20 
(1.9) (3.0) (0.0) (2.1) 
Aspirin/Ticlopidine  
2 0 0 2 
(0.3) (0.0) (0.0) (0.2) 
Carbasalate 
6 0 0 6 
(0.9) (0.0) (0.0) (0.6) 
Dipyridamole 
4 2 0 6 
(0.6) (0.9) (0.0) (0.6) 
Ozagrel 
0 0 1 1 
(0.0) (0.0) (1.5) (0.1) 
Triflusal 
2 0 0 2 
(0.3) (0.0) (0.0) (0.2) 
 
All values are reported as no. (%) unless otherwise noted.   
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As shown in Table 5-7, the occurrence of bleeding events was higher in early 
cessation users (5.2%) followed by interrupted/stopped users (1.5%). The total 
bleeding events were spread fairly between ICH and ECH. Similarly, early 
cessation users had the highest event of ICH and ECH compared to the other two 
groups. 
 
Table 5-7: Frequency of bleeding events following antiplatelet exposure 
Bleeding 
Persistent 
user 
n=670 
Early 
cessation 
user 
n=232 
Interrupted/ 
Stopped 
user n=68 
Overall 
n=970 
ICH 
3 7 1 11 
(0.4) (3.0) (1.5) (1.1) 
ECH 
6 6 0 12 
(0.9) (2.6) (0.0) (1.2) 
Total bleeding 
9 12 1 22 
(1.3) (5.2) (1.5) (2.3) 
 
All values are reported as no. (%) unless otherwise noted. ICH=intracranial 
haemorrhage, ECH=extracranial haemorrhage. 
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5.3.3 Antiplatelet exposure and cardiovascular event 
The main analysis assessed the effects of persistent, early cessation and 
interrupted/stopped antiplatelet users prescribing at any time following acute 
ischaemic stroke prior to index date, on the risk of cardiovascular event. 
Unadjusted and adjusted OR for the association between cardiovascular event and 
the types of antiplatelet exposures of interest are summarized in Table 5-8 and 
Table 5-9.  
 
Univariable analysis 
Compared to persistent users, early cessation users and interrupted/stopped users 
had a similar risk of cardiovascular event (OR,1.07; 95% CI, 0.67-1.71; p=0.784 and 
OR, 0.67; 95% CI, 0.34-1.36; p=0.269 respectively) (Table 5-8).  
 
Table 5-8: Univariate analyses (conditional logistic regression) of antiplatelet 
exposures against outcome of being “case”. 
Antiplatelet exposures Cases Controls OR (95% CI) p-value 
Early cessation 48 (24.7) 184 (23.7) 1.07 (0.67-1.71) 0.784 
Stopped/Interrupted 10 (5.2) 58 (7.5) 0.67 (0.34-1.36) 0.269 
Persistent  136 (70.1) 534 (68.8) 1.00   
 
All values are reported as no. (%) unless otherwise noted. CI=confidence interval, 
OR=odds ratio. 
 
Multivariable analysis  
No association was observed between early cessation and cardiovascular event 
when compared with persistent users after adjusting for diabetes and previous TIA 
(adjusted OR, 1.04; 95% CI, 0.62-1.74; p=0.876) (Table 5-9). Similarly, after 
adjustment with similar variables, interrupted/stopped users did not have a higher 
risk compared to persistent users (adjusted OR, 0.70; 95% CI, 0.33-1.48; p=0.352). 
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Table 5-9: Multivariable conditional logistic regression of explanatory variables 
against outcome of being “case” 
Characteristics 
Adjusted odds ratio  
(95% CI) 
p-value* 
First model, all variables   
Caucasian 0.89 (0.52-1.54) 0.684 
Current Smoker 1.18 (0.77-1.81) 0.442 
Baseline NIHSS 0.98 (0.95-1.02) 0.331 
Hypertension 1.04 (0.65-1.67) 0.862 
Diabetes 1.60 (1.03-2.49) 0.036 
Atrial fibrillation 1.32 (0.76-2.29) 0.318 
Heart failure  1.33 (0.69-2.55) 0.398 
Ischaemic heart disease 0.99 (0.65-1.50) 0.964 
Previous TIA 2.15 (1.15-4.01) 0.016 
Previous stroke 0.97 (0.59-1.59) 0.896 
rt-PA 1.05 (0.72-1.54) 0.787 
Early cessation† 1.09 (0.60-1.96) 0.779 
Stopped/Interrupted† 0.72 (0.32-1.65) 0.441 
Final model   
Diabetes 1.72 (1.17-2.52) 0.006 
Previous TIA 1.90 (1.06-3.40) 0.031 
Early cessation AP† 1.04 (0.62-1.74) 0.876 
Stopped/Interrupted AP† 0.70 (0.33-1.48) 0.352 
 
*Adjusted for other variables in model. †Compared to Persistent users. AP=antiplatelet, 
CI=confidence interval, NIHSS=National Institutes of Health Stroke Scale, rt-
PA=recombinant tissue plasminogen activator, TIA=transient ischaemic attack. 
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5.4 Discussion 
In an effort to elucidate the rate of stopping or interruption antiplatelet in acute 
ischaemic stroke, a nested case-control study was performed and assessed the 
types of antiplatelet exposure and its association with cardiovascular event in 194 
cases and 776 controls of acute ischaemic stroke. The present study found no 
evidence for an increased risk of cardiovascular event among patients who had 
early cessation or interrupted/stopped antiplatelet therapy within 90 days 
following acute ischaemic stroke.  
 
There was no significant association with early cessation or interrupted/stopped 
antiplatelet therapy and the risk of cardiovascular event in the present study, 
which was inconsistent with previous studies. Studies by Maulaz, et al. (2005), 
Broderick, et al. (2011) and García Rodríguez, et al. (2011) found that patients 
who discontinued antiplatelet within one to six months is associated with an 
increased risk of stroke. The differences may be due to the small number of 
patients included in the current study compared with studies by Broderick, et al. 
(2011) and García Rodríguez, et al. (2011). In addition, there were differences in 
terms of duration of follow-up between the present and previous studies. For 
example, the study cohort in García Rodríguez, et al. (2011) was followed up at 
approximately 3.4 years which allow more number of events to be captured. On 
the other hand, similar findings were reported from Mehran, et al. (2013) and 
Ferreira-Gonzalez, et al. (2012) who also did not detect any associations between 
antiplatelet interruption and cardiovascular events. Although the finding in the 
present study was consistent in all studies, the interruption rates and subsequent 
outcomes were low in these cohorts and thus may not be able to detect small 
differences. 
 
Antiplatelet therapy is indicated following ACS and acute ischaemic stroke in order 
to reduce recurrence event. Randomized clinical trials by Altman, et al. (1994), 
Diener, et al. (1996) and Gent, et al. (1996) have demonstrated that antiplatelet 
therapy is valuable after an acute ischaemic stroke and acute coronary syndrome. 
Aspirin has been shown to reduce the risk of recurrence stroke by 15% (Johnson, 
et al., 1999), whereas clopidogrel and combination of aspirin/dipyridamole have 
shown a similar efficacy in prevention of second strokes (Sacco, et al., 2008).  
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According to NICE guidelines for management of ischaemic stroke, antiplatelet 
therapy should be continued for a long term (National Institute for Health and 
Clinical Excellence, 2008) and a study by Biondi-Zoccai, et al. (2006) recommends 
that antiplatelet therapy should never be interrupted for patients with 
cardiovascular disease. Under certain circumstances, there are reasons to stop or 
interrupt antiplatelet therapy, especially when there is associated with adverse 
events such as bleeding or allergic reactions; or interrupted by physician to reduce 
the risk of bleeding during procedures. Any reasons to stop or interrupt 
antiplatelet therapy, could expose patients to an increased risk of thrombotic 
event.    
 
The absence of an association with early cessation or interrupted/stopped 
antiplatelet therapy with the risk of cardiovascular event in the present study is 
warrant further investigation. It is important to conduct this study looking for an 
association of antiplatelet exposure as the risk of recurrent stroke is greatest 
during the first three months after stroke. Although this study found no evidence 
for an increased risk of cardiovascular event among patients who 
interrupted/stopped and early cessation antiplatelet, the occurrence of bleeding 
events was found higher in those who took antiplatelet less than three days (early 
cessation users) prior to cardiovascular event. However, other than bleeding 
events, other reasons for interruption and stopped antiplatelet could not be 
captured in this study.  
 
5.4.1 Strengths and limitations 
A major strength of the present study is the use of VISTA database sample which 
provided data that were prospectively collected during clinical trials in patients 
with confirmed ischaemic stroke. This cohort of ischaemic stroke patient from 
which all cases of cardiovascular event following ischaemic stroke and a random 
sample of controls without cardiovascular event were selected. The nested case-
control study design is useful to determine if a drug exposure is associated with 
an outcome. This study design avoided the common problem of selection bias 
which is typical in many case-control studies. Selection bias was minimised by 
including all cases of cardiovascular event within the study cohort and matched 
controls were drawn from the same population as the cases and selected 
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independently of their exposure status. Cases were matched up to four controls 
could increase the precision of the study findings. Matching by age and sex could 
increase the study efficiency in the present study and helped ensure that cases 
and controls were comparable. Rose and van der Laan (2009) has also described 
that matching between cases and controls according to certain characteristics 
able to eliminate confounding and to gain in efficiency. 
 
As with all observational studies, this study has limitations. One reason why this 
study did not show a significant difference to assess the association of 
cardiovascular event and antiplatelet exposures due to small numbers of patients 
included in this study. Due to small sample size, the study had low power to detect 
associations, thus, the study findings should be interpreted bearing in mind the 
likelihood of type II error. On the other hand, due to lack of data on the cause of 
ischaemic stroke, dose of antiplatelet therapy, medication compliance and 
reasons for interrupted, stopped or early cessation of antiplatelet regimen, may 
have masked a true relationship between cardiovascular event and exposure of 
antiplatelet. Lastly, this study was based on data available in the stroke trial 
registry, thus only included patients who met the eligibility of inclusion criteria of 
clinical trial and excluded any individuals not participate in trials. 
 
5.5 Conclusion 
In patients who have suffered ischaemic stroke, this study found that early 
cessation or interrupted/stopped antiplatelet therapy was not associated with an 
increased risk of cardiovascular events compared to persistent users. This could 
be due to the sample size may be too small and has insufficient power to detect 
this effect. Further research is needed to investigate reasons for antiplatelet 
interrupted and stopped and its association with the risk of recurrence ischaemic 
stroke. 
Chapter 6 DAPT cessation Post-ACS 147 
 
6 Cardiovascular events after dual antiplatelet 
therapy cessation in patients with a history of 
an acute coronary syndrome 
6.1 Introduction 
Antiplatelet therapy is indicated after an acute coronary syndrome (ACS) because 
it lowers mortality and reduces the early risk of recurrence. Dual antiplatelet 
therapy (DAPT), typically using aspirin and an ADP receptor antagonist such as 
clopidogrel, ticagrelor or prasugrel, is superior to use of a single antiplatelet 
agent. Clopidogrel, when given together with aspirin and fibrinolytic therapy has 
been shown to reduce the rate of death or re-infarction without major increased 
bleeding risk following ST-elevation myocardial infarction (STEMI) when compared 
with aspirin alone (Chen, et al., 2005; Sabatine, et al., 2005b). Further, in the 
CURE trial, ACS patients were randomised to either clopidogrel or placebo in 
addition to aspirin for 3 to 12 months. The results showed a significant reduction 
in incidence of death from cardiovascular causes, non-fatal myocardial infarction 
or stroke in the clopidogrel treatment group (9.3 % compared to 11.4 % in placebo) 
(Yusuf, et al., 2001). 
 
There are reports supported the cardiovascular risk is increased in the period 
following cessation of DAPT and initiation of monotherapy. Studies by Ho et al. 
found the first 90 days interval after clopidogrel cessation was associated with 
significantly higher risk of cardiovascular events compared with 91-180 days 
interval in both medical or PCI-treated patients (Ho, et al., 2008b; Ho, et al., 
2010). There are suggestions that this event maybe due to a rebound in platelet 
activity (Lordkipanidze, et al., 2009; Sambu, et al., 2011a). It is clear that data 
show cessation of DAPT may put patients at risk and a better understanding of this 
may allow strategies to mitigate this risk. 
 
The National Health Service Greater Glasgow and Clyde (NHSGGC) Safe Haven is a 
secure data repository consisting of Scottish Morbidity Record (SMR), General 
Register Office for Scotland (GROS) death registration and the Prescribing 
Information System (PIS) database. Thus, it allows identification of patients with 
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ACS, identification of any performed coronary interventions, information on 
prescription redemption, and follow-up of clinical outcomes. This data source was 
used to assess the incidence and predictors of cardiovascular event after 
discontinuation of DAPT in patients who have suffered ACS. 
 
6.2 Methods 
6.2.1 Study setting and study population 
General details of the study setting and study population are described in section 
2.2.2. Data were incorporated from few datasets, Scottish Morbidity Record, 
General Register Office for Scotland death registration, Prescribing Information 
System and Scottish Care Information – Diabetes Collaboration (SCI-DC) and 
General Practice database. 
 
Patients were included in the study if they experienced an ACS event between 1 
January 2008 and 31 December 2013, dispensed with DAPT, filled a prescription 
for DAPT within 60 days of hospital discharge and continued with single 
antiplatelet therapy after treatment of DAPT. An ACS event was defined as 
emergency hospital admission with a main discharge diagnosis of ACS 
(International Classification of Diseases [ICD-10] codes I20, I21 or I22).  
 
6.2.2 Demographic data 
For each patient, data on age, sex, hospital admissions and discharge dates, and 
operations were obtained from SMR01 dataset. Baseline demographic data such as 
smoking status, hypertension, hyperlipidaemia, renal disease and ischaemic heart 
disease were obtained from General Practice dataset, whereas diabetes data from 
the SCI-DC database. These comorbidities were defined as a condition reported 
from general practitioners before the ACS event or in any subsequent visit to 
general practitioner of ACS occurrence. Whereas, for a coronary revascularization 
procedure, it was defined as a procedure listed in operation field from SMR01 
dataset during the index admission. Revascularization procedures include 
coronary artery bypass graft (CABG) (English Office of Population Censuses and 
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Surveys (OPCS-4) codes K40-46) and percutaneous transluminal coronary 
angioplasty (PTCA) (OPCS-4 codes K49-50 and K75). 
 
6.2.3 Medication use 
The usage of DAPT was identified through PIS data, which records the date 
dispensed and the number of days supplied for each dispensed medication. DAPT 
use included and combination of aspirin-clopidogrel, aspirin-dipyridamole, 
aspirin-ticagrelor and aspirin-prasugrel. The number of pills dispensed for each 
prescription was used to calculate the duration of DAPT use. Discontinuation of 
DAPT was defined when there is no refill prescription of one antiplatelet drug in 
the combination regime, or dispense date more than 14 days from the last DAPT 
refill date plus the number of days supplied for that last refill. The last day of 
DAPT use was based on the date of last prescription refills plus the number of days 
supplied for that refill. 
 
6.2.4 Study endpoints 
The primary endpoint of the study was a cardiovascular event, which consists of 
composite of all-cause mortality, ACS (myocardial infarction (MI) or unstable 
angina), transient ischaemic attack (TIA), stroke or heart failure after cessation 
of DAPT. Information on death was obtained through General Register Office for 
Scotland database. The ICD-10 codes were used to identified hospitalizations for 
ACS (I20 – I25), TIA (G458-G459), stroke (I63-I64) and heart failure (I50) (Appendix 
5).  
 
6.2.5 Statistical analysis 
Descriptive statistics were recorded for recent ACS patients. A separate analysis 
of descriptive statistics was also recorded for patients during DAPT treatment and 
for those who were event-free at DAPT cessation, differentiating between patient 
with medical and revascularization therapy. Categorical variables were 
summarised using frequencies and proportions and continuous variables as mean 
[standard deviation (SD)] or median [interquartile range (IQR)]. Patients reached 
the end of the follow-up period without experiencing an endpoint were censored. 
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The life table method was used to calculate unadjusted incidence rates per 1000 
patient-days of cardiovascular events for each 90-day interval during DAPT and 
after DAPT cessation and stratified by medical and revascularization treated 
patients. Incidence rate ratios (IRR) with 95% confidence interval (95% CI) was 
calculated to compare a difference between incidence rates for medical and 
revascularization-treated patients from the same interval. 
 
Several analyses were then performed to assess the association between time 
interval after stopping DAPT and risk of cardiovascular events; and to determine 
predictors in cardiovascular event after stopping DAPT. First, Poisson regression 
was used to assess the association between time interval after stopping DAPT and 
risk of cardiovascular events, where incidence rate ratios was calculated and 
adjusting for age, medical or revascularization therapy and duration of DAPT. In 
these models, the risk of cardiovascular events in the first 90 days interval after 
stopping DAPT was compared with the 91 to 360 days interval and with the 91 to 
180 days interval consistent with prior studies (Ho, et al., 2008b; Ho, et al., 2010). 
Second, Cox proportional hazards regression analysis was used to model the risk 
factors of cardiovascular event after stopping DAPT. Univariate Cox proportional 
hazards regression analysis was used to estimate the risk ratios for all factors 
under consideration. Then multivariate proportional hazards regression analysis 
was performed to identify the collection of risk factors making independent 
contributions to risk of cardiovascular event. With regard to statistical analysis, 
the models were adjusted for age, medical or revascularization therapy and 
duration of DAPT. Adjustment was not made for hypertension, diabetes, 
hyperlipidaemia, chronic renal failure and ischaemic heart disease because of 
missing data. 
 
Sub-group analysis was performed for medical vs revascularization treated 
patients, duration of DAPT six months and less vs more than six months, and 
antiplatelet therapy used after DAPT cessation i.e. clopidogrel vs aspirin. The 
hazard ratios (HRs) for cardiovascular event were generated using Cox 
proportional hazard models as described in the earlier paragraph. 
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Statistical software IBM SPSS Statistics version 21.0 (IBM Corp, 2012) was used to 
perform all descriptive, survival analysis, the Poisson regression and the Cox 
proportional hazard regression, while StatsDirect Statistical Software version 
3.0.171 was used to compare two incidence rates between medical and 
revascularization-treated patients. A value of p<0.05 was considered statistically 
significant. 
 
6.3 Results 
6.3.1 Patient selection 
A total of 7232 patients admitted with ACS during the study period. Of these, 1872 
patients refilled DAPT within 60 days of hospital discharge. Of 1872 patients, 1340 
(71.6%) stopped DAPT and continued with single antiplatelet therapy (Figure 6-1). 
Among 1340 patients, 1129 (84.3%) were event-free at DAPT cessation.  
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Figure 6-1: Flow diagram describing the selection of data from the NHS Scotland 
National safe haven for the analysis reported. 
AP=antiplatelet, DAPT=dual antiplatelet therapy, SAPT=single antiplatelet therapy  
1129 patients 
event free prior 
DAPT cessation 
419 pts interrupted > 15 days 
112 pts end observation period  
2899 patients were on single AP 
1531 patients without AP recorded 
7232 patients hospitalized for ACS 
from 2008-2013 
1872 patients refill DAPT within 60 
days of hospital discharge 
930 patients refill AP > 60 days 
of hospital discharge 
1872 patients 
on DAPT 
1340 patients  
DAPT to SAPT 
1 patients 
continue 
DAPT 
531 patients 
DAPT 
interrupted 
211 patients experienced 
cardiovascular events 
2802 patients were dispensed with 
clopidogrel / ticagrelor / prasugrel / 
dipyridamole 
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6.3.2 Demographics of samples 
Demographic characteristics for the population hospitalised with ACS, during DAPT 
and after DAPT cessation patients are displayed in Table 6-1. The mean (SD) age 
for ACS population was 68.98 (13.90) years, and 42.8% were female. On the other 
hand, the mean (SD) age for during DAPT sample was 64.94 (13.02) years, and 
38.1% were female. As for after DAPT cessation sample, the mean (SD) age for was 
64.55 (12.98) years, and 36.2% were female.  
 
 
Table 6-1: Demographic characteristics 
Characteristics 
ACS patients 
(n=7232) 
During DAPT 
(n=1340) 
After DAPT 
cessation 
(n=1129) 
Age, years    
Mean (SD) 68.96 (13.95) 64.94 (13.02) 64.55 (12.98) 
Median (IQR) 70 (58-80) 64 (55-75) 64 (55-75) 
Sex, n (%)    
Female 3098 (42.8) 510 (38.1) 409 (36.2) 
Male 4134 (57.2) 830 (61.9) 720 (63.8) 
 
SD=standard deviation, IQR=interquartile range 
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An additional analysis was performed to compare the study sample with the 
excluded sample (Table 6-2). There was a significant difference in the age at the 
time of ACS diagnosis between patients included in the study sample and those 
excluded from the analysis: the median age of the latter group was 71 years (IQR, 
59-81 years) versus 64 years (IQR, 55-75 years) (p<0.0001). The proportion of 
female patients was significantly less in the study sample (38% vs 44%; p=0.000). 
 
 
Table 6-2: Comparison of the study sample with the sample excluded from analysis 
Characteristics 
Patients included 
in study sample 
(n=1340) 
Patients excluded 
from analysis 
(n=5892) 
p-value 
Age, years    
Mean (SD) 64.94 (13.02) 69.88 (13.99) <0.0001* 
Median (IQR) 64 (55-75) 71 (59-81)  
Sex, n (%)    
Female 510 (38.1) 2588 (43.9) 0.000† 
Male 830 (61.9) 3304 (56.1)  
 
*Statistical analysis of the difference in mean age (Mann-Whitney U test). †Statistical 
analysis (Χ2 test). SD=standard deviation, IQR=interquartile range 
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6.3.3 Baseline characteristics of study samples 
Baseline characteristics of during DAPT and after DAPT cessation patients are 
shown in Table 6-3. Among the 1340 patients while on DAPT, 28.3% were current 
smokers, 34.6% had hypertension, 17.5% had diabetes, 64.7% had hyperlipidaemia, 
14.5% had chronic renal failure and 24.1% had ischaemic heart disease. All patients 
were treated with aspirin and more than 90% combined with clopidogrel (94.2%) 
followed by ticagrelor (3.1%), dipyridamole (2.4%) and prasugrel (0.2%). 
 
The 1129 patients after DAPT cessation, were predominantly male (63.8%) with a 
mean age (SD) of 64.55 (12.98) years. Cardiac risk factors included current 
smoking (28.3%), hypertension (35.2%), diabetes (17.8%), hyperlipidaemia (65.6%), 
chronic renal failure (15.1%) and ischaemic heart disease (25.0%). Thirty-two 
percent patients in this group were on prior antiplatelet. All patients in this study 
sample were on aspirin and in combination with clopidogrel (94.4%), ticagrelor 
(3.1%), dipyridamole (2.1%) and prasugrel (0.3%). Mean total duration (SD) of DAPT 
therapy following ACS was 176.64 (154.48) days. After DAPT cessation, mono 
antiplatelet therapy aspirin was commonly prescribed (79.1%) than clopidogrel 
(19.8%), followed by dipyridamole (0.6%) and ticagrelor (0.4%).  
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Table 6-3: Baseline characteristics 
Characteristics 
During DAPT  After DAPT cessation  
All patients 
(n=1340) 
Medical 
treated 
(n=933) 
Revasculariz
ation treated 
(n=407) 
 
All patients 
(n=1129) 
Medical 
treated 
(n=754) 
Revasculariz
ation treated 
(n=375) 
Age, years        
Mean (SD) 
64.94 
(13.02) 
66.68 
(13.12) 
60.94 
(11.86) 
 64.55 
(12.98) 
66.44 
(13.28) 
60.75 
(11.44) 
Median (IQR) 64(55-75) 67(57-77) 60(52-69)  64(55-75) 67(57-77) 60(52-68) 
Sex        
Female 510(38.1) 377(40.4) 133(32.7)  409(36.2) 291(38.6) 118(31.5) 
Male 830(61.9) 556(59.6) 274(67.3)  720(63.8) 463(61.4) 257(68.5) 
Current smoker 
296/1047 
(28.3) 
178/694 
(25.6) 
118/353 
(33.4) 
 259/914 
(28.3) 
152/580 
(26.2) 
107/334 
(32.0) 
Medical history        
Hypertension 463(34.6) 336(36.0) 127(31.2)  397(35.2) 276(36.6) 121(32.3) 
Diabetes 234(17.5) 157(16.8) 77(18.9)  201(17.8) 129(17.1) 72(19.2) 
Hyperlipidaemia 867(64.7) 591(63.3) 276(67.8)  741(65.6) 486(64.5) 255(68.0) 
CRF 194(14.5) 140(15.0) 54(13.3)  170(15.1) 118(15.6) 52(13.9) 
IHD 323(24.1) 218(23.4) 105(25.8)  282(25.0) 186(27.7) 96(25.6) 
Prior antiplatelet therapy 
No prior AP 885(66.0) 576(61.7) 309(75.9)  770(68.2) 483(64.1) 287(76.5) 
Aspirin 316(23.6) 234(25.1) 82(20.1)  253(22.4) 177(23.5) 76(20.3) 
Clopidogrel 35(2.6) 29(3.1) 6(1.5)  24(2.1) 19(2.5) 5(1.3) 
Dipyridamole 6(0.4) 6(0.6) 0(0)  5(0.4) 5(0.7) 0(0) 
Aspirin + 
clopidogrel 
59(4.4) 52(5.6) 7(1.7) 
 
50(4.4) 44(5.8) 6(1.6) 
Aspirin + 
dipyridamole 
33(2.5) 30(3.2) 3(0.7) 
 
24(2.1) 23(3.1) 1(0.3) 
Aspirin + 
ticagrelor 
5(0.4) 5(0.5) 0(0) 
 
3(0.3) 3(0.4) 0(0) 
DAPT combinations post-ACS 
Aspirin + 
clopidogrel 
1261(94.2) 861(92.3) 400(98.3) 
 
1066(94.4) 697(92.4) 369(98.3) 
Aspirin + 
dipyridamole 
33(2.4) 30(3.2) 3(0.7) 
 
24(2.1) 22(2.9) 2(0.6) 
Aspirin + 
ticagrelor 
42(3.1) 38(4.0) 4(1.0) 
 
35(3.1) 31(4.1) 4(1.1) 
Aspirin + 
prasugrel 
3(0.2) 3(0.3) 0(0) 
 
3(0.3) 3(0.4) 0(0) 
Duration of DAPT        
Mean (SD) 
175.09 
(155.30) 
164.28 
(148.17) 
199.85 
(168.10) 
 176.64 
(154.48) 
163.02 
(143.03) 
204.03 
(172.22) 
Median (IQR) 
113 
(78-208) 
109 
(76-185) 
126 
(85-311) 
 112 
(78-221) 
108 
(75-187) 
128 
(85-317) 
≤ 6 months 955(71.3) 695(74.5) 260(63.9)  793(70.2) 558(74.0) 235(62.7) 
> 6 months 385(28.7) 238(25.5) 147(36.1)  336(29.8) 196(26.0) 140(37.3) 
≤ 12 months 1139(85.0) 812(87.0) 327(80.3)  948(84.0) 651(86.3) 297(79.2) 
> 12 months 201(15.0) 121(13.0) 80(19.7)  181(16.0) 103(13.7) 78(20.8) 
Follow-up duration after stopping DAPT, days 
Mean (SD) - - - 
 1009.34 
(534.79) 
950.28 
(553.12) 
1126.97 
(475.55) 
Median (IQR) - - - 
 1067 
(615-1394) 
982 
(509-1364) 
1155 
(828-1463) 
Single AP after DAPT cessation 
Aspirin - - -  893(79.1) 596(79.0) 297(79.2) 
Clopidogrel - - -  224(19.8) 146(19.4) 78(20.8) 
Dipyridamole - - -  7(0.6) 7(0.9) 0(0) 
Ticagrelor - - -  5(0.4) 5(0.7) 0(0) 
 
All values are reported as no. (%) unless otherwise noted. AP=antiplatelet, CRF=chronic 
renal failure, DAPT=dual antiplatelet therapy, IHD=ischaemic heart disease, 
SD=standard deviation, IQR=interquartile range.  
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6.3.4 Study endpoints 
Of 1340 patients, while on DAPT, incidence of cardiovascular events occurred in 
211 (15.7%) patients. Cardiovascular events occurred in 179 (19.2%) medical 
treated patients and 32 (7.9%) revascularization treated patients. Of 1129 patients 
after DAPT cessation, cardiovascular events occurred in 188 (16.7%) patients, 
which 154 (20.4%) occurred in medical and 34 (9.1%) in revascularization therapy 
(Table 6-4).  
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Table 6-4: Cardiovascular events during DAPT and after DAPT cessation 
 
During DAPT 
(n=1340) 
After DAPT cessation 
(n=1129) 
All 
Medical 
treated 
(n=933) 
Revascularization 
treated 
(n=407) 
All 
Medical 
treated 
(n=754) 
Revascularization 
treated 
(n=375) 
Cardiovascular events 211 (15.7) 179 (19.2) 32 (7.9) 188 (16.7) 154 (20.4) 34 (9.1) 
ACS 179 (13.4) 155 (16.6) 24 (5.9) 60 (5.3) 46 (6.1) 14 (3.7) 
Ischaemic stroke/TIA 2 (0.1) 2 (0.2) 0 (0) 24 (2.1) 16 (2.1) 8 (2.1) 
Heart failure 24 (1.8) 19 (2.0) 5 (1.2) 9 (0.8) 8 (1.1) 1 (0.3) 
All death 44 (3.3) 35 (3.8) 9 (2.2) 135 (12.0) 120 (15.9) 15 (4.0) 
 
All values are reported as no. (%) unless otherwise noted. ACS=acute coronary syndrome, DAPT=dual antiplatelet therapy, TIA=transient ischaemic 
attack. 
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6.3.5 Incidence rates of cardiovascular event 
The incidence rates of cardiovascular event during DAPT and after DAPT cessation 
are presented in Table 6-5 and Figure 6-2 for each 90-day interval. While on DAPT, 
the incidence rate was higher in 0-90-day interval than in the next 90-day interval, 
1.88 and 0.33 per 1000 patient-days, respectively. After cessation of DAPT, the 
incidence rate was lower in 0-90-day interval than in the next 90-day interval, 
0.15 and 0.23 per 1000 patient-days, respectively. 
 
 
Table 6-5: The risk of cardiovascular events following ACS while on DAPT and up to 
two years after DAPT cessation 
Period, days 
Number at 
risk 
Number of 
events 
Incidence rate  
per 1000  
patient-days  
During DAPT 
0-90 1340 181 1.882 
91-180 797 17 0.328 
181-270 354 5 0.184 
271-360 250 3 0.152 
361-450 189 1 0.088 
451-540 64 1 0.231 
541-630 32 1 0.453 
631-720 17 0 0.000 
After DAPT cessation 
0-90 1129 15 0.151 
91-180 1072 22 0.234 
181-270 1017 21 0.234 
271-360 978 10 0.115 
361-450 950 17 0.203 
451-540 910 16 0.119 
541-630 876 17 0.220 
631-720 840 15 0.205 
 
ACS=acute coronary syndrome, DAPT=dual antiplatelet therapy. 
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Figure 6-2: Incidence rate during and after DAPT cessation 
 
Figure 6-3 shows the incidence rate for both medically and revascularization-
treated patients while on DAPT and after DAPT cessation. The incidence rate for 
the first 90-day interval was higher in medically-treated patients than 
revascularization-treated patients, 2.34 and 0.91 per 1000 patient-days, 
respectively. Compared with revascularization-treated patients, medically-
treated patients were associated with significantly increased risk of cardiovascular 
event for 0-90-day interval (IRR, 2.57; 95% CI, 1.71-3.99; p<0.0001) (Figure 6-
3(a)).  
 
After DAPT discontinuation, in the first 90-day interval, there was no difference 
in the incidence rate of cardiovascular event between medically-treated patients 
and revascularization-treated patients (IRR, 3.30; 95% CI, 0.75-30.12; p=0.096) 
(Figure 6-3(b) and Table 6-6). However, there were significantly increased risk of 
cardiovascular event for 91-180 days and 181-270 days in medically-treated 
patients (IRR, 5.16; 95% CI, 1.25-5.54; p=0.014 and IRR, 3.31; 95% CI, 0.97-17.54; 
p=0.042 respectively). 
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(a) During DAPT 
 
(b) After DAPT cessation 
 
Figure 6-3: Incidence rate (a) during DAPT and (b) after DAPT cessation for medically- 
and revascularization-treated patients   
*p<0.01, †p<0.05, compared with revascularization-treated patients from the 
same interval. 
†  † 
* 
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Table 6-6: Incidence rate of cardiovascular events after DAPT cessation for medical and revascularization treated patients 
Period, 
days 
Medically-treated 
 
Revascularization-treated 
Incidence rate ratio* 
(95% CI) 
p-value 
Number 
at risk 
Number of 
events 
Incidence 
rate per 1000 
patient-days 
 
Number 
at risk 
Number of 
events 
Incidence rate 
per 1000 
patient-days 
0-90 754 13 0.199 
 
375 2 0.060 3.30 (0.75-30.12) 0.096 
91-180 706 20 0.325 
 
366 2 0.062 5.16 (1.25-5.54) 0.014 
181-270 660 18 0.311 
 
357 3 0.094 3.31 (0.97-17.54) 0.042 
271-360 628 10 0.180 
 
350 0 0.000 - - 
361-450 605 14 0.263 
 
345 3 0.100 2.64 (0.74-14.34) 0.112 
451-540 577 12 0.237 
 
333 4 0.135 1.76 (0.53-7.51) 0.319 
541-630 550 14 0.290 
 
326 3 0.104 2.82 (0.79-15.30) 0.089 
631-720 522 10 0.221 
 
318 5 0.179 1.24 (0.39-4.64) 0.689 
 
*Incidence rate ratio compared a difference incidence rate between medical and revascularization-treated patients. CI=confidence interval.
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The incidence rates of cardiovascular events following DAPT discontinuation for 
yearly interval are shown in Figure 6-4 and Table 6-7. The Incidence rate was 
higher in year two than in year one after DAPT cessation, 0.21 and 0.18 per 1000 
patient-days, respectively. The rate was decreased over the next three years and 
similar pattern can be seen for medically-treated patients. At the same time, 
medically-treated patients experienced a higher incidence rate compared to 
revascularization-treated patients for one-, two- and three-year interval after 
discontinuation of DAPT (IRR, 4.62; 95% CI, 2.22-11.98; p<0.0001; IRR, 1.97; 95% 
CI, 1.09-3.78; p=0.019 and IRR 2.94; 95% CI, 1.09-9.91; p=0.022 respectively). 
 
 
 
 
Figure 6-4: Incidence rate after DAPT cessation, stratified by medical and 
revascularization therapy 
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Table 6-7: Incidence rate of cardiovascular events yearly after DAPT cessation 
Period, 
years 
Number 
at risk 
Number 
of 
events 
Incidence 
rate per 
1000 
patient-
days† 
Medically-treated Revascularization-treated 
Incidence rate 
ratio*  
(95% CI) 
p-value 
Number 
at risk 
Number 
of 
events 
Incidence  
rate per 
1000 
patient-
days 
Number 
at risk 
Number 
of 
events 
Incidence 
rate per 
1000 
patient-
days 
1 1129 68 0.182 754 61 0.249 375 7 0.054 4.62 (2.22-11.98) <0.0001 
2 950 65 0.208 605 50 0.255 345 15 0.129 1.97 (1.09-3.78) 0.019 
3 786 28 0.117 484 23 0.156 302 5 0.053 2.94 (1.09-9.91) 0.022 
4 549 20 0.139 334 15 0.170 215 5 0.089 1.91 (0.66-6.71) 0.203 
5 252 7 0.120 156 5 0.138 96 2 0.090 1.53 (0.25-16.04) 0.670 
 
*Incidence rate ratio compared a difference incidence rate between medical and revascularization-treated patients. CI=confidence interval.
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6.3.6 Adjusted incidence rate ratios 
The adjusted IRR of cardiovascular event in the first 90 days compared, first, to 
the second 90 days (91-180-day) and second, to the 91-360-day interval after DAPT 
cessation are shown in Table 6-8. After adjusting for age, medical or 
revascularization therapy and total duration of DAPT treatment, there was no 
increased risk of cardiovascular event when compared the first 90 days with the 
91-360-day interval (adjusted IRR, 0.59; 95% CI, 0.30-1.17; p=0.129). There were 
similar observations in medically and revascularization-treated group.  
 
When compared with 91-180-day interval, after adjusting for age, medical or 
revascularization therapy and total duration of DAPT treatment, there was no 
increased risk of cardiovascular event the first 90 days (adjusted IRR, 0.70; 95% 
CI, 0.32-1.55; p=0.375). Similar observations were found in medical and 
revascularization therapy group.
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Table 6-8: Adjusted incidence rate ratios for the cardiovascular event after DAPT cessation 
Patient 
cohort 
After DAPT cessation  
(n=1129) 
 Medical therapy 
(n=754) 
 Revascularization therapy 
(n=375) 
n 
Adjusted IRR 
(95% CI) 
p-value 
 
n 
Adjusted IRR 
(95% CI) 
p-value 
 
n 
Adjusted IRR 
(95% CI) 
p-value 
All 
patients* 
1129 0.59 (0.30-1.17) 0.129 
 
754 0.54 (0.26-1.13) 0.101 
 
375 0.98 (0.16-6.04) 0.980 
            
All 
patients† 
1129 0.70 (0.32-1.55) 0.375 
 
754 0.64 (0.28-1.50) 0.306 
 
375 1.18 (0.13-10.96) 0.882 
 
*comparing the initial 90-day interval versus the 91 to 360-day interval after stopping DAPT. 
†comparing the initial 90-day interval versus the 91 to 180-day interval after stopping DAPT 
All the Poisson regression models adjusted for age, medical or revascularization therapy and duration of DAPT. CI=confidence interval, 
IRR=incidence rate ratio. 
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6.3.7 Predictors of cardiovascular events after DAPT cessation 
The univariate analysis of possible predictors of risk of cardiovascular events after 
stopping DAPT is presented in Table 6-9. Ten variables appeared to be significant 
predictors of cardiovascular events in the univariate analysis. The results of the 
final model of multivariate analysis are summarized in Table 6-10. The 
multivariate model indicated that increased age (HR, 1.07; 95% CI, 1.05-1.08; 
p=0.000) was significantly associated with an increased risk of cardiovascular 
event, whereas patients treated with revascularization (HR, 0.58; 95% CI, 0.39-
0.85; p=0.005) and longer duration of DAPT (HR, 0.997; 95% CI, 0.995-0.998; 
p=0.000) were associated with a decreased risk.  
 
6.3.8 Sub-group analysis 
Sub-group analyses data are presented as a forest plot in Figure 6-5. Whereas, 
Figures 6-6 to 6-8 presents the survival curves showing the cumulative rates of 
cardiovascular events for the sub-group analyses. 
 
a) Medically- and revascularization-treated patients 
In unadjusted model, there is a decreased risk of cardiovascular events in 
revascularization-treated patients compared to medically treated (HR, 0.38; 95% 
CI, 0.26-0.55; p=0.000). The same is true in the model adjusting for age and 
duration of DAPT (HR, 0.58; 95% CI, 0.39-0.85; p=0.005). Figure 6-6 presents the 
survival curves among those with revascularization and those with medically 
treated. 
 
b) DAPT duration 
DAPT duration of ≤ 6 months was associated with an increased risk of 
cardiovascular event following discontinuation of DAPT, compared to those with 
DAPT duration more than 6 months (unadjusted HR, 2.23; 95% CI, 1.50-3.32; 
p=0.000). Even after adjustment, the difference in cardiovascular events risk 
between patients with DAPT duration ≤ 6 months and those with DAPT duration > 
6 months remains statistically significant (adjusted HR, 1.51; 95% CI, 1.01-2.27; 
p=0.046). Figure 6-7(a) shows the survival curves between duration of DAPT ≤6 
months vs >6 months. 
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Similarly, for DAPT duration ≤ 12 months, the risk of cardiovascular event was 
associated with increased risk compared to those with DAPT duration more than 
12 months (unadjusted HR, 6.66; 95% CI, 2.74-16.20; p=0.000). After adjustment, 
the difference in cardiovascular event risk between those who received DAPT ≤ 12 
months and >12 months patients remains statistically significant, with four times 
increase in risk of cardiovascular event among ≤ 12 months group as compared to 
>12 months group (adjusted HR, 4.14; 95% CI, 1.69-10.14; p=0.002). Figure 6-7(b) 
shows the survival curves between duration of DAPT ≤12 months vs >12 months. 
 
c) Single antiplatelet therapy after DAPT cessation 
In the unadjusted model, there is an increased risk of cardiovascular event in those 
who continued with clopidogrel as compared to those continued with aspirin 
(unadjusted HR, 1.40; 95% CI, 1.01-1.94; p=0.046). However, after adjustment for 
age, medical or revascularization therapy, and duration of DAPT, there is no 
statistically significant difference between clopidogrel and aspirin group in terms 
of cardiovascular event risk (adjusted HR, 1.33; 95% CI, 0.95-1.85; p=0.095). 
Figure 6-8 shows the survival curves between clopidogrel vs aspirin therapy. 
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Table 6-9: Univariate Cox proportional hazards regression analyses of possible 
predictors of cardiovascular events after DAPT cessation 
Characteristics HR (95% CI) p-value 
Age 1.08 (1.06-1.09) 0.000 
Male 0.52 (0.39-0.69) 0.000 
Current smoker 1.35 (0.69-2.66) 0.380 
Hypertension 3.72 (2.44-5.66) 0.000 
Diabetes 5.85 (2.75-12.45) 0.000 
Hyperlipidaemia 1.56 (1.17-2.08) 0.002 
Chronic renal failure 1.76 (1.08-2.85) 0.023 
Ischaemic heart disease 5.34 (2.97-9.58) 0.000 
Revascularization vs medical 
therapy 
0.38 (0.26-0.55) 0.000 
Prior vs no prior AP 2.02 (1.51-2.70) 0.000 
DAPT duration 0.995 (0.994-0.997) 0.000 
 
AP=antiplatelet, CI=confidence interval, DAPT=dual antiplatelet therapy, HR=hazard 
ratio. 
 
 
Table 6-10: Final multivariate model of predictors of risk of cardiovascular events 
after stopping DAPT  
Characteristics HR (95% CI) p-value 
Age 1.07 (1.05-1.08) 0.000 
Revascularization vs medical 
therapy 
0.58 (0.39-0.85) 0.005 
DAPT duration 0.997 (0.995-0.998) 0.000 
 
CI=confidence interval, DAPT=dual antiplatelet therapy, HR=hazard ratio.
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Figure 6-5: Forest plot showing outcomes for (a) unadjusted and (b) adjusted analysis.  
All adjusted analyses were adjusted for age, medical or revascularization therapy and duration of DAPT. AP=antiplatelet, CI=confidence interval, 
DAPT=dual antiplatelet therapy. 
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Figure 6-6: Survival curve showing the cumulative rates of the combined end point 
acute coronary syndrome or death or ischaemic stroke among those medically- and 
revascularization-treated patients after DAPT cessation 
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(a) ≤6 months vs >6 months 
 
(b) ≤12 months vs >12 months 
 
Figure 6-7: Survival curve showing the cumulative rates of cardiovascular events 
among those with DAPT duration (a) ≤ 6 months vs > 6 months; and (b) ≤12 months 
vs >12 months. 
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Figure 6-8: Survival curve showing the cumulative rates of the combined end point 
acute coronary syndrome or death or ischaemic stroke among those continued 
aspirin and those continued with clopidogrel after DAPT cessation. 
 
6.4 Discussion 
The objective of the present study was to determine the incidence and predictors 
of cardiovascular events after DAPT cessation in patients who have suffered ACS. 
The main findings of the current analysis are as follows; (1) incidence of 
cardiovascular events occurred in 188 (16.7%) patients after DAPT cessation; (2) 
the incidence rate was lower in 0-90-day interval than in the next 90-day interval 
after DAPT cessation, 0.15 and 0.23 per 1000 patient-days, respectively; (3) in the 
multivariate analysis, age, having medical or revascularization therapy and 
duration of DAPT were independent predictors of cardiovascular event after DAPT 
cessation; (4) duration of DAPT six months and less was associated a significantly 
higher risk for cardiovascular event; (5) continuation of monotherapy agent post-
DAPT cessation with clopidogrel compared with aspirin was not associated with 
higher risk for cardiovascular event.  
 
The incidence of cardiovascular events following DAPT cessation in the literature 
varies between studies (4-17%). The incidence in the present study are higher than 
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previous studies (Ho, et al., 2010; Stephenson, et al., 2011; Charlot, et al., 2012) 
but similar to the data from Ho, et al. (2008b). This may be due to differences in 
definitions used of cardiovascular event between studies that could lead to 
markedly different results (Kip, et al., 2008). In this study, cardiovascular event 
was defined according to ACC/AHA (Hicks, et al., 2015). On the other hand, the 
mean (SD) duration of DAPT after ACS in the present study was 177 (155) days, 
which was shorter than previous studies (Stephenson, et al., 2011; Charlot, et al., 
2012). Previous studies have shown that thienopyridine therapy for more than six 
months was associated with lower rates of cardiovascular events (Rossini, et al., 
2011; Varenhorst, et al., 2014). 
 
The present study found the incidence rate of cardiovascular event in the first 90 
days following discontinuation of DAPT was lower than 91-180-day interval. These 
findings are substantially different from those in recent studies from Ho, et al. 
(2008b); (Ho, et al., 2010); Stephenson, et al. (2011) and Charlot, et al. (2012) 
where they reported a higher incidence rate of death or MI in the 0-90-day interval 
after stopping clopidogrel compared with 91-180-day interval. This may be due to 
the smaller sample size of patients included in the present study. In addition, the 
prevalence of medically-treated patients in the present study was 67%, much 
higher than the findings from Ho, et al. (2008b) (50%) and Stephenson, et al. 
(2011) (25%). Evidenced-based data have shown that invasive strategy i.e. 
coronary angiography followed by revascularization performed in the setting of 
AMI reduces subsequent MI, severe angina and death compared with 
pharmacological therapy (Mehta, et al., 2005). 
 
In terms of patients treated with or without revascularization, the present study 
found no increased incidence rate of cardiovascular event in the first 90-day 
period of DAPT discontinuation compared with later follow-up interval. There is a 
potential explanation for the lower number of cardiovascular events after 
stopping DAPT in the 0-90-day interval. One explanation is that there were maybe 
less patients in this study that may have stopped clopidogrel, prasugrel or 
ticagrelor early due to clinical deterioration or bleeding. They probably had 
stopped DAPT regimen under physician-guided or they had completed the 
recommended duration of DAPT. This is supported by findings from Mehran et al, 
2013 in the PARIS (patterns of non-adherence to antiplatelet regimens in stented 
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patients) study where they found patients who had physician-guided 
discontinuation of DAPT were at lower risk of major cardiovascular event (Mehran, 
et al., 2013). In the present study, we also found the incidence rates in the 
cardiovascular event as time passed from the DAPT discontinuation were higher in 
patients treated medically compared to revascularization-treated patients. One 
possible reason is because revascularization-treated patients had longer DAPT 
duration compared to medically treated patients. Ho, et al. (2010) and Charlot, 
et al. (2012) have described that longer duration of DAPT was associated with 
lower risk of cardiovascular event following discontinuation of DAPT. 
 
This study found that increasing age, shorter DAPT duration and lack of 
revascularization therapy for the ACS was associated with increased risk of 
cardiovascular events after DAPT cessation.  The present study found that longer 
duration of DAPT was associated with a decreased risk of cardiovascular event in 
patients who have suffered ACS. In addition, shorter term DAPT (≤6 months) was 
associated with an increased risk of cardiovascular event compared to longer term 
(>6 months). Similarly, duration of DAPT ≤12 months was associated with an 
increased risk compared with >12 months. These findings are consistent with those 
from previous studies that demonstrated that usage of clopidogrel for more than 
six months was associated with lower rates of death, myocardial infarction and/or 
stent thrombosis (Rossini, et al., 2011; Varenhorst, et al., 2014). These data 
suggest that ACS patients may benefit from longer duration of DAPT. On the other 
hand, findings of PRODIGY trial found that there was no difference in death, MI or 
ischaemic stroke between DAPT duration of six months compared with 24 months 
(HR, 0.94; 95% CI, 0.69-1.27; p=0.67) (Costa, et al., 2015). Although longer 
treatment with DAPT might be beneficial, optimal DAPT duration for patients with 
ACS still in unclear because longer DAPT duration correlates with the risk of 
bleeding (Valgimigli, et al., 2012; Mauri, et al., 2014). 
 
6.4.1 Study strengths 
In this study, aspirin use was available through the Prescribing Information System 
database. Thus, we were able to confirm that all patients included in this study 
were taking aspirin plus either clopidogrel or prasugrel or ticagrelor. Compare to 
others, aspirin used was not available (Ho, et al., 2010; Stephenson, et al., 2011; 
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Sachdeva, et al., 2012). This information is important since there is a possibility 
that patients could not tolerate or allergic to aspirin and just prescribed with 
clopidogrel alone. Moreover, we could confirm whether patients took aspirin or 
another antiplatelet agent after discontinuing DAPT regimen. 
 
As compared with others, the present study included patients in the West of 
Scotland as the data were collected and managed by NHSGGC Safe Haven. The 
current analysis is a study of all individuals in a community with an ACS identified 
through resources of the NHSGGC Safe Haven, regardless of sex and health care 
insurance. In previous studies, they only able to include predominantly male 
patients (Ho, et al., 2008b) or patients with insured and received care in large 
pre-paid health plan (Ho, et al., 2010; Stephenson, et al., 2011) and there was a 
possibility underinsured or non-insured were left out. Furthermore, the large 
number of patients, long period of follow-up, and use of Cox proportional hazards 
regression analysis in this study allowed us to develop more precise models to 
predict survival and cardiovascular events after stopping DAPT regimen. 
 
6.4.2 Study limitations 
There are limitations of the present study that must be considered. The analysis 
of this study was performed using a non-randomized registry database. The choice 
of antiplatelet used were not randomly assigned. Whereas for subgroup analysis, 
there are possibilities of patient selection bias and non-randomized groups. After 
DAPT discontinuation, the differences in time of follow-up for CV events is 
potential for biases. The use of single or dual antiplatelet therapy was based on 
pharmacy dispensing data. However, we could not measure medication 
compliance such as medication possession ratio (MPR), as this formula needs at 
least two prescriptions, and it is possible we will leave out any patients with only 
one prescription. Moreover, we had comprehensive pharmacy dispensing data in 
terms of what and when the antiplatelet was dispensed and number of pills 
supplied. Furthermore, pharmacy dispensing data are a validated measure of 
medication taking and is strongly correlated with a broad range of patient 
outcomes (Osterberg and Blaschke, 2005; Ho, et al., 2008a) and also, the use of 
prescriptions filled has been shown to reflect medication use by the patient with 
a high degree of accuracy (Lau, et al., 1997). 
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We also do not know the specific reasons for stopping the second antiplatelet 
therapy, but potential reasons are, they might have completed the DAPT course 
which is the expected reason for most of the patients; or the occurrence of side 
effects from antiplatelet therapy, such as bleeding. Additionally, the patients in 
the study sample were five years younger and less female than the original 
population. As a consequence, generalizability of findings in this study is limited. 
The present study included patients who have suffered ACS in the West of 
Scotland, thus, generalizability to other populations and practice setting is 
unknown. 
 
6.5 Conclusion 
The present study found that, in patients who have suffered ACS, incidence of 
cardiovascular events occurred in 188 (16.7%) patients after DAPT cessation and 
the incidence rate was lower in 0-90-day interval than in the next 90-day interval 
after DAPT cessation, 0.15 and 0.23 per 1000 patient-days, respectively. This 
study found that age was associated with increased risk of cardiovascular events, 
whereas, longer duration of DAPT and patients treated with revascularization 
were associated with decreased risk of cardiovascular events. 
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7 Stopping dual antiplatelet therapy following 
acute coronary syndrome; A metabolic analysis 
7.1 Introduction 
There have been reports of cardiovascular events after clopidogrel cessation 
among patients with ACS either received medical therapy or treated with PCI. In 
2008, a study by Ho, et al. (2008b) using the cohort from Veterans Health 
Administration, found a clustering of cardiovascular events after clopidogrel 
cessation. In multivariate analysis, the study found the first 90-day interval after 
clopidogrel cessation was associated with significantly higher risk of 
cardiovascular events compared with 91-180 days interval (incidence rate ratio 
(IRR), 1.98; 95% confidence interval (CI), 1.46-2.69). Another study by Ho, et al. 
(2010) using cohort from an integrated health care delivery system in Colorado 
found similar observations. The risk of MI or death was greater (IRR, 2.74; 95% CI, 
1.69 to 4.44) in day 0-90 compared with 91-360-day interval. 
 
According to the current guidelines, antiplatelet drugs should be prescribed 
following acute myocardial infarction and ischaemic stroke (National Institute for 
Health and Clinical Excellence, 2008; National Institute for Health and Clinical 
Excellence, 2013). These include aspirin which reduces production of 
thromboxane A2 via inhibition of COX-1. Clopidogrel and ticagrelor bind to the 
P2Y12-receptor on platelet cell membrane to prevent ADP secretion and thus, 
prevent platelet activation. Both aspirin and clopidogrel / ticagrelor are 
prescribed for varying durations after MI or ACS and at the end of this period the 
clopidogrel / ticagrelor is stopped. As described above, this may be associated 
with an increased risk of cardiovascular events.  
 
Detailed metabolomic analysis in patients taking DAPT was performed before and 
after stopping DAPT. The metabolite changes between these two-time points will 
be compared. In this preliminary study, we hypothesized that metabolomics might 
help identify metabolites influencing outcomes and risk of recurrence following 
DAPT cessation. 
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7.2 Methods 
7.2.1 Study design 
The prospective study was conducted in the Western Infirmary and Queen 
Elizabeth University Hospital. Patients receiving DAPT with aspirin and clopidogrel 
or ticagrelor for a proposed fixed duration were recruited from the Cardiac 
Rehabilitation Centre and the wards of Western Infirmary (NHS Greater Glasgow 
& Clyde (NHSGGC)).  
 
7.2.2 Main inclusion / exclusion criteria 
Inclusion criteria for patients 
1. Adult male or female 
2. Age > 18 years 
3. Diagnosis of ACS  
4. Taking DAPT with aspirin and clopidogrel / ticagrelor since the diagnosis of 
ACS being made 
5. Planned stop date for dual anti-platelet therapy 
Exclusion criteria for patients 
1. Current use of anticoagulant drugs 
2. Active cancer 
3. Recurrent urinary tract infection (UTI)*  
4. Inability to provide informed consent 
 
*For urinary metabolomics study, patients with recurrent UTI were excluded. This 
is because, these patients are at high risk of developing adverse event. Previous 
studies have shown that metabolites identified from patients with UTI, such as 
para-aminohippuric acid, scyllo-inositol and a few unidentified compounds has 
been suggested as main markers related to patients morbidity (Nevedomskaya, et 
al., 2012). 
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7.2.3 Ethical considerations  
This study was carried on accordance with the World Medical Association 
Declaration of Helsinki (1964) and it’s revisions (Tokyo (1975), Venice (1983), Hong 
Kong (1989), South Africa (1996), Edinburgh (2000), Washington (2002), Tokyo 
(2004), Seoul (2008) and Fortaleza (2013)). Patients were only allowed to enter 
the study once they have provided written informed consent. This study was 
approved by the North West – Greater Manchester East Research Ethics Committee 
(Appendix 9 & Appendix 10). Access to the hospital for research was obtained 
from the Research and Development Office, Western Infirmary (Appendix 11). 
 
7.2.4 Identification of participants and consent 
Participants were identified through clinical teams in the Cardiac Rehabilitation 
Centre and the wards of the Western Infirmary. Study advertisements were placed 
in these settings and interested patients were asked to contact the study team 
(Appendix 12). Letter of invitations were sent from the clinical team to patients 
who met our inclusion and exclusion criteria (Appendix 13 & Appendix 14). 
Interested patients were asked to contact us. We then discussed the study by 
telephone, confirmed the predicted DAPT stop date and sent the participant 
information sheets (Appendix 15).  
 
7.2.5 Visit schedule 
Participants attended the Acute Stroke Unit, Western Infirmary or Glasgow 
Research Facility, Queen Elizabeth University Hospital for a first visit in the month 
prior to the planned DAPT stop date. All participants provided written informed 
consent (Appendix 16) prior to study inclusion. At this visit, baseline demographic 
data, current medication, use of non-steroidal anti-inflammatory medications and 
medical history were recorded in the case report form (CRF) (Appendix 17). 
Medication compliance was recorded and assessed by self-reported Morisky scale 
questionnaire (Appendix 18). Blood and urine sampling were performed during 
this visit (Figure 7-1). 
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Participants then attended the Acute Stroke Unit, Western Infirmary or Glasgow 
Research Facility, Queen Elizabeth University Hospital for a further blood and 
urine sample in the month after stopping DAPT (at least 7 days after stopping). 
Current medications were recorded in the CRF. A 90-day followed up were done 
by accessed to participant clinical records.  
 
 
 
3-12 months 3 months 
  
 
DAPT 
 
Single AP  
(monitoring of cv events) 
 
 
 
Figure 7-1: Study design and protocol of laboratory and monitoring cardiovascular 
events.  
ACS=acute coronary syndrome, AP=antiplatelet, cv=cardiovascular, DAPT=dual 
antiplatelet therapy, MI=myocardial infarction. 
 
 
7.2.6 Blood sampling and storage 
I personally performed venepuncture in approximately 90% of the participants (the 
remaining 10% were performed by experienced research nurses from Acute Stroke 
Unit). Blood samples were obtained from the antecubital fossa. In all cases blood 
was taken using a tourniquet with a 21-gauge needle blood collection set. The 
blood was drawn into two 10 ml clot activator tubes.  
 
In metabolomics studies, serum and plasma samples are commonly used. In this 
study, serum sample was chosen. Once the blood exposed to clot activator in the 
tube, platelets become activated. In the serum, various of metabolites, lipids and 
proteases were released from the activated platelets during the coagulation 
process (Yin, et al., 2015). On the other hand, exposure of plasma for long hours 
Blood/urine 
sampling 
ACS or MI Clopidogrel/ 
Ticagrelor 
cessation 
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to room temperature may resulted significant changes of the analysed metabolites 
(Yang, et al., 2013). 
 
The blood was allowed to clot at room temperature for 15 minutes. Then, blood 
samples were centrifuged for 15 minutes. Serum samples were separated and 
stored at -80˚C immediately. Samples were stored in a locked university freezer 
in the Western Infirmary and were transported at the end of the study to the 
Glasgow Polyomics facility at the University of Glasgow. 
 
7.2.7 Assessment of medication compliance 
Self-reported adherence was determined using Morisky Medication Adherence 
Scale-4 (MMAS-4) at Visit 1. The MMAS-4 is a validated, 4-item self-reported 
adherence measure and a high adherence will be defined as a zero point 
(Appendix 18) (Morisky, et al., 1986). This scale has been shown to be predictive 
of adherence to cardiovascular medication and blood pressure control (Morisky, 
et al., 1986; Shalansky, et al., 2004). 
 
7.2.8 Assessment of cardiovascular event / follow up 
Patients were followed-up for cardiovascular event through a telephone call at 
day 90 or via access to their clinical records if contact could not be made. They 
were asked if there was any admission within the last 90 days and then we 
accessed patient medical records. If they developed event(s), their types of 
events were recorded in their CRF.  
 
7.2.9 Definition of cardiovascular event 
Cardiovascular event was defined as re-admission to hospital for a cardiovascular 
event, which includes ACS, stroke, TIA, heart failure, stent thrombosis or death 
due to a cardiac cause or stroke. The cardiovascular event outcomes were based 
on a primary discharge diagnosis or death using the ICD-10 codes in Appendix 5.  
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7.2.10 Metabolite measurements by LCMS 
Once transferred to Glasgow Polyomic facility, serum samples were mixed as 
Chloroform : Methanol : sample in a 1:3:1 ratio. This was then mixed vigorously 
on a cooled (4°C) shaker for 5 minutes and then centrifuged for 3 minutes at 
13,000g at 4°C. Supernatant was removed and stored at -80°C until analysis by 
Liquid Chromatography Mass Spectrometry (LC-MS). Samples were then analysed 
using ultra-high resolution mass spectrometry. 
 
7.2.11 Quality control (QC) 
In this untargeted metabolomics approach by LC-MS, QCs were applied to assess 
and ensure the process of analytical is done appropriately. The pooled QC samples 
were used to assess the running of the instrument for reproducibility. The pooled 
samples were run throughout the sample analysis, every 5th sample.  
 
7.2.12 Liquid chromatography-mass spectrometry  
The sample platform chosen for this project was liquid chromatography coupled 
with mass spectrometry. Metabolites were separated using a ZIC-pHILIC column 
(150mm x 4.6mm, 5µm column, Merck Sequant) on a Dionex Ultimate 3000 RSLC 
system (Thermo Fisher Scientific, Hemel Hempstead, UK). Analysis was performed 
using 10 µl injection volume and a flow rate of 300 µl/min. For mass spectrometry 
analysis, a Thermo Orbitrap Exactive (Thermo Fisher scientific) was operated in 
both positive and negative detection ion modes. The work was done by researchers 
at the Glasgow Polyomics Facility. 
 
7.2.13 Metabolomic data analysis 
Samples for Metabolomic Analysis 
Limits of quantitation (LOQ) parameter, the smallest concentration of analyte, 
was set at 1000 intensity. Samples detected below of this level were excluded 
from data analysis. 
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Data Processing 
Data were analysed using an in-house suite of software built using XCMS (Smith, 
et al., 2006), MzMatch (Jankevics, et al., 2012) and IDEOM version 18 software. 
The software consists of state-of-the-art peak-picking, alignment and filtering 
algorithms that effectively mine raw metabolomics data to produce meaningful 
information. A full suite of statistical tools is also built in to the software.  
 
7.2.14 Statistical analysis 
Descriptive statistics were recorded. For categorical variables such as 
demographics and medical history data, they were summarised using frequencies 
and proportions. Whereas for continuous variables, they were summarised using 
mean [standard deviation (SD)] or median [interquartile range (IQR)]. 
 
This is an exploratory study so no sample size calculation was performed. There 
are no data available on the metabolic signature of clopidogrel and/or ticagrelor 
while taking these two antiplatelet agents and after discontinuation. The baseline 
time refers to before clopidogrel or ticagrelor cessation (pre-). The differences of 
metabolite changes before and after DAPT cessation was determined using paired 
t-test with a p-value of <0.05 was considered to represent statistical significance.  
 
7.3 Results 
7.3.1 Participant characteristics 
A total of 29 patients were screened in the study. One patient withdrew 
prematurely due to inconvenience associated with multiple hospital visits required 
for venesection, 11 patients were excluded because they did not know the planned 
stop date for clopidogrel/ticagrelor and there were 7 patients where the durations 
of clopidogrel/ticagrelor were longer than the study duration. Study data are 
presented on 10 patients.  
 
Baseline characteristics and demographics of the study population are provided in 
Table 7-1. The participants were predominantly male (60%) with a mean age (SD) 
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of 64.6 (7.2) years. Cardiac risk factors included hyperlipidaemia (30%), 
hypertension (20%) and active smoking (20%). All participants were on aspirin 
75mg daily, statin and beta-blocker therapy. Nine (90%) patients were on 
ticagrelor 90mg twice daily, one (10%) patient was on clopidogrel 75mg daily, 7 
(70%) were on angiotensin-converting enzyme (ACE) inhibitors or angiotensin 
receptor blockers (ARB) and 4 (40%) were on proton pump inhibitors. The mean 
total duration (SD) of DAPT therapy following ACS was 174 (28.4) days.  
Chapter 7 Stopped DAPT: Metabolic analysis 186 
 
Table 7-1: Baseline characteristics 
Characteristics  
All patients 
n=10 
Metabolomics analysis 
n=7 
Age, years   
Mean (SD) 64.6 (7.152) 66.0 (7.188) 
Median (IQR) 65.5 (59-70) 68 (60-72) 
Sex   
Female 4 (40) 3 (42.9) 
Male 6 (60) 4 (57.1) 
Current smoker 2 (20) 1 (14.3) 
Medical history   
Hypertension 2 (20) 2 (28.6) 
Diabetes 0 (0) 0 (0) 
Hyperlipidaemia 3 (30) 2 (28.6) 
Stroke/TIA 1 (10) 1 (14.3) 
IHD 1 (10) 0 (0) 
LV systolic function (LVEF)   
Good (LVEF >50%) 9 (90) 6 (85.7) 
Moderate (LVEF 30-50%) 1 (10) 1 (14.3) 
Poor (LVEF <30%) 0 (0) 0 (0) 
Indication for DAPT   
ST-elevation MI 5 (50) 5 (71.4) 
Non-ST-elevation MI 3 (30) 2 (28.6) 
Unstable angina 1 (10) 0 (0) 
ACS 1 (10) 0 (0) 
DAPT duration, days   
Mean (SD) 173.5 (28.383) 167.4 (32.501) 
Median (IQR) 182.5 (172-188) 180 (171-184) 
Antiplatelet therapy   
Aspirin  10 (100) 7 (100) 
Clopidogrel  1 (10) 0 (0) 
Ticagrelor  9 (90) 7 (100) 
Other medication   
Statin 10 (100) 7 (100) 
Beta-blockers 10 (100) 7 (100) 
ACE-inhibitors/ARB 7 (70) 5 (71.4) 
Diuretics 1 (10) 1 (14.3) 
Proton pump inhibitors 4 (40) 3 (42.9) 
 
All values are reported as no. (%) unless otherwise noted. ACE=angiotensin-converting 
enzyme, ACS=acute coronary syndrome, ARB=angiotensin receptor blocker, DAPT=dual 
antiplatelet therapy, IHD=ischaemic heart disease, IQR=inter-quartile range, LV=left 
ventricular, LVEF=left ventricular ejection fraction, MI=myocardial infarction, 
PCI=percutaneous coronary intervention, SD=standard deviation, TIA=transient ischaemic 
attack. *All patients. †After exclusion.   
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7.3.2 Clinical events 
During the study follow-up, no patients developed subsequent cardiovascular 
event as defined in section 7.2.9. However, there was one patient admitted to 
the hospital, for one night, 12 days after stopping clopidogrel with a complaint of 
left leg pain and swelling. 
 
7.3.3 Changes in metabolite levels after discontinuation of DAPT 
For metabolomics analysis, three patients were removed from the analysis i.e. 
one patient treated with clopidogrel and two patients with poor signal (LOQ < 
1000). Thus, metabolomics analysis data are presented for 7 patients. Baseline 
characteristics and demographics for 7 patients as shown in Table 7-1. 
 
In metabolomics analysis, 311 putative metabolites were identified (Appendix 
19). Figure 7-2 shows the distribution of metabolites identified before and after 
DAPT cessation according to their grouped pathways. The majority of metabolites 
identified were from lipid pathway (39%), which most of them came from 
glycerophospholipid and fatty acyls pathways. Amino acid pathway accounted for 
about 22% and followed by carbohydrate metabolism, at 8.4%. There were 23% 
metabolites from unknown pathways. The remaining 8% metabolites were from 
nucleotide, cofactors and vitamins, peptide, energy and biosynthesis of secondary 
metabolites pathway. 
 
Data analysed using IDEOM v18 found 16 putative metabolites significantly altered 
by DAPT discontinuation in the seven included patients (Table 7-2). Of these, 7 
metabolites were from lipid pathway, 1 from carbohydrate metabolism, 1 from 
nucleotide metabolism. Lipid pathway was significantly affected by DAPT 
cessation. Most of the compounds identified were downregulated especially 
compounds in lipid pathway, which downregulated some up to 3-fold. Whereas for 
adenosine, metabolite identified from nucleotide metabolism, was upregulated 
2.6-fold.  
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Figure 7-2: Pie chart of putative metabolites identified according to their group of 
pathway following DAPT cessation in ACS patients. 
 
There were 7 compounds identified from lipid pathway which majority came from 
fatty acyls metabolism, and the remaining from lipid metabolism and sphingolipid 
metabolism. The metabolites were 4-8dimethylnonanoylcarnitine, 10-undecenoic 
acid, 2-methyl-2-dodecenoic acid, 9,12-hexadecadienoic acid, 9Z,12Z,15Z-
octadecatrienoic acid, 11Z-eicosenoic acid and sphingomyelin. Figure 7.3 shows 
the graphs of seven individual metabolites identified before and after DAPT 
cessation from lipid pathways with mean peak intensities and error bars. As we 
can see, the mean intensity for octadecatrienoic acid compound was the highest 
compared to others even before and after DAPT cessation. 
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Table 7-2: Significant metabolites changes detected following DAPT cessation. 
Formula Putative metabolite 
KEGG 
ID 
Map/Pathway 
Post-DAPT 
cessation 
p-
value*† 
ClHO4 perchlorate - 0 0.82 0.010 
C21H41NO4 Tetradecanoylcarnitine - 0 0.62 0.048 
C19H37NO4 1,2-dioctanoyl-1-amino-2,3-propanediol - 0 0.59 0.050 
C12H18O2 4-Hexyloxyphenol C14305 0 0.59 0.024 
C21H37NO4 3, 5-Tetradecadiencarnitine - 0 0.50 0.037 
C29H48O2 (24R,24'R)-Fucosterol epoxide C03910 0 0.40 0.035 
C10H12O3 Coniferyl alcohol C00590 
Biosynthesis of 
Secondary Metabolites 
0.48 0.046 
C6H14O6 D-Sorbitol C00794 Carbohydrate Metabolism 0.26 0.032 
C18H35NO4 4-8dimethylnonanoylcarnitine - Lipid Metabolism 0.63 0.002 
C11H20O2 [FA (11:1)] 10-undecenoic acid C13910 Lipids: Fatty Acyls 0.67 0.041 
C13H24O2 [FA methyl(12:1)] 2-methyl-2-dodecenoic acid - Lipids: Fatty Acyls 0.67 0.039 
C16H28O2 [FA (16:2)] 9,12-hexadecadienoic acid - Lipids: Fatty Acyls 0.52 0.041 
C18H30O2 
[FA (18:3)] 9Z,12Z,15Z-octadecatrienoic acid (alpha-
Linolenic acid) 
C13910 Lipids: Fatty Acyls 0.47 0.037 
C20H38O2 [FA (20:0)] 11Z-eicosenoic acid C13910 Lipids: Fatty Acyls 0.44 0.034 
C41H81N2O6P SM(d18:1/18:1(9Z)) (Sphingomyelin) C13910 Lipids: Sphingolipids 0.78 0.044 
C10H13N5O4 Adenosine C13910 Nucleotide Metabolism 2.60 0.028 
Metabolites identified with confidence 10 (matching authentic standard) are highlighted in grey. Data were generated on IDEOM v18. *Paired t-test 
was performed to calculate p-value. †uncorrected p-value.
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Figure 7-3: Fatty acid metabolism differences following DAPT cessation in patients 
with ACS. Graphs showing the mean intensity of compounds of before (pre) and after 
(post) DAPT cessation, with error bars. 
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Table 7-3 shows 7 putative metabolites identified from nucleotide metabolism. 
Five metabolites were downregulated and two metabolites were upregulated. 
Adenosine was found significantly altered following DAPT cessation (p=0.028) and 
inosine was a borderline significant trend (p=0.082). The remaining metabolites in 
this pathway were not significantly associated with ticagrelor cessation. Mean 
peak intensities and error bars for adenosine compound is presented in Figure 7.4. 
The mean intensities for adenosine was increased from 2042 to 5306 following 
ticagrelor cessation.  
 
Table 7-3: Nucleotide metabolism differences after DAPT cessation.  
Formula Putative metabolite 
Post-DAPT 
cessation 
p-value*† 
C10H13N5O4 Adenosine 2.60 0.028 
C5H4N4O2 Xanthine 1.05 0.868 
H2O4S Sulfate 0.88 0.276 
C5H4N4O Hypoxanthine 0.88 0.793 
C9H12N2O6 Uridine 0.81 0.538 
C10H12N4O5 Inosine 0.78 0.082 
C5H4N4O3 Urate 0.78 0.172 
 
Metabolites identified with confidence 10 (matching authentic standard) are highlighted 
in grey. Significant metabolites changes are highlighted in blue. Data were generated on 
IDEOM v18. *Paired t-test was performed to calculate p-value. †uncorrected p-value. 
 
 
 
 
Figure 7-4:  Adenosine compound differences following DAPT cessation in patients 
with ACS. Graph showing the mean intensity of compound of before (pre) and after 
(post) DAPT cessation, with error bars.  
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Only one putative metabolite was significant from carbohydrate metabolism i.e. 
D-sorbitol (Table 7.4). The mean intensities for D-sorbitol was decreased from 
37482 to 9642 following ticagrelor cessation (Figure 7-5). 
 
Table 7-4: Changes detected in carbohydrate metabolism after DAPT cessation. 
Formula Putative metabolite 
Post-DAPT 
cessation 
p-
value*† 
C4H8O2 Butanoic acid 0.98 0.831 
C4H8O2 (R)-Acetoin 0.97 0.421 
C6H12O7 D-Gluconic acid 0.94 0.696 
C6H12O6 myo-Inositol 0.93 0.610 
C6H10O5 2-Dehydro-3-deoxy-L-rhamnonate 0.90 0.547 
C5H10O5 D-Xylulose 0.88 0.532 
C4H8O4 D-Erythrose 0.88 0.461 
C3H4O3 3-Oxopropanoate 0.87 0.488 
C6H6O6 cis-Aconitate 0.87 0.703 
C5H8O4 2-Acetolactate 0.87 0.512 
C5H10O4 Deoxyribose 0.85 0.710 
C5H10O5 D-Ribose 0.84 0.583 
C5H10O6 L-Arabinonate 0.84 0.425 
C6H13NO5 D-Galactosamine 0.84 0.391 
C6H12O5 L-Rhamnulose 0.84 0.318 
C5H6O5 2-Oxoglutarate 0.79 0.510 
C6H8O7 Citrate 0.75 0.374 
C4H8O3 4-Hydroxybutanoic acid 0.75 0.330 
C4H6O5 (S)-Malate 0.74 0.570 
C4H8O5 
[FA trihydroxy(4:0)] 2,3,4-trihydroxy-
butanoic acid 
0.74 0.209 
C3H8O3 Glycerol 0.71 0.186 
C5H6O6 4-Hydroxy-2-oxoglutarate 0.68 0.399 
C3H4O3 Pyruvate 0.66 0.484 
C3H6O3 (R)-Lactate 0.51 0.420 
C6H8O6 Ascorbate 0.47 0.430 
C6H14O6 D-Sorbitol 0.26 0.032 
 
Metabolites identified with confidence 10 (matching authentic standard) are highlighted 
in grey. Significant metabolites changes are highlighted in blue. Data were generated on 
IDEOM v18. *Paired t-test was performed to calculate p-value. †uncorrected p-value. 
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Figure 7-5: D-sorbitol compound differences following DAPT cessation in patients 
with ACS. Graph showing the mean intensity of D-sorbitol before (pre) and after 
(post) DAPT cessation, with error bars.   
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7.4 Discussion 
Ten ACS patients were recruited in this preliminary study. All patients were 
treated with aspirin 75mg daily and combination with thienopyridine; nine 
patients were on ticagrelor and only one patient was on clopidogrel. One of the 
objectives of the study was to see metabolite changes after clopidogrel cessation, 
as clopidogrel cessation are known to cause increased risk of cardiovascular event, 
especially within the first 90 days after discontinuation. However, due to changes 
in clinical practice with the approval of ticagrelor for the treatment of post-PCI 
and ACS in the United Kingdom in October 2011 (National Institute for Health and 
Clinical Excellence, 2011), there were more patients prescribed with ticagrelor 
than clopidogrel in this study. Thus, for metabolomics analysis purposes, one 
patient treated with clopidogrel and two patients with poor signals were excluded 
from the analysis. Although at the moment, there is no evidence of increased risk 
of cardiovascular event following discontinuation of ticagrelor, in this section, 
discussion will be focusing on metabolite changes related to ticagrelor. 
 
In the present pilot study, the level of adenosine was significantly increased and 
inosine level was decreased with almost approached significance, following 
ticagrelor cessation. These findings are not completely understood. Logically, 
adenosine level should decrease following ticagrelor cessation as others (van 
Giezen, et al., 2012; Armstrong, et al., 2014; Bonello, et al., 2014) have reported 
that ticagrelor increases adenosine concentration in ACS patients via inhibiting 
cellular uptake of adenosine (refer Figure 7-6). Although further study is needed, 
there are possible mechanisms that maybe responsible for these findings. First, 
adenosine levels in the extracellular space mainly derive from phosphor-hydrolysis 
of precursor nucleotides such as adenosine triphosphate (ATP), adenosine 
diphosphate (ADP) and adenosine monophosphate (AMP) (Eltzschig, 2009) (Figure 
7-6). Thus, it is speculated that there is on-going platelet activation secondary to 
exposure with the damaged endothelium tissue. Studies by Schultheiss, et al. 
(1994) and Ault, et al. (1999) supported that platelet remains activated within 
one month following ACS, in patients with stable coronary artery diseases (CAD) 
(Furman, et al., 1998) and remains activated up to six months following STEMI 
(Scalone, et al., 2011). Under conditions of endothelium injury, adenosine is 
released at sites of tissue injury through degradation of released ATP and ADP 
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(Park and Gupta, 2013). Second, extracellular adenosine half-life is about few 
seconds (Moser, et al., 1989) as it is quickly taken up by cells and break down to 
inosine (Park and Gupta, 2013), thus, there is a possibility of poor uptake of 
adenosine by cells such as platelets and erythrocytes. Finally, another possible 
explanation is due to a low level of enzyme adenosine deaminase (ADA) that 
converts adenosine to inosine or adenosine kinase (ADK) that converts adenosine 
to AMP, could contribute to increase level of adenosine. Thus, it is speculated that 
with increased intracellular adenosine level, it will be transported via sodium-
independent equilibrative nucleotide transporter (ENT1) to extracellular and thus 
increased extracellular adenosine. High level of extracellular adenosine might not 
be harmful to patients, but enhance the biological effects of adenosine. 
 
 
 
 
Figure 7-6: Formation of adenosine and its intracellular uptake and metabolism, 
which are reduced by ticagrelor through inhibition of ENT1. 
Possibilities of contribution of increase level of adenosine following ticagrelor cessation, 
1) on-going tissue damage, 2) poor uptake of adenosine, 3) low level of adenosine 
kinase or adenosine deaminase. Adapted from Cattaneo, et al. (2014) (Permissions 
obtained from Elsevier, License Number 3827770177972) 
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In this observational pilot study, several lipid compounds levels were decreased 
after ticagrelor cessation. One putatively identified compound was sphingomyelin. 
Sphingomyelin level was decreased significantly from the baseline. Although this 
result is not completely understood, there is one possible explanation for this, i.e. 
it is because all ACS patients in this study were treated with a cholesterol-lowering 
agent i.e. simvastatin or atorvastatin. Sphingomyelin is known to associate with 
cardiovascular disease risk (Stegemann, et al., 2014). Jiang, et al. (2000) found 
that plasma sphingomyelin was significantly higher in patients with CAD and few 
years later, Schlitt, et al. (2006) found that sphingomyelin was associated with 
myocardial infarction and cardiovascular death in ACS patients. Another study by 
Chen, et al. (2011) found sphingomyelin levels were higher among patients with 
CHD and in those with left ventricular (LV) systolic dysfunction (LVEF<50%) than 
in patients without CHD or LV dysfunction. It is speculated that statin therapy 
decreased level of sphingomyelin. Sphingosine-1-phosphate (S1P), a major 
metabolite produced following sphingomyelin degradation, activates endothelial 
NO synthase (eNOS) in vascular endothelial cells by binding to G-protein-coupled 
S1P1 receptors (Igarashi, et al., 2001; Igarashi and Michel, 2001; Igarashi, et al., 
2003). Igarashi, et al. (2007) found that statins increased eNOS activity in response 
to stimulation with S1P and upregulated S1P1 receptor expression, thus, this may 
lead to metabolism of sphingomyelin and decrease sphingomyelin’s level following 
statin therapy. 
 
Although, only 16 putative metabolites significantly altered following ticagrelor 
cessation, it is important to note that there are another 19 putative metabolites 
that almost reach nominal significance (p-value between 0.051 to 0.10) in this 
study still may be scientifically important and bear further investigation. Future 
works on targeted analyses may be necessary to support the findings from this 
study. Moreover, the findings in this study do not only provide metabolite changes 
detected following ticagrelor discontinuation, but also provide metabolic 
signatures of ticagrelor response. Metabolomics, the study of metabolism, can 
help us identify pathways involved in drug clinical efficacy as well as risk of 
cardiovascular events associated with antiplatelet therapy (Lewis, et al., 2013; 
Yerges-Armstrong, et al., 2013; Ellero-Simatos, et al., 2014).  
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7.4.1 Strengths and limitations 
This preliminary study has several strengths. First, this study was performed in 
ACS patients, and thus it able to reflect the effect of ticagrelor cessation in 
patients with ischaemia and coronary artery disease. Second, untargeted 
metabolomics approach by LCMS is able to generate rich metabolomics data, for 
example in this study, 311 putative metabolites were detected.  
 
There are limitations in this present work. Firstly, it describes a clinical 
observation in a small number of patients. There are challenges in recruiting 
research participants. Many potential participants did come forward after 
received invitation letters but many were ineligible as they were not sure the date 
of stopping DAPT or were unable to attend as they need to travel long distances 
for study visits. Although with a small sample size, this study collected samples 
from multiple time-points for a single subject, which able to reduce the variability 
level (B.Dunn, et al., 2013). Secondly, sampling bias is likely in this study. To 
increase the number of recruitment and to make the study more attractive, the 
study allowed the two visits at any time of the day. There are many factors 
influence metabolite profiles such as dietary intake and what time they eat (Park, 
et al., 2009). Nevertheless, the study collected blood samples under a similar 
condition where all patients were allowed to eat and drink as normal. 
 
7.5 Summary 
This is a preliminary report on multiple metabolites changes following DAPT 
cessation in a small sample of patients with ACS. Findings suggest the possibility 
of relevant changes in platelet related metabolism post-DAPT cessation. A long-
term goal is to associate metabolites changes with cardiovascular event post-DAPT 
cessation. 
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8 Conclusion  
Antiplatelet therapy is the cornerstone of secondary prevention following an acute 
coronary syndrome (ACS) or ischaemic stroke, and antiplatelet agents have been 
shown to improve clinical outcome in these conditions. However, despite the use 
of antiplatelet therapy in these populations, cardiovascular events still occurred. 
Several studies have been carried out to assess certain clinical aspects when using 
antiplatelet in patients who have suffered ACS or ischaemic stroke. 
 
Antiplatelet therapy is normally prescribed as a secondary prevention medication 
in order to prevent recurrent event, however, there are patients who experience 
a stroke whilst taking antiplatelet. So in chapter 3, the Virtual International Stroke 
Trials Archive (VISTA) data were used to test whether those who change to a new 
antiplatelet regimen following acute stroke have better clinical outcomes. The 
study found that patients who changed their pre-existing antiplatelet therapy was 
not associated with a lower risk of recurrence stroke than continuing on the same 
antiplatelet regimen. Patients who changed to a new antiplatelet regimen was 
associated with more favourable functional outcome at day 90, although this 
observation might be due to confounding at the baseline. The results may have 
relevance to the clinical practice, yet, the selection of an antiplatelet agent 
should be individualized based on patient characteristics. 
 
Guidelines suggest initiation of antiplatelet therapy within 24 to 48 hours following 
acute stroke or it must be avoided for 24 hours following thrombolytic therapy. In 
chapter 4, the study examines whether early initiation (initiated on the same or 
following day after stroke) of antiplatelet therapy associated with better clinical 
outcomes. The study observed, in patients who have suffered ischaemic stroke, 
early initiation of antiplatelet therapy was not associated with better outcomes 
than later initiation. Furthermore, early initiation was associated with an 
increased risk of bleedings. Although, the results might be applicable to clinical 
practice, these findings need to be confirmed in randomised and larger trials. 
 
Interrupting or stopping antiplatelet therapy has been previously shown to 
associate with increased risk of cardiovascular events. Nevertheless, the impact 
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of interruption or stopping antiplatelet therapy in patients who have suffered 
ischaemic stroke is still lacking, thus, in chapter 5, the clinical outcomes following 
early cessation, interruption and stopping antiplatelet therapy were explored 
using a nested case-control study. In this observational study, early cessation or 
interrupted/stopped antiplatelet therapy was not associated with an increased 
risk of cardiovascular events compared to persistent users. The study used VISTA 
data, which has shorter study follow up (up to 90 days), could be one of the 
reasons the clinical outcomes could not be captured in this study. Further 
prospective and randomized trials are warranted to confirm these findings.  
 
Cessation of DAPT may put patients at risk of cardiovascular event. Thus, in 
chapter 6 describes the incidence and predictors or cardiovascular events after 
DAPT cessation in patients who have suffered ACS using the NHS Greater Glasgow 
and Clyde Safe Haven database. The pertinent observations from this study were 
that: i) incidence of cardiovascular events occurred in 188 (16.7%) patients after 
DAPT cessation; ii) the incidence rate was lower in 0-90-day interval than in the 
next 90-day interval after DAPT cessation, 0.15 and 0.23 per 1000 patient-days, 
respectively; and iii) age, having medical or revascularization therapy and 
duration of DAPT were independent predictors of cardiovascular events. The 
evidence presented in this real life setting, may be found useful by clinician and 
cardiologist to guide DAPT cessation in their patients. 
 
There are concerns regarding clustering of cardiovascular events that has been 
reported previously following clopidogrel cessation and it is essential to determine 
whether there are metabolite changes affected after DAPT cessation. In chapter 
7, in patients who have suffered ACS, there were 311 putative metabolites 
identified after ticagrelor cessation. Of the 311 metabolites, 16 (5.1%) putative 
metabolites significantly altered following ticagrelor cessation, especially 
adenosine. Also, there were 19 putatively identified metabolites almost reach 
significance which requires further confirmation in larger sample. These 
putatively identified metabolites may have play a role in cardiovascular events 
following DAPT cessation that need to be investigated further. 
 
The strength and limitations of each study in this thesis have been discussed in 
each individual chapter. Thus, in overall, the findings from the individual studies 
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described in this thesis raise important clinical questions that warrant further 
investigations. On the other hand, the conclusions obtain in relation to 
antiplatelet therapy and recurrent ischaemic stroke must be interpreted with 
caution. This is because the analyses were performed using a non-randomized 
clinical trial data from VISTA that were collated from numerous clinical trials. The 
study observed low events rate of recurrent stroke and lacks statistical power 
could be the reasons why the study may not detect significant difference between 
groups. Most analyses presented in this thesis were conducted retrospectively, 
thus need validation and further analyses using prospective studies.  
 
8.1 Clinical implications 
 
Ischaemic stroke and TIA are commonly complicated by increased risk of 
recurrence following acute event. Early prevention and multiple approaches could 
be beneficial for patients in order to improve disability following a stroke. The 
findings in this thesis suggested those who took antiplatelet therapy before a 
stroke, switching to a new antiplatelet regimen after ischaemic stroke might have 
a better functional outcome at 90 days. In patients who suffered ischaemic stroke, 
it is suggested appropriate and clinically guided interruptions to antiplatelet 
therapy may not put patients at significant increased risk within 90 days. 
 
Discontinuation of DAPT is associated by increased risk of cardiovascular events. 
A better understanding of this may allow strategies to mitigate this risk. In this 
thesis, it is suggested to monitor closely ACS patients who is at risk i.e. elderly, 
those who received shorter DAPT duration (less than 6 months) and those who 
were not treated with revascularization. This evidence could be useful for 
clinicians in decision making or management of DAPT for their patients. 
Furthermore, these data suggest that ACS patients may benefit from longer 
duration of DAPT. Following DAPT cessation, there were no differences of 
cardiovascular event risk when continued either aspirin or clopidogrel mono 
antiplatelet therapy. 
  
Chapter 8 Conclusion 201 
 
8.2 Future directions of research 
 
Future directions include: 
 
a) Long term clinical outcome data following ticagrelor cessation in patients 
who have suffered ACS are needed. 
 
b) Metabolite changes between two time points could be compared before and 
after clopidogrel cessation in ACS patients. 
 
c) Identification of novel biomarkers between patients with and without 
cardiovascular events following DAPT cessation could have potential 
implications. 
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Appendices 
A1. Data security letter (VISTA) 
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A2. Keywords for stroke/TIA 
Recurrent stroke Transient ischaemic attack 
2ND INFARCT IN HEAD OF CAUDATE NUCLEUS R 
A LARGE INFARCT IN ANTERIA CEREBRI MEDIA 
ACUTE BRAIN INFARCT AT PONTINE LEVEL 
ACUTE ISCHEMIC STROKE 
ACUTE ISCHEMIC STROKE (PROGRESSIVE) 
ACUTE LEFT CORTICAL INFARCT 
ACUTE RIGHT CEREBROVASCULAR ACCIDENT 
ARTERIA CEREBRI MEDIA INFARCTION LEFT 
ARTERIAL INTERNAL CAROTID ARTERY DISSECT 
ARTERIAL INTERNAL CARTOID ARTERY DISSECT 
ASYMPTOMATIC LEFT HEMISPHERIC INFARCTION 
BILATERAL ISCHEMIC STROKE 
BRAIN INFARCTION 
BRAIN STEM INFARCTION 
BRAIN STEM INFARCTION  
CARDIOEMBOLIC MAJOR BRAIN STEM INFARCTIO 
CEREBELLAR INFARCT 
CEREBELLAR INFARCTION  
CEREBRAL INF SIN 
CEREBRAL INFARCT 
CEREBRAL INFARCTION 
CEREBRAL INFARCTION  
CEREBRAL REINFARCTION 
CEREBRAL RE-ISCHEMIA RIGHT HEMISPHERE 
CEREBRAL VASCULAR ACCIDENT 
CEREBROVASCULAR ACCIDENT 
INFARCTION RT. MIDDLE CEREBRAL ARTERY  
EMBOLIC STROKE 
ISCHAEMIC STROKE 
ISCHAEMIC STROKE NOS 
ISCHAEMIC STROKE ON THE LEFT SIDE 
ISCHEMIC CEREBELLAR STROKE BILATERAL (NE 
ISCHEMIC CEREBRAL INFARCTION 
ISCHEMIC STROKE 
ISCHEMIC STROKE - NEW 
ISCHEMIC STROKE (FOLLOW UP) 
ISCHEMIC STROKE IN LEFT HEMISPHERE 
ISCHEMIC STROKE RECURRENCE 
LACUNAR INFARCTION 
LACUNAR STROKE 
LARGE LEFT CORTICAL INFARCT 
LARGE MALIGNANT INFARCT WITH MILD HEMORR 
LARGE RIGHT HEMISPHERIC STROKE 
LEFT BRAIN INFARCTION, NEW RESTROKE 
LEFT BRAIN INFARCTION, RESTROKE 
LEFT MIDDLE CEREBRAL ARTERY TERRITORY IN 
LEFT SIDED CEREBROVASCULAR ACCIDENT 
MALIGNANT CEREBRAL INFARCTION 
MALIGNANT INFARCTION 
MALIGNANT MCA INFARCTION – MIDDLE CEREBRAL ARTERY 
MALIGNANT RIGHT MCA INFARCT WITH EDEMA 
MASSIVE RIGHT CORTICAL HEMISPHERE INFARC 
MEDIA INFARCT LEFT SIDE 
MIDDLE CEREBRAL ARTERY INFARCT 
MIDDLE CEREBRAL ARTERY STROKE 
MULTIPLE ISCHEMIC STROKE 
MULTIPLE NEW STROKE 
MULTIPLE NEW STROKES - ISCHEMIC 
NEW ACUTE ISCHEMIC STROKE 
NEW BRAIN STEM CVA 
NEW BRAIN STROKE 
NEW BRAINSTEM STROKE 
NEW CEREBRAL INFARCTION  
NEW INFARCTION IN CONTRALATERAL HEMISPHE  
NEW ISCHAEMIC STROKE 
NEW ISCHEMIC ACUTE INFARCTION RIGHT FRON 
NEW ISCHEMIC STROKE 
NEW ISCHEMIC STROKE #1 
NEW ISCHEMIC STROKE (RIGHT MIDDLE CEREBR 
NEW ISCHEMIC STROKE WITH HEMMORRHAGIC TR 
NEW ISCHEMIC STROKE WITH RIGHT HEMIPARES 
MULTIPLE TIA 
RECURRENT T.I.A 
RECURRING TRANSIENT ISCHEMIC ATTAACK 
TIA 
TIA ATTACK 
TIA LEFT HEMISPHERE  
TRANS ISCHEMIC ATTACKS 
TRANSIENT ISCHAEMIC ATTACK 
TRANSIENT ISCHAEMIC ATTACK  
TRANSIENT ISCHEMIC ATACK 
TRANSIENT ISCHEMIC ATTACK 
TRANSIENT ISCHEMIC ATTACK, MULTIPLE 
TRANSIENT ISCHEMIC ATTACKS 
TRANSITORIC ISCHEMIC ATTACK 
TRANSITORY ISCHAEMIC ATTACK 
VERTEBROBASILAR TRANSIENT ISCHEMIC ATACK 
VERTEBROBASILAR TRANSIENT ISCHEMIC ATTAC 
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Recurrent stroke Transient ischaemic attack 
NEW ISCHEMIC STROKE, RIGHT SUBCORTICAL 
NEW LEFT ISCHEMIC CVA 
NEW ONSET ISCHEMIC STROKE 
NEW RIGHT CEREBELLAR INFARCTION 
NEW RIGHT ISCHEMIC CVA 
NEW STROKE 
NEW STROKE - ISCHEMIC 
NEW STROKE (BRAINSTEM) 
NEW STROKE (INFARCTION) 
NEW STROKE (ISCHEMIC) 
NEW STROKE HEMORRHAGIC 
NEW STROKE ISCHEMIC 
NEW STROKE LEFT BRAIN HAEMATOMA IN MCA T 
NEW STROKE LEFT OCCIPITAL ISCHEMIC STROK 
NEW STROKE SYMPTOMS IN REGIO CEREBELLARI 
NEW STROKE, ISCHAEMIC 
NEW STROKE/ISCHEMIC 
ORIGINAL LEFT MIDDLE CEREBRAL ARTERY INF 
ORIGIONAL ACUTE ISCHEMIC STROKE 
REC. STROKE 
RECIDIVE BRAIN INFARCTION 
RECURREND STROKE 
RECURRENT ACUTE ISCHEMIC STROKE - CEREBE 
RECURRENT CEREBRAL ISCHEMIA 
RECURRENT CEREBROVASCULAR ACCIDENT 
RECURRENT IPSILATERAL STROKE 
RECURRENT ISCHAEMIC NEW STROKE LEFT HEMI 
RECURRENT ISCHAEMIC STROKE 
RECURRENT ISCHEMIC CEREBROVASCULAR STROK 
RECURRENT ISCHEMIC STROKE 
RECURRENT ISCHEMIC STROKE - RIGHT POSTER 
RECURRENT LEFT HEMISPHERIC STROKE 
RECURRENT NEW ISCHEMIC STROKE 
RECURRENT RIGHT MCA STROKE 
RECURRENT STROKE 
RECURRENT STROKE (FOLLOW UP) 
RE-INFARCTION OF LEFT LENTIFORM NUCLEUS 
RE-STROKE ISCHEMIC 
RIGHT CEREBRAL INFARCT 
RIGHT MIDDLE CEREBRAL ARTERY STROKE 
RIGHT PARIETAL ISCHEMIC INFARCT 
RT. MCA INFARCT WITH MASSIVE CEREBRAL ED 
STROKE 
STROKE (ACV) 
STROKE (ISCHAEMIC) 
STROKE (ISCHEMIC) 
STROKE (LEFT MIDDLE CEREBRAL ART.) 
STROKE (NEW EVENT) 
STROKE (NEW) 
STROKE (RECURRENCE) 
STROKE BRAINSTEM 
STROKE IN RIGHT ANTERIOR AND MIDDLE CERE 
STROKE RECURRENCE 
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A3. Keywords for bleeding 
Intracranial 
Extracranial  
(gastrointestinal, non-gastrointestinal) 
BILATERAL SUBDURAL HEMATOMA 
ACUTE HEMORRHAGIC STROKE 
AND SUBARACHNOID HEMORRHAGE 
ASYMPTOMATIC CEREBRAL HAEMORRHAGIC TRANS 
ASYMPTOMATIC HAEMORRHAGIC INFARCTION (ON 
ASYMPTOMATIC INTRACRANIAL BLEEDING 
ASYMPTOMATIC MILD INTRA-CEREBRAL BLEEDIN 
ASYMTOMATIC CEREBRAL BLEEDING 
BASAL GANGELION HAEMORRHAGE 
BLEEDING INTRACRANIAL 
BRAIN HAEMORRHAGE 
BRAIN HEMATOMA 
BRAIN HEMATOMA INTRAVENTRICULAR HEMORRHA 
BRAIN HEMATOMA WITH INTRAVENTRICULAR HEM 
BRAIN HEMATOMA WITH SUBARACHNOID HEMORRH 
BRAIN HEMORRHAGE 
CEREBELLAR HAEMORRHAGE (ARTEFACT?) REPOR 
CEREBELLAR HEMORRHAGE 
CEREBRAL BLEEDING 
CEREBRAL HAEMORRAGE 
CEREBRAL HAEMORRHAGE 
CEREBRAL HEMATOMA 
CEREBRAL HAEMATOMA 
CEREBRAL HEMORRAGE 
CEREBRAL HEMORRHAGE 
CEREBRAL HEMORRHAGE  
CEREBRAL HEMORRHAGE (FOLLOW-UP) 
CEREBRAL HEMORRHAGE EVENT 
CEREBRAL HEMORRHAGY 
CEREBRAL HAEMORRHAGE 
HAEMATOMA SUBDURAL 
HAEMORRHAGE (INTRACRANIAL) 
HAEMORRHAGE BRAIN 
HAEMORRHAGE INTO CEREBRAL INFARCTION 
HAEMORRHAGE INTO ORIGINAL INFARCT 
HAEMORRHAGE INTRACRANIAL 
HAEMORRHAGIC CEREB.INFARCT.IN PRIMARY FO 
HAEMORRHAGIC CEREBRAL INFARCTION 
HAEMORRHAGIC STROKE 
HEMMORHAGIC STROKE 
HEMORRHAGE (CEREBRAL) 
HEMORRHAGE (INTRACRANIAL) 
HEMORRHAGE BRAIN 
HEMORRHAGE CEREBRAL 
HEMORRHAGE IN STROKE TERRITORY BY MRI 
HEMORRHAGE INTRACEREBRAL 
HEMORRHAGE INTRACRANIAL 
HEMORRHAGE LEFT BASAL GANGLIA 
HEMORRHAGE LEFT FRONTAL LOBE 
HEMORRHAGE WITHIN THE ISCHAEMIC TERRITOR 
HEMORRHAGE, CEREBRAL 
HEMORRHAGE, ENLARGEMENT OF INFARCTED ARE 
HEMORRHAGIC STROKE 
HEMORRHAGIC STROKE (HEMORRHAGICAL TRANSF 
I.C. HAEMORRHAGES 
IC HAEMORRHAGIA DX WITH SLIGHT CLINICAL 
ICH ( INTRACRANIAL CEREBRAL HEMORRHAGE) 
INTRA CEREBRAL HAEMORRHAGE 
INTRA CEREBRAL HEMORRHAGE 
INTRA CRANIAL BLEED 
INTRA VENTRICULAR HEMORRHAGE WITH CLINIC 
INTRACEBRAL BLEEDING 
INTRACEREBELLAR HAEMORHAGY 
INTRACEREBRA HEMORRHAGE TYPE 2 
INTRACEREBRAL & VENTRICULAR BLEEDING 
INTRACEREBRAL BLEED 
INTRACEREBRAL BLEEDING 
INTRACEREBRAL BLEEDING AFTER TROMBOLYSIS 
INTRACEREBRAL HAEMATOMA 
INTRACEREBRAL HAEMORRAGE 
ANAEMIA DUE TO GASTROINTESTINAL BLOOD LO 
BLEEDING DUODENAL ULCER 
BLEEDING FROM THE ULCER IN STOMACH  
BLEEDING GASTRIC ULCER 
BLEEDING GASTRIC ULCERS 
BLEEDING GASTROINTESTINAL TRACT 
BLEEDING IN ABDOMINAL LOCALITY WITH ABDO 
BLOOD CLOT IN URINE 
BLOOD IN STOOL 
BLOOD IN URINE 
BLOOD IN URINE  
BLOOD VOMITING 
BLOODY STOOL  
COFFEE GROUND EMESIS 
COFFEE GROUND VOMITING 
DUODENAL HEMORRHAGE 
ENTERORHAGY – INTESTINAL HAEMORRHAGE 
FRANK HAEMATURIA 
GASTRIC BLEEDING 
GASTRIC HAEMORRHAGE 
GASTRIC HEMORRHAGE 
GASTRIC ULCER WITH SERIOUS BLEEDING 
GASTRO DUODENAL BLEEDING 
GASTRO INTESTINAL BLEED 
GASTRO INTESTINAL BLEEDING 
GASTROINTESTINAL BLEED 
GASTROINTESTINAL BLEED SECONDARY TO GAST 
GASTROINTESTINAL BLEEDING 
GASTROINTESTINAL HAEMORRAGE 
HAEMORRHAGE OF RECTUM 
GASTROINTESTINAL HAEMORRHAGE 
GASTROINTESTINAL HEMORRHAGE 
GASTROINTESTINAL TRACT BLEED NOS 
GI BLEED 
GI BLEEDING 
GI HAEMORRHAGE 
GROSS HEMATURIA 
MASSIVE EPISTAXIS 
MASSIVE EPISTAXIS WITH HEMORRHAGIC SHOCK  
HAEMATEMESIS 
HAEMATURIA 
HAEMORRHAGE FROM DIGESTIVE TRACT 
HAEMORRHAGE FROM THE URINARY TRACT 
HAEMORRHAGE GASTROINTESTINAL 
HAEMORRHAGE URINARY TRACT 
HEMATOCHEZIA 
HEMATOCHEZIA – STOOLS WITH BLOOD 
HEMATURIA 
HEMATURIA AGGRAVATED 
HEMATURIA TRAUMATIC  
HEMORRHAGE OF GASTROINTESTINAL TRACT 
HEMORRHAGIC SHOCK 
INTESTINAL BLEEDING 
INTESTINAL HAEMORRHAGE 
INTRA-ABDOMINAL HEMORRHAGE 
RECTAL BLEED 
RECTAL BLEEDING 
RECTAL BLOOD POST BOWEL MOVEMENT SEC TO 
RECTAL HAEMORRHAGE 
RECTAL HEMORRHAGE 
HEMORRHAGE OF RECTUM AND ANUS 
LOWER GASTROINTESTINAL BLEED 
LOWER GASTROINTESTINAL HEMORRHAGE 
LOWER GI BLEED 
MELAENA 
MELAENA  
MELAENAS  
MELENA 
MELENA  
MELENA DUE TO DUODENAL ULCER 
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Intracranial 
Extracranial  
(gastrointestinal, non-gastrointestinal) 
INTRACEREBRAL HAEMORRAGHE 
INTRACEREBRAL HAEMORRHAGE 
INTRA-CEREBRAL HAEMORRHAGE 
INTRACEREBRAL HAEMORRHAGE (FOLLOW-UP) 
INTRACEREBRAL HAEMORRHAGE INTO ACUTE INF 
INTRACEREBRAL HEMMORRHAGE 
INTRACEREBRAL HEMORRAGE  NEW STROKE 
INTRACEREBRAL HEMORRHAGE 
INTRA-CEREBRAL HEMORRHAGE 
INTRACEREBRAL HEMORRHAGE (NEW) 
INTRACEREBRAL HEMORRHAGE ASYMPTOMATIC (T 
INTRACEREBRAL HEMORRHAGE MALIGNANT OEDEM 
INTRACEREBRAL HEMORRHAGE S/P FALL 
INTRACRANIAL BLEEDING 
INTRACRANIAL BLEEDING  
INTRACRANIAL HAEMATOMA 
INTRACRANIAL HAEMORRHAGE 
INTRACRANIAL HAEMORRHAGE NOS 
INTRACRANIAL HEMATOMA 
INTRACRANIAL HEMORRAGE 
INTRACRANIAL HEMORRHAGE 
INTRACRANIAL HEMORRHAGE, UNSPECIFIED 
INTRAVENTRICULAR HEMORRHAGE 
LEFT CAPSULA INTERNA BLEEDING 
LEFT INTRACEREBRAL HEMORRHAGE (LARGE) 
MASSIVE RIGHT INTRACEREBRAL HEMORRHAGE  
MINOR CEREBRAL BLEED RELATED TO BRAIN BI 
MINOR INTRACEREBRAL HAEMORRHAGE 
NEW HEMMORRHAGIC STROKE 
NEW HEMORRHAGIC STROKE 
NEW INTRACEREBRAL HEMORRHAGE 
PETECHIAL HAEMORRHAGE OF INF. AREA 
PETECHIAL INTRACEREBRAL BLEEDING, ASYMPT 
PETECHIAL INTRACEREBRAL HEMATOMA, ASYMPT 
POST TPA CEREBRAL PARENCHYMAL HEMORRHAGE 
PRIMARY INTRA-CEREBRAL HAEMORRHAGE 
RECURRENT HEMORRHAGIC STROKE 
REPERFUSION HEMORRHAGE OF BRAIN 
RIGHT SIDED INTRACRANIAL HAEMORRHAGE 
SECONDARY HEMORRHAGE IN INFARCTED AREA 
SEVERE HAEMORRHAGIC STROKE 
SMALL RIGHT FRONTAL CEREBRAL HEMORRHAGE 
SUB DURAL HAEMATOMA 
SUBARACHNOID HAEMORRHAGE 
SUBARACHNOID HEMORRHAGE 
SUBDURAL HAEMATOMA 
SUBDURAL HEMATOMA 
SUBDURAL HEMATOMA (TRAUMATIC) 
SUBDURAL HEMORRHAGE 
SUBDURAL HEMORRHAGE, BILATERAL 
SPINAL EPIDURAL HEMATOMA 
SYMPTOMATIC INTRACRANIAL HEMORRHAGE 
THALAMUS HAEMATOMA 
TRAUMATIC SUBDURAL HEMATOMA 
EPIDURAL HAEMATOMA 
HEMORRHAGISATION OF STROKE IN TERRITORRY 
HEMORRHAGE OF RECTUM 
OESOPHAGEAL BLEEDING 
PEPTIC ULCER HAEMORRHAGE 
PEPTIC ULCER WITH HAEMORRHAGE 
PEPTIC ULCER WITH HAEMORRHAGY 
RETENTION OF CLOTS (HAEMATURIA-BLOOD IN 
SEVERE GASTROINTESTINAL BLEEDING LEADING 
SHOCK DUE TO GASTROINTESTINAL BLEEDING 
STOMACH ULCER HEMORRHAGE 
TARRY STOOLS 
UNSPECIFIED GASTRIC (STOMACH) HEMORRHAGE 
UPPER GASTRO INTESTINAL BLEEDING 
UPPER GASTROINTESTINAL BLEED 
UPPER GASTROINTESTINAL BLEEDING 
UPPER GASTROINTESTINAL BLEEDING SECONDAR 
UPPER GASTROINTESTINAL HAEMORRHAGE 
UPPER GASTROINTESTINAL HEMORRHAGE 
UPPER GI BLEED 
UPPER GI HEMORRHAGE ^/= HEMATEMESIS 
VOMITING BLOOD 
WITH MACRO HEMATURIA 
HEMORRHAGE 
MALLORY WEISS SYNDROME  
MALLORY WEISS TEAR 
MULTIPLE GASTRIC ULCERS WITH HEMORRHAGE 
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A4. Safe Haven application feedback 
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A5. ICD-10 codes for cardiovascular events 
Events 
ICD-10 
codes 
Diseases 
ACS 
I20.0 Unstable angina 
I21 Acute myocardial infarction 
I21.0 Acute transmural myocardial infarction of anterior wall 
I21.1 Acute transmural myocardial infarction of inferior wall 
I21.2 Acute transmural myocardial infarction of other sites 
I21.3 Acute transmural myocardial infarction of unspecified site 
I21.4 Acute subendocardial myocardial infarction 
I21.9 Acute myocardial infarction, unspecified 
I22 Subsequent myocardial infarction 
I22.0 Subsequent myocardial infarction of anterior wall 
I22.1 Subsequent myocardial infarction of inferior wall 
I22.8 Subsequent myocardial infarction of other sites 
I22.9 Subsequent myocardial infarction of unspecified site 
Heart 
failure 
I50 Heart failure 
TIA 
G45.8 Other transient cerebral ischaemic attacks and related syndromes 
G45.9 Transient cerebral ischaemic attack, unspecified 
Stroke 
I63 Cerebral infarction 
I63.0 Cerebral infarction due to thrombosis of precerebral arteries 
I63.1 Cerebral infarction due to embolism of precerebral arteries 
I63.2 
Cerebral infarction due to unspecified occlusion or stenosis of 
precerebral arteries 
I63.3 Cerebral infarction due to thrombosis of cerebral arteries 
I63.4 Cerebral infarction due to embolism of cerebral arteries 
I63.5 
Cerebral infarction due to unspecified occlusion or stenosis of 
cerebral arteries 
I63.6 
Cerebral infarction due to cerebral venous thrombosis, 
nonpyogenic 
I63.8 Other cerebral infarction 
I63.9 Cerebral infarction, unspecified 
I64 Stroke, not specified as haemorrhage or infarction 
Cardiac 
death 
I46.1 Sudden cardiac death 
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A6. ICD-10 codes for major bleeding 
ICD-10 codes Diseases 
Subarachnoid 
I60 Subarachnoid haemorrhage 
I60.0 
Subarachnoid haemorrhage from carotid siphon and 
bifurcation 
I60.1 Subarachnoid haemorrhage from middle cerebral artery 
I60.2 
Subarachnoid haemorrhage from anterior communicating 
artery 
I60.3 
Subarachnoid haemorrhage from posterior communicating 
artery 
I60.4 Subarachnoid haemorrhage from basilar artery 
I60.5 Subarachnoid haemorrhage from vertebral artery 
I60.6 Subarachnoid haemorrhage from other intracranial arteries 
I60.7 
Subarachnoid haemorrhage from intracranial artery, 
unspecified 
I60.8 Other subarachnoid haemorrhage 
I60.9 Subarachnoid haemorrhage, unspecified 
Intracerebral 
I61 Intracerebral haemorrhage 
I61.0 Intracerebral haemorrhage in hemisphere, subcortical 
I61.1 Intracerebral haemorrhage in hemisphere, cortical 
I61.2 Intracerebral haemorrhage in hemisphere, unspecified 
I61.3 Intracerebral haemorrhage in brain stem 
I61.4 Intracerebral haemorrhage in cerebellum 
I61.5 Intracerebral haemorrhage, intraventricular 
I61.6 Intracerebral haemorrhage, multiple localized 
I61.8 Other intracerebral haemorrhage 
I61.9 Intracerebral haemorrhage, unspecified 
Others 
I62 Other nontraumatic intracranial haemorrhage 
I62.0 Subdural haemorrhage (acute)(nontraumatic) 
I62.1 Nontraumatic extradural haemorrhage 
I62.9 Intracranial haemorrhage (nontraumatic), unspecified 
Intraocular 
H11.3 Conjunctival haemorrhage (Subconjunctival harmorrhage) 
H31.3 Choroidal haemorrhage and rupture 
H35.6 Retinal haemorrhage 
H43.1 Vitreous haemorrhage 
Retroperitoneal 
R58 Haemorrhage, not elsewhere classified 
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A7. Additional analyses (Chapter 3) 
 
a) Clinical outcomes at 90 days 
Outcomes 
Change 
n=538 
Continue 
n=591 
Adjusted OR* 
(95% CI) 
p-value 
Recurrent stroke 
22/532 
(4.1) 
25/588 
(4.3) 
1.35 (0.70-2.60) 0.367 
ICH 
13/532 
(2.4) 
15/581 
(2.6) 
0.98 (0.40-2.41) 0.957 
ECH 
25/527 
(4.7) 
17/584 
(2.9) 
2.03 (1.04-3.98) 0.039 
 
All values are reported as no. (%) unless otherwise noted. *All models are adjusted for 
age, baseline NIHSS, hypertension, AF, prior TIA, prior stroke and rt-PA. AF= atrial 
fibrillation, CI=confidence interval, ICH=intracranial haemorrhage, ECH=extracranial 
haemorrhage, OR=odds ratio, rt-PA=recombinant tissue plasminogen activator, TIA= 
transient ischaemic attack. 
 
 
b) Distribution of mRS outcome at day 90 in patients suffering ischaemic stroke (change 
vs continue group) 
 
 
Adjusted OR, 1.47; 95% CI, 1.11-1.83; p=0.002* 
 
Diagram showing association of functional outcome at day 90 between change and 
continue group. *Model is adjusted for age, baseline NIHSS, hypertension, AF, prior TIA, 
prior stroke and rt-PA. AF= atrial fibrillation, CI=confidence interval, OR=odds ratio, rt-
PA=recombinant tissue plasminogen activator, TIA= transient ischaemic attack. Values 
provided in each box denote the percentage of patients belonging to a specific 
treatment category (change or continue) and representing the mRS score corresponding 
to the box.  
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A8. Multiple variables matching using SAS software 
 
%LET AGERANGE = 10; 
%LET RATIO = 4; 
DATA CASES CONTROLS; 
SET All; 
IF EVENT = 0 THEN OUTPUT CASES; 
ELSE OUTPUT CONTROLS; 
PROC FREQ NOPRINT DATA=CASES; 
TABLES AGE*DIABETES/OUT=CASEOUT; 
 
%MACRO SAMPLE  
(V_AGE,V_RESPONSE,V_COUNT); 
DATA QUALIFY1; SET CONTROLS; 
WHERE (&V_AGE-&AGERANGE 
<=AGE<=&V_AGE+&AGERANGE) 
AND (DIABETES = "&V_RESPONSE"); 
 
CASES_AGE=&V_AGE; 
CASES_DIABETES="&V_DIABETES"; 
 
SEED=RANUNI(0); 
PROC SORT; BY SEED; 
 
DATA QUALIFY2; 
SET QUALIFY1 NOBS=TOTOBS; 
IF _N_<=&V_COUNT*&RATIO; 
IF &V_COUNT*&RATIO <= TOTOBS THEN TAG = 'YES'; 
ELSE TAG = 'NO'; 
 
PROC APPEND BASE=MATCHES DATA=QUALIFY2; 
 
PROC SORT DATA=QUALIFY2 OUT=TEMP1 
(KEEP=NUMBER); BY NUMBER; 
 
PROC SORT DATA=CONTROLS OUT=TEMP2; 
BY NUMBER; 
 
DATA CONTROLS; 
MERGE TEMP1(IN=IN1) TEMP2(IN=IN2); 
BY NUMBER; IF IN2 AND NOT IN1; 
 
%MEND SAMPLE; 
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